<SEC-DOCUMENT>0001193125-20-278378.txt : 20201027
<SEC-HEADER>0001193125-20-278378.hdr.sgml : 20201027
<ACCEPTANCE-DATETIME>20201027160253
ACCESSION NUMBER:		0001193125-20-278378
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		10
CONFORMED PERIOD OF REPORT:	20201216
FILED AS OF DATE:		20201027
DATE AS OF CHANGE:		20201027
EFFECTIVENESS DATE:		20201027

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50484
		FILM NUMBER:		201264151

	BUSINESS ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-369-7100

	MAIL ADDRESS:	
		STREET 1:		11455 EL CAMINO REAL
		STREET 2:		SUITE 250
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d17046ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
(Rule <FONT STYLE="white-space:nowrap">14a-101)</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified in its Charter) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g17046g1017042551817.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">October&nbsp;27, 2020 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the Stockholders of MEI Pharma, Inc.: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the Annual Meeting of the Stockholders of MEI Pharma, Inc., a Delaware corporation. The annual meeting will
be a completely virtual meeting of stockholders, which will be conducted via live webcast. Stockholders will be able to attend the annual meeting remotely, vote and submit questions during the annual meeting by visiting
<B><U>www.meetingcenter.io/291997584</U></B> and using the password MEIP2020 and entering their control number. We are pleased to utilize virtual stockholder meeting technology to promote social distancing pursuant to guidance provided by the
Centers for Disease Control and Prevention (&#147;CDC&#148;) and the U.S. Securities and Exchange Commission (&#147;SEC&#148;) due to&nbsp;the novel coronavirus <FONT STYLE="white-space:nowrap">(COVID-19).</FONT> The virtual meeting format allows
attendance from any location in the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The annual meeting will be held at 9:00 a.m. (Pacific Time), on Thursday, December 16, 2020,
unless postponed or adjourned to a later date. I&nbsp;look forward to meeting virtually with many of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the Annual
Meeting, we will discuss each item of business described in the Notice of Annual Meeting and the proxy statement and report on MEI Pharma&#146;s business. You will also have an opportunity to ask questions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On behalf of our employees and Board of Directors, I would like to express our appreciation for your continued interest in MEI Pharma, Inc.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:4%">


<IMG SRC="g17046dsp2a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Christine A. White, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Chair of the Board </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma,
Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This proxy statement is dated October&nbsp;27, 2020, and is first being mailed or made available to stockholders of MEI Pharma, Inc.
on or about October&nbsp;27, 2020. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON DECEMBER 16, 2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the
Stockholders of MEI Pharma, Inc.: </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On behalf of the Board of Directors of MEI Pharma, Inc., a Delaware corporation (&#147;MEI
Pharma&#148;), MEI Pharma is pleased to deliver the accompanying proxy statement in connection with the annual meeting of stockholders of MEI Pharma. This year&#146;s annual meeting will be our first time hosting a completely virtual meeting of
stockholders, which will be conducted solely online via live webcast. MEI Pharma stockholders will be able to attend and participate in the annual meeting online, vote their shares electronically and submit questions prior to and during the annual
meeting by visiting <B><U>www.meetingcenter.io/291997584</U></B><B> </B>and using the password MEIP2020 and entering their control number. We are pleased to utilize virtual stockholder meeting technology to promote social distancing pursuant to
guidance provided by the Centers for Disease Control and Prevention (&#147;CDC&#148;) and the U.S. Securities and Exchange Commission (&#147;SEC&#148;) due to the novel coronavirus <FONT STYLE="white-space:nowrap">(COVID-19).</FONT> The virtual
meeting format allows attendance from any location in the world. You are cordially invited to attend the annual meeting, which will be held for the following purposes: </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect three directors to our Board of Directors, to serve until the expiration of their terms in fiscal year
2024 and until their successors are elected and qualified; </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan (the &#147;2008
Equity Plan&#148;) to increase the number of shares of common stock that may be subject to award and make certain other changes to the plan terms included in the plan document attached as Annex A; </P></TD></TR></TABLE>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers as disclosed
in the accompanying proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of BDO USA, LLP, an independent registered public accounting firm, as our independent
auditors for the fiscal year ending June&nbsp;30, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the meeting or any adjournment or postponement
thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposals are described in more detail in this proxy statement, which MEI Pharma encourages you to read
carefully and in its entirety before voting. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This year, we are again using the Securities and Exchange Commission&#146;s Notice and
Access model (&#147;Notice and Access&#148;), which allows us to deliver proxy materials via the Internet. We believe Notice and Access provides stockholders with a convenient method to access the proxy materials and vote, while allowing us to
conserve natural resources and reduce the costs of printing and distributing the proxy materials. On or about October&nbsp;27, 2020, we mailed stockholders of record a Notice of Internet Availability of Proxy Materials with instructions on how to
access the proxy materials electronically. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The close of business on October 20, 2020 has been fixed as the record date for determining
those holders of MEI Pharma common stock entitled to receive notice of and vote at the annual meeting. Accordingly, only record holders of MEI Pharma common stock at the close of business on that date are entitled to notice of and to vote at the
annual meeting and at any adjournments or postponements thereof. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All holders of MEI Pharma common stock are cordially invited to attend
the annual meeting in person. You may revoke your proxy in the manner described in this proxy statement at any time before it is voted at the annual meeting. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Important Notice Regarding Internet Availability of Proxy Materials for the Annual Meeting to be Held on December 16, 2020: </B>MEI
Pharma&#146;s Proxy Statement, 2020 Annual Report and Form of Proxy Card are also available at
<B><U>https:/</U></B><B><U>/</U></B><B><U>w</U></B><B><U>ww</U></B><B><U>.</U></B><B><U>e</U></B><B><U>d</U></B><B><U>oc</U></B><B><U>u</U></B><B><U>me</U></B><B><U>n</U></B><B><U>tvi</U></B><B><U>e</U></B><B><U>w</U></B><B><U>.</U></B><B><U>com/ME</U>
</B><B><U>I</U></B><B><U>P</U></B>. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your vote is important regardless of the number of shares of common stock you own. Whether or not you
expect to attend the annual meeting, please submit your proxy by Internet, telephone or mail following the instructions found on your Notice of Internet Availability of Proxy Materials or proxy card so that your shares of common stock may be
represented and voted at the annual meeting. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By order of the Board of Directors, </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g17046g03v42.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Secretary and
Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;27,
2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>MEI PHARMA PROXY STATEMENT TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_1">THE ANNUAL MEETING OF MEI PHARMA STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_2">ELECTION OF DIRECTORS (PROPOSAL NO. 1)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_3">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_4">Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_5">Information about the Board of Directors and its Committees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_6">Audit Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_7">Compensation Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_8">Nominating and Governance Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_9">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_10">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_11">Board Role in Risk Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_12">Anti-Hedging and Pledging Policies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_13">Stockholder Communications with the Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_14">Appointment of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_15">Attendance of Directors at Board Meetings and Shareholder
Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_16">Code of Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_17">Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_18">APPROVAL OF AMENDED AND RESTATED 2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN (PROPOSAL
 NO. 2)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_19">Description of the 2008 Equity Plan as Proposed to be Amended and
Restated</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_20">ADVISORY VOTE ON EXECUTIVE COMPENSATION (PROPOSAL NO. 3)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_21">COMPENSATION DISCUSSION AND ANALYSIS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_22">Compensation Philosophy and Objectives</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_23">The Compensation Committee&#146;s Process</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_24">Severance and Change in Control Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_25">Tax and Accounting Considerations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_26">CEO Pay Ratio</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_27">COMPENSATION COMMITTEE REPORT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_28">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_29">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_30">Employment Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_31">Grants of Plan-Based Awards For Fiscal Year Ended June 30,
2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_32">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_33">Option Exercises and Stock Vested</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_34">Compensation of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_35">Indemnification Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_36">RATIFICATION OF APPOINTMENT OF BDO USA, LLP (PROPOSAL NO. 4)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_37">Background</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_38">Fees Paid to Auditors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_39"><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies and Procedures
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_40">AUDIT COMMITTEE REPORT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_41">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_42">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF MEI PHARMA
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_43">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_44">OTHER MATTERS FOR STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_45">Stockholder Proposals</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_46">Communication with the MEI Pharma Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_47">Householding of Proxy Materials for MEI Pharma Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc17046_48">ANNEX A &#150; AMENDED AND RESTATED MEI PHARMA INC. 2008 STOCK OMNIBUS EQUITY
 COMPENSATION PLAN</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11455 El Camino Real, Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, CA 92130 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_1">
</A>THE ANNUAL MEETING OF MEI PHARMA STOCKHOLDERS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held via Live Webcast on December&nbsp;16, 2020, at 9:00 a.m. (Pacific Time)
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; Meeting To Be Held
on&nbsp;December&nbsp;16,&nbsp;2020 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement and our annual report to security holders for the fiscal year ended June 30, 2020 are
available at <B><U>https:</U></B><B><U>//www.edocumentview.com/MEIP.</U></B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information Concerning Solicitation and Voting </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this proxy statement, &#147;MEI Pharma&#148;, &#147;the Company&#148;, &#147;we&#148;, &#147;us&#148;, and &#147;our&#148; refer to MEI Pharma, Inc.,
unless the context otherwise provides. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are furnishing this proxy statement to holders of our common stock in connection with the solicitation of proxies by our Board of Directors
for use at our annual meeting of stockholders (the &#147;Annual Meeting&#148;) to be held on December 16, 2020 and at any adjournment or postponement thereof. Pursuant to rules adopted by the SEC, we are using the Internet as the primary means of
furnishing proxy materials to our stockholders. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) to our stockholders. The Notice contains instructions on how to access the proxy materials and
vote your shares of common stock over the Internet. The Notice also contains instructions on how to request a printed copy of the proxy materials. In addition, stockholders may request to receive proxy materials in printed form by mail or
electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of the proxy materials on the Internet to help reduce the environmental impact of our annual meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Date, Time and Place and Voting Instructions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Annual Meeting will be conducted completely virtually via live webcast. Stockholders will be able to attend the annual meeting remotely,
vote and submit questions prior to and during the annual meeting by visiting <B><U>www.meetingcenter.io/291997584</U> </B>and using the password MEIP2020 and entering their control number. We are pleased to utilize virtual stockholder meeting
technology to promote social distancing pursuant to guidance provided by the CDC and the SEC due to the novel coronavirus <FONT STYLE="white-space:nowrap">(COVID-19).</FONT> The virtual meeting format allows attendance from any location in the
world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders are entitled to participate in the Annual Meeting only if they were stockholders of the Company as of the close of
business on the Record Date, or if they hold a valid proxy for the Annual Meeting. Stockholders will be able to attend the Annual Meeting online and submit questions prior to and during the meeting by visiting
<B><U>www.meetingcenter.io/291997584</U></B>. Stockholders also will be able to vote their shares online by attending the Annual Meeting by webcast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To participate in the Annual Meeting, stockholders will need to review the information included on their Notice, on their proxy card or on the
instructions that accompanied the proxy materials. The password for the meeting is MEIP2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a stockholder holds shares through an
intermediary, such as a bank or broker, they must register in advance using the instructions below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The online meeting will begin
promptly at 9 a.m., Pacific Time. We encourage stockholders to access the meeting prior to the start time leaving ample time for the check in. Please follow the registration instructions as outlined in this proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Registered stockholders (i.e., whose shares are held through our transfer agent, Computershare), do not need to register to attend the Annual
Meeting virtually on the Internet. Please follow the instructions on the notice or proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If shares are held through an
intermediary, such as a bank or broker, stockholders must register in advance to attend the Annual Meeting virtually on the Internet. To register to attend the Annual Meeting online by webcast, stockholders must submit proof of their proxy power
(legal proxy) reflecting their MEI Pharma holdings along with their name and email address to Computershare. Requests for registration must be labeled as &#147;Legal Proxy&#148; and be received no later than 5:00 p.m., Eastern Time, on
December&nbsp;11, 2020. Stockholders will receive a confirmation of their registration by email after we receive your registration materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Requests for registration should be directed to us at the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><U>By&nbsp;email</U>:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Forward the email from your broker, or attach an image of your legal proxy, to legalproxy@computershare.com
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="top" ALIGN="left"><U>By&nbsp;mail</U>:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Computershare </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">MEI Pharma Legal Proxy </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">P.O. Box 43001 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="11%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Providence, RI 02940-3001 </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purposes of the MEI Pharma Annual Meeting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purposes of the Annual Meeting are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect three directors to the Board of Directors, each to serve until the annual meeting of stockholders in
fiscal year 2024 and until their successors are elected and qualified or until their earlier resignation or removal; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan (the &#147;2008
Equity Plan&#148;) to increase the number of shares of common stock that may be subject to award and make certain other changes to the plan terms included in the plan document attached as Annex A; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers as disclosed
in this proxy statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To ratify the appointment of BDO USA, LLP as MEI Pharma&#146;s independent registered public accounting firm
for the fiscal year ending June 30, 2021; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To conduct such other business as may properly come before the Annual Meeting or any adjournment, postponement
or continuation thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Record Date; Shares of Common Stock Outstanding and Entitled to Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have fixed the close of business on October 20, 2020 as the record date for determination of the holders of our common stock entitled to
notice of and to attend and vote at the Annual Meeting or any adjournment or postponement thereof. There were approximately 649 holders of record of our common stock at the close of business on the record date. At the close of business on the record
date, 112,521,964 shares of our common stock were issued and outstanding. Each share of common stock entitles the holder thereof to one vote at the Annual Meeting on all matters properly presented at the Annual Meeting. See the section titled,
&#147;Security Ownership of Certain Beneficial Owners and Management of MEI Pharma&#148; in this proxy statement for information regarding persons known to our management to be the beneficial owners of more than 5% of the outstanding shares of our
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting and Revocation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proxy accompanying this proxy statement is solicited on behalf of the Board of Directors of MEI Pharma for use at the Annual Meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record of MEI Pharma as of the record date referred to above, you may vote via the Internet during the Annual
Meeting or, prior to the Annual Meeting, via the Internet by following the instructions provided in the Notice, via telephone by calling the <FONT STYLE="white-space:nowrap">toll-free</FONT> number found on the proxy card, or vote by proxy using the
enclosed proxy card. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the meeting: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote on the Internet, go to the website indicated on the Notice to complete an electronic proxy card. You will
be asked to provide MEI Pharma&#146;s number and a control number from the enclosed proxy card. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote over the telephone, dial the toll-free number on your proxy card or voting instruction form using a
touch-tone phone and follow the recorded instructions. You will be asked to provide MEI Pharma&#146;s number and control number from the enclosed proxy card. Your vote must be received by 1:00 a.m. (Pacific Time) on December 16, 2020 to be counted.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To vote using the proxy card, simply mark, sign and date your proxy card and return it promptly in the
postage-paid envelope provided. If we receive your signed proxy card before the Annual Meeting, we will vote your shares as you direct. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker as your nominee (that is, in &#147;street name&#148;), you will need to obtain a proxy card from the
institution that holds your shares and follow the instructions included on that proxy card regarding how to instruct your broker to vote your MEI Pharma shares. If you do not give instructions to your broker, your broker can vote your MEI Pharma
shares with respect to &#147;discretionary&#148; items but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-discretionary&#148;</FONT> items. The proposals relating to the election of directors (Proposal No.&nbsp;1), the approval of
the Amended and Restated 2008 Equity Plan (Proposal No.&nbsp;2) and the approval, on an advisory basis, of the compensation of the Company&#146;s named executive officers (Proposal No.&nbsp;3) are
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> items. On <FONT STYLE="white-space:nowrap">non-discretionary</FONT> items, for which you do not give your broker instructions, your broker will not vote your shares and, accordingly, the
shares will be treated as broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All properly executed proxies that are not revoked
will be voted at the Annual Meeting and at any adjournments or postponements of the Annual Meeting in accordance with the instructions contained in the proxy. If a holder of our common stock executes and returns a proxy and does not specify
otherwise, the shares represented by that proxy will be voted &#147;FOR&#148; Proposal No.&nbsp;1 electing the three nominees to our Board of Directors; &#147;FOR&#148; Proposal No.&nbsp;2 to approve the adoption of the 2008 Equity Plan to increase
the number of shares of common stock that may be subject to awards and make certain other changes to the plan terms included in the plan document attached as Annex A; &#147;FOR&#148; Proposal No.&nbsp;3 to approve, on an advisory basis, the
compensation paid to MEI Pharma&#146;s named executive officers; and &#147;FOR&#148; Proposal No.&nbsp;4 ratifying the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stockholders of record may change their votes at any time before their proxy is voted at the Annual Meeting in one of three ways. First, a
stockholder of record can send a written notice to the Secretary of MEI Pharma stating that the stockholder would like to revoke its proxy. Second, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder of record can submit new proxy instructions either on a new proxy card, by telephone or via the Internet. Third, a stockholder of record can attend the Annual Meeting and vote via the
Internet. Attendance alone will not revoke a proxy. If a stockholder of record has instructed a broker to vote its shares of common stock, the stockholder must follow directions received from its broker to change those instructions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quorum and Vote of MEI Pharma Stockholders Required </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. The presence, in person or by proxy, of the holders of <FONT
STYLE="white-space:nowrap">one-third</FONT> of the shares of the common stock issued and outstanding and entitled to vote at the Annual Meeting will constitute a quorum. If a quorum is not present at the Annual Meeting, we expect that the meeting
would be adjourned or postponed to solicit additional proxies. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Proposal No.&nbsp;1, the affirmative vote of a plurality of the votes cast is required to elect a director when a quorum is present.
&#147;Votes cast&#148; excludes abstentions and any broker <FONT STYLE="white-space:nowrap">non-votes.</FONT> Accordingly, abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> (shares held by brokers that do not have
discretionary authority to vote on the matter and have not received voting instructions from their clients) will have no effect on the election of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Proposals No.&nbsp;2, 3 and 4, the affirmative vote of the holders of a majority of the shares represented in person or by proxy and
entitled to vote on the proposal will be required for approval. An abstention with respect to these proposals will be deemed present, but will not be voted. Accordingly, an abstention will have the effect of a vote &#147;against&#148; the proposal.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> on a proposal will have no effect on determining whether stockholders have approved the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the record date for the Annual Meeting, the directors and executive officers of MEI Pharma owned less than 1% of the outstanding shares of
MEI Pharma common stock entitled to vote at the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Solicitation of Proxies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to solicitation by mail, our directors, officers, employees and agents may solicit proxies from our stockholders by personal
interview, telephone, telegram or otherwise. Arrangements will also be made with brokerage firms and other custodians, nominees and fiduciaries who are record holders of our common stock for the forwarding of solicitation materials to the beneficial
owners of our common stock. We will pay the cost of soliciting proxies, including reimbursing applicable brokers, custodians, nominees and fiduciaries for the reasonable
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses they incur in connection with the forwarding of solicitation materials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_2"></A>ELECTION OF DIRECTORS (PROPOSAL NO. 1) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has nominated Dr.&nbsp;Kevan&nbsp;E. Clemens, Dr.&nbsp;Daniel&nbsp;P. Gold and Ms.&nbsp;Tamar&nbsp;D. Howson to serve
as directors for a term expiring at the annual meeting of stockholders to be held in fiscal 2024 and until their successors have been elected and qualified. Each of the nominees has consented to be named herein and to serve if elected. We do not
know of anything that would preclude any of the nominees from serving if elected. If any of the nominees become unable to stand for election as a director at the Annual Meeting as a result of an event not anticipated by the Board of Directors, the
proxy may be voted for a substitute designated by the Board of Directors. The identity and a brief biography of each nominee is set forth below. The Board of Directors has determined that Dr.&nbsp;Kevan&nbsp;E. Clemens and Ms.&nbsp;Tamar&nbsp;D.
Howson are independent directors within the meaning of the listing standards of the NASDAQ Capital Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that the authorized number of directors shall be determined by a resolution of the Board of Directors, but shall be between two and nine.
The number of directors currently authorized by the Board of Directors is nine. Under our amended and restated certificate of incorporation and amended and restated bylaws, our Board of Directors is divided into three classes, with the classes
serving <FONT STYLE="white-space:nowrap">three-year</FONT> staggered terms. Each class contains, as near as possible, <FONT STYLE="white-space:nowrap">one-third</FONT> of the whole number of directors, with members of each class holding office for a
three-year term. There are currently three directors whose terms expire at the annual meeting to be held in fiscal 2022, three directors whose terms expire at the annual meeting to be held in fiscal 2023 and three directors whose terms expire at the
Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kevan&nbsp;E. Clemens, Dr.&nbsp;Daniel&nbsp;P. Gold and Ms.&nbsp;Tamar&nbsp;D. Howson are members of the class
of directors whose terms expire at the Annual Meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Experience of Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Kevan E. Clemens, Ph.D., age 76, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Clemens has been a director of MEI Pharma since December 2014. He has a long and distinguished career in the pharmaceutical industry,
highlighted by 25 years at Labratorios Syntex SA and <FONT STYLE="white-space:nowrap">Hoffman-La</FONT> Roche in a number of development, sales and marketing positions. As Executive Vice President, Business Director at Roche, he was responsible for
the blockbuster Global Oncology franchise, including its strategic plans, development and marketing. Prior to that, he was Vice President, Global Head of Specialty Care, Vice President, Global Head of Project Management and Vice President, Global
Head of Clinical Operations for North and South America. Dr.&nbsp;Clemens served on the board of directors of Chelsea Therapeutics International from 2004 until its acquisition by H. Lundbeck A/S in June 2014. He also served on the board of
directors of Kosan Biosciences from 2005 to 2008. Dr.&nbsp;Clemens obtained his Ph.D. in Chemistry from the University College London. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Daniel P. Gold, Ph.D., age 66, President, Chief Executive Officer and Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gold was appointed President and Chief Executive Officer in April 2010. He joined the Company with approximately 25 years of drug
discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a <FONT STYLE="white-space:nowrap">mid-stage</FONT> oncology company. Prior to his tenure at Prospect, Dr.&nbsp;Gold was founder
and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the company&#146;s lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds
for Cancer Research. Dr.&nbsp;Gold&#146;s academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He
holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor&#146;s degree in Biology from the University of California Los Angeles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tamar D. Howson, age 72, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Howson was appointed a director in July 2019. She is a highly experienced business development executive and consultant with more than
30 years of service in the pharmaceutical and biotechnology industries. Ms.&nbsp;Howson currently serves on the board of directors of Immunic Pharma and Cue Pharma. Between 2009 to 2019 she served on the boards of various other life sciences
companies including Actavis plc, Aradigm Corporation, ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec PLC, Idenix Pharmaceuticals Inc., Organovo Holdings Inc, OXiGENE, Inc., and Scientus Pharma, a private company. From 2009 to
2011, Ms.&nbsp;Howson served as a member of the transaction advisory firm JSB-Partners, providing business development support to life sciences companies. From 2007 to 2008, Ms.&nbsp;Howson served as Executive Vice President, Corporate Business
Development at Lexicon Pharmaceuticals, a public biotech company. Prior to joining Lexicon, Ms.&nbsp;Howson served as Senior Vice President, Corporate and Business Development at Bristol-Myers Squibb and SmithKline Beecham plc. Ms.&nbsp;Howson holds
an M.B.A from Columbia University, a M.S. from City University of New York, and a B.S. in Chemical Engineering from the Technion, Israel. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTE REQUIRED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming a
quorum is met, a nominee for director must receive a plurality of the votes cast by holders of the shares of common stock represented in person or by proxy at the Annual Meeting to be elected as a director. Votes may be cast in favor or withheld.
Votes that are withheld and broker non-votes, if any, will be counted for purposes of determining the presence or absence of a quorum, but will have no effect on the election of the director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE &#147;FOR&#148; THE ELECTION
OF KEVAN E. CLEMENS, Ph.D., DANIEL P. GOLD, Ph.D. AND TAMAR D. HOWSON AS DIRECTORS OF MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_3"></A>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_4"></A>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set
forth below are the names and certain biographical information regarding our directors who are not being considered for re-election at the Annual Meeting. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Positions Held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Expiration of Term</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles V. Baltic III</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal 2022 Annual Meeting of Stockholders</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas R. Glover, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal 2022 Annual Meeting of Stockholders</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederick W. Driscoll</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fiscal 2022 Annual Meeting of Stockholders</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cheryl L. Cohen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal 2023 Annual Meeting of Stockholders</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas C. Reynolds, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal 2023 Annual Meeting of Stockholders</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine A. White, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fiscal 2023 Annual Meeting of Stockholders</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Charles V. Baltic III, age 59, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Baltic has been a director of MEI Pharma since October 2011. Mr.&nbsp;Baltic has been affiliated with Needham&nbsp;&amp; Company, LLC
since 2009, as Managing Director and <FONT STYLE="white-space:nowrap">Co-Head</FONT> of Healthcare until 2019 and as Senior Advisor since 2019. Mr.&nbsp;Baltic also is an Executive Vice President and Chief Operating Officer of SIDIS Corp., a life
sciences management and investment company, since 2019. Mr.&nbsp;Baltic was a Managing Director and head of the biotechnology practice at CRT Capital Group from 2006 to 2008. From 2001 to 2006, he served as a Managing Director in Healthcare
Investment Banking at Wachovia Securities. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director in Healthcare Investment Banking. Prior to beginning his investment banking
career in 1996, Mr.&nbsp;Baltic practiced corporate and securities law with the firm of Dewey Ballantine, representing numerous healthcare and securities clients. Mr.&nbsp;Baltic served as a Director of SIDIS Corp. from 2013 to 2019. Mr.&nbsp;Baltic
was also a Director of the <FONT STYLE="white-space:nowrap">non-profit</FONT> trade association Life Science Washington (formerly the Washington Biotechnology and Biomedical Association), serving from 2013 to 2018, and a member of the U.S.
Securities and Exchange Commission&#146;s Advisory Committee on Small and Emerging Growth Companies, serving from 2013 to 2015, and a Director of MedVantage Inc., which was ultimately acquired by IMS Health in 2011. Mr.&nbsp;Baltic was a founding
Trustee of the <FONT STYLE="white-space:nowrap">non-profit</FONT> Hope Funds for Cancer Research, serving from 2007 to 2017 in that capacity, and remains on the Council of Advisors. Mr.&nbsp;Baltic earned his B.A and J.D. degrees from Georgetown
University and M.B.A. degree in Finance from the Wharton School of the University of Pennsylvania. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Nicholas R. Glover, Ph.D., age
51, Director </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Glover has been a director of MEI Pharma since June 2013. He served as President and Chief Executive Officer
of Sierra Oncology (NASDAQ: SRRA), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive
Officer of YM Biosciences&#146;, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences in February 2013. Previously, Dr.&nbsp;Glover was President and Chief Executive Officer of Viventia Biotech, a
biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm.
Dr.&nbsp;Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Frederick W. Driscoll, age 70, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Driscoll has been a director of MEI Pharma since February 2018. He currently serves on the board of directors of Cue Biopharma,
Cellectar Biosciences, Inc., NantKwest, Inc. and SmartPharm Therapeutics. He served as the chief financial officer of Flexion Therapeutics, Inc. from 2013 to 2017. Prior to joining Flexion, he was the chief financial officer at Novavax, Inc. from
2009 to 2013. From 2008 to 2009, Mr.&nbsp;Driscoll served as the chief executive officer at Genelabs Technologies, Inc. and from 2007 to 2008 he served as the company&#146;s chief financial officer. He was also the chief executive officer of
OXiGENE, Inc. from 2000 to 2006. Mr.&nbsp;Driscoll also served as the chairman of the board and audit committee chair at OXiGENE and as a member of the audit committee for Cynapsus Therapeutics, Inc. Mr.&nbsp;Driscoll earned a bachelor&#146;s degree
in accounting and finance from Bentley University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cheryl L. Cohen, age 54, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Cohen has been a director of MEI Pharma since April 2020. She has been President of CLC Consulting, a pharmaceutical and biotechnology
consulting firm which she incorporated in 2008, that specializes in new product <FONT STYLE="white-space:nowrap">start-ups</FONT> and commercialization. Most recently, Ms.&nbsp;Cohen served as Chief Commercial Officer of Medivation, Inc. where she
built the company&#146;s commercial organization and lead her team to successfully launch the blockbuster oncology drug, Xtandi<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. In 2016, Medivation was acquired by Pfizer Inc. for
$14&nbsp;billion. Prior to joining Medivation, Ms.&nbsp;Cohen spent over 10 years at Johnson&nbsp;&amp; Johnson &#150; most notably as Vice President of the Rheumatology Franchise. In this role, Ms.&nbsp;Cohen was responsible for over
$2&nbsp;billion in annual sales and led multiple commercial entities including marketing, sales, and life cycle management. From June 1998 through November 2007, Ms.&nbsp;Cohen oversaw multiple launches of Remicade<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> in several indications across a variety of specialties including Gastroenterology and Rheumatology. Ms.&nbsp;Cohen began her career at Solvay Pharmaceuticals in management and sales.
Ms.&nbsp;Cohen currently serves on the board of directors of Aerpio Pharmaceuticals and NantKwest, both of which are publicly traded companies. She earned a B. A. degree from Saint Joseph College. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Thomas C. Reynolds, M.D., Ph.D., age 61, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Reynolds has been a director of MEI Pharma since February 2013. He has been President of Two Paddles Consulting LLC since December
2013, providing consulting services to biotechnology companies. Dr.&nbsp;Reynolds currently serves as an independent director of Trillium Therapeutics Inc. (NASDAQ: TRIL; TSX: TR), an immuno-oncology company, since March 2014. Previously, he served
as Chief Medical Officer of Seattle Genetics from March 2007 until his retirement in February 2013. While at Seattle Genetics, he was responsible for building and leading an integrated clinical development, regulatory and medical affairs
organization, highlighted by the development and approval of ADCETRIS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. From 2002 to 2007, Dr.&nbsp;Reynolds served at ZymoGenetics (acquired by Bristol-Myers Squibb in 2010), most recently as
Vice President, Medical Affairs, where he oversaw the clinical development and regulatory filing of RECOTHROM<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Previously, he was Vice President, Clinical Affairs at Targeted Genetics, and
before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr.&nbsp;Reynolds received his M.D. and Ph.D. in biophysics from Stanford University and a B.A. in chemistry from Dartmouth College. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Christine A. White, M.D., age 68, Director </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;White has been a director of MEI Pharma since August 2010. She served as Lead Director from January 2013 until she was appointed Chair
of the Board in December 2015. She was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played an integral role in the development and commercialization of Rituxan<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Zevalin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Previously, she served as the Director of Clinical Oncology Research and Chair of the Department of Medicine at Scripps
Memorial Hospitals in La Jolla and Encinitas, California. Dr.&nbsp;White served as a member of the board of directors of Arena Pharmaceuticals from 2006 to 2018. She previously served as a member of the board of directors at Genoptix Medical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Laboratory, Monogram Biosciences and Pharmacyclics Inc. Dr.&nbsp;White earned her B.A. in Biology and her M.D. from the University of Chicago and is Board certified in both Internal Medicine and
Medical Oncology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_5"></A>Information about the Board of Directors and its Committees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has responsibility for the overall corporate governance of MEI Pharma. During the fiscal year ended June&nbsp;30, 2020,
a majority of the members of the Board of Directors were, and as of the date of this report are, independent within the meaning of the NASDAQ Stock Market (&#147;NASDAQ&#148;) rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has established an Audit Committee to oversee the Company&#146;s financial matters, a Compensation Committee to oversee the
Company&#146;s compensation policies, plans and programs and a Nominating and Governance Committee to assist the Board of Directors in nominating board members to be elected by the stockholders at the Annual Meeting, to fill vacancies and newly
created directorships, and to evaluate and monitor all matters with respect to governance of the Company and oversee compliance by the Company with its legal and regulatory obligations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Schedule of Committee Members </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Board Member</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Audit Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Compensation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Committee</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nominating&nbsp;&amp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Governance&nbsp;Committee</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Charles V. Baltic, III</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g17046g1017042552129.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kevan E. Clemens</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g17046g1017042552129.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Cheryl L. Cohen</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Frederick W. Driscoll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042552129.jpg" ALT="LOGO">



<IMG SRC="g17046g1017042552487.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Nicholas R. Glover</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Tamar D. Howson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Thomas C. Reynolds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Christine A. White</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042551988.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">=</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Member</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042552129.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">=</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Committee Chair</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g17046g1017042552487.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">=</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial Expert</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_6"></A>Audit Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors has been established in accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act
of 1934, as amended (the &#147;Exchange Act&#148;). The Audit Committee&#146;s responsibilities include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing financial and accounting activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">selecting and recommending the annual appointment of independent auditors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the scope of audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> assignments and
related fees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing annually the Company&#146;s major financial risks and exposures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the independence and performance of the independent auditors: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the accounting principles used in financial reporting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and assessing our financial reporting activities and disclosures included in our periodic reports and
the accounting standards and principles followed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing the adequacy and effectiveness of our internal control over financial reporting; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving related party transactions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Driscoll has served as Chairman of the Audit Committee since August&nbsp;29, 2019. The other members of the Audit Committee are
Mr.&nbsp;Baltic, Ms.&nbsp;Cohen (beginning on June&nbsp;17, 2020) and Dr.&nbsp;Glover. Mr.&nbsp;William Rueckert, a former member of the Board of Directors, served on the Audit Committee until his retirement from the Board of Directors in December
2019. Mr.&nbsp;Driscoll has been determined by the Board of Directors to be an &#147;audit committee financial expert&#148; as defined by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined that each of the Audit Committee members is independent, as defined by applicable NASDAQ and SEC
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rules. The Company has adopted an Audit Committee Charter, which is posted on its website at <B><U>www.meipharma.com</U></B>. The Audit Committee met four times during the fiscal year ended
June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_7"></A>Compensation Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee acts on behalf of the Board to fulfill the Board&#146;s responsibilities to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">oversee, review, modify and approve our compensation strategy and policies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assess the independence of compensation consultants and legal advisors prior to engagement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise sole power to retain compensation consultants and advisors and to determine the scope of the associated
engagements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and approve annual corporate performance goals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the chief executive officer&#146;s and executive officers&#146; performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and determine the compensation to be paid to our executive officers, including the allocation of equity
related grants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommend the compensation and terms of appointment of <FONT STYLE="white-space:nowrap">non-executive</FONT>
directors to the Board of Directors for review and approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure the Company meets the reporting requirements promulgated by the SEC regarding compensation and disclosure
of compensation and compensation related practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assess potential compensation related risks; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate and ensure compliance with &#147;Say-on-Pay&#148; requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee also consults with and considers the recommendations of the chief executive officer with respect to the appropriate
level and mix of the various compensation components, focused primarily on the particular goals of applicable executives and employees in a particular year. The Board of Directors has adopted a written charter for the Compensation Committee, which
is available on our website at <B><U>www.meipharma.com</U></B>. Dr.&nbsp;Clemens has served as the Chairman of the Compensation Committee since August&nbsp;1, 2016. The other members of the Compensation Committee are Dr.&nbsp;Glover, Ms.&nbsp;Howson
(beginning on December&nbsp;5, 2019) and Dr.&nbsp;Reynolds. Mr.&nbsp;William Rueckert, a former member of the Board of Directors, served on the Compensation Committee until his retirement from the Board of Directors in December 2019. The Board of
Directors has determined that each member of the Compensation Committee is independent as defined by applicable NASDAQ rules. The Compensation Committee met three times during the fiscal year ended June&nbsp;30, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_8"></A>Nominating and Governance Committee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Governance Committee is responsible for assisting the Board of Directors in: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying qualified individuals who possess the desired experience and skills to serve on the Board;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">proposing chairpersons and members on committees to the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">considering all qualified director candidates identified by the Nominating and Governance Committee, or by
stockholders, in the event any member of the Board of Directors does not wish to continue in service or if the Board of Directors decides not to <FONT STYLE="white-space:nowrap">re-nominate</FONT> a member for
<FONT STYLE="white-space:nowrap">re-election;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overseeing the Board evaluation process and evaluating the size and composition of the Board; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating any stockholder proposal and whether to recommend to the Board of Directors and whether the Company
shall support or oppose the proposal. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Baltic has served as Chairman of the Nominating and Governance Committee
since September 2012. The other members of the Nominating Committee are Ms.&nbsp;Howson (beginning on June&nbsp;17, 2020), Dr.&nbsp;Reynolds and Dr.&nbsp;White. MEI Pharma&#146;s Nominating and Governance Committee Charter is posted on its website
at <B><U>www.m</U></B><B><U>e</U></B><B><U>iph</U></B><B><U>a</U></B><B><U>rma</U></B><B><U>.</U></B><B><U>co</U></B><B><U>m</U></B>. The Board of Directors has determined that each of the Nominating and Corporate Governance Committee members is
independent, as defined by applicable NASDAQ and SEC rules. The Nominating and Governance Committee met five times during the fiscal year ended June 30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who would like to propose an independent director candidate for consideration for nomination by the Board of Directors at next
year&#146;s annual meeting of stockholders may do so by submitting the candidate&#146;s name, resume and biographical information to the attention of Brian G. Drazba, Secretary, MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego,
California 92130. All stockholder nominations received by the Secretary, which comply with the advance notice provisions of the Company&#146;s Amended and Restated Bylaws, will be presented to the Nominating and Governance Committee for the same
consideration as individuals identified by the Nominating and Governance Committee through other means. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Governance
Committee reviews the prospective candidate&#146;s biographical information and assesses each candidate&#146;s independence, diversity, skills and expertise based on a variety of factors, including the following criteria: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the candidate has exhibited behavior that indicates he or she is committed to the highest ethical
standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the candidate has had broad business, governmental, <FONT STYLE="white-space:nowrap">non-profit</FONT> or
professional experience that indicates that the candidate will be able to make a significant and immediate contribution to the Board of Directors&#146; discussion and decision-making; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the candidate will be able to devote sufficient time and energy to the performance of his or her duties
as a director. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application of these factors requires the exercise of judgment by members of the Nominating and
Governance Committee when the Committee makes recommendations to the Board of Directors, and cannot be measured in a quantitative way. In addition, the Nominating and Governance Committee considers, as one factor among many, the diversity of Board
candidates, which may include diversity of skills and experience as well as geographic, gender, age, and ethnic diversity. The Nominating and Governance Committee does not, however, have a formal policy with regard to the consideration of diversity
in identifying Board candidates. The Nominating and Governance Committee and the Board of Directors generally value the broad business experience and independent business judgment in the health care, life sciences and other fields of each member.
Specifically, Dr.&nbsp;White is qualified for the Board based on her business and medical experience in the healthcare field, including oncology research. Mr.&nbsp;Baltic is qualified for the Board based on his business experience in the health care
investment banking industry. Dr.&nbsp;Clemens is qualified for the Board based on his business and pharmaceutical industry experience in the areas of commercialization, strategic marketing, business development and drug development in oncology.
Ms.&nbsp;Cohen is qualified for the Board based on her business and pharmaceutical industry experience in the areas of commercialization, strategic marketing, business development and drug development in oncology. Mr.&nbsp;Driscoll is qualified for
the Board based on his business experience in the pharmaceutical industry in the area of finance and his status as an &#147;audit committee expert&#148;. Dr.&nbsp;Glover is qualified for the Board based on his business experience and his drug
development experience in the oncology field. Ms.&nbsp;Howson is qualified for the Board based on her business experience in the pharmaceutical industry in the area of business development. Dr.&nbsp;Reynolds is qualified for the Board based on his
medical experience and experience in clinical development and regulatory and medical affairs. Dr.&nbsp;Gold is qualified for the Board based on his experience as the Company&#146;s chief executive officer and other experience in clinical development
and the pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Nominating and Governance Committee oversees compliance by the Company with its legal
and regulatory obligations and periodically reviews: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s Code of Business Conduct and Ethics; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s Insider Trading Policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s Corporate Disclosure Policy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s restated certificate of incorporation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company&#146;s amended and restated bylaws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the independent status of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_9"></A>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors has determined the independence of each director in accordance with the elements of independence set forth in the NASDAQ
listing standards. Based upon information solicited from each director, the Board of Directors has determined that each of Dr.&nbsp;White, Mr.&nbsp;Baltic, Dr.&nbsp;Clemens, Ms.&nbsp;Cohen, Mr.&nbsp;Driscoll, Dr.&nbsp;Glover, Ms.&nbsp;Howson and
Dr.&nbsp;Reynolds has no material relationship with MEI Pharma and is &#147;independent&#148; within the meaning of NASDAQ&#146;s director independence standards as currently in effect. In making the foregoing determinations, the Board of Directors
has considered both the objective tests set forth in the NASDAQ independence standards and subjective measures with respect to each director necessary to determine that no relationships exist that would interfere with the exercise of independent
judgment by each such director in carrying out responsibilities of a director. Dr.&nbsp;Gold, as President and Chief Executive Officer, is not considered independent in accordance with NASDAQ&#146;s requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_10"></A>Board Leadership Structure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Previously, the Board of Directors created the position of Lead Director to carry out the duties of the Chair until the Nominating and
Governance Committee identified, and the Board appointed, a director to the Chair position. In December 2015, the Board of Directors eliminated the Lead Director position and elected Dr.&nbsp;White to the position of Chair of the Board.
Dr.&nbsp;White previously held the position of Lead Director since March 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors does not have a policy addressing
whether the same person should serve as both the Chief Executive Officer and Chair of the Board or if the roles should be separate. Our Board believes that it should have the flexibility to make its determination based upon what it considers to be
the appropriate leadership structure for the Company at the time. The Board believes that its current leadership structure, with Dr.&nbsp;Gold serving as President and Chief Executive Officer and Dr.&nbsp;White serving as Chair of the Board is
appropriate for the Company at this time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_11"></A>Board Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk is an integral part of the Board and Committee deliberations throughout the year. While the Board has the ultimate oversight
responsibility for the risk management process, various committees of the Board also have responsibility for risk management. In particular, the Audit Committee focuses on financial risk, including internal controls, and receives financial risk
assessment reports from management. Risks related to the compensation programs are reviewed by the Compensation Committee. The Nominating and Governance Committee exercises oversight of governance risks, including succession planning and legal
compliance. The Board is advised by these committees of significant risks and management&#146;s response through periodic updates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_12">
</A>Anti-Hedging and Pledging Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Insider Trading Policy, all directors, officers, employees and consultants of the
Company are subject to restrictions on hedging of securities of the Company. These restrictions apply to securities of the Company owned by such persons, regardless of whether such securities were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
granted by the Company to such persons as compensatory awards. Our Insider Trading Policy prohibits such persons from engaging in short sales of securities of the Company or in transactions in
publicly traded options with respect to securities of the Company. In addition, our Insider Trading Policy permits, but discourages, such persons from holding securities of the Company in a margin account or pledging securities of the Company as
collateral for a loan and from entering standing orders with respect to securities of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_13"></A>Stockholder
Communications with the Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s stockholders may communicate with the Board of Directors, including <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors or officers, by sending written communications addressed to such person or persons in care of MEI Pharma, Inc., Attention: Secretary, 11455 El Camino Real, Suite 250, San Diego, California,
92130. All communications will be compiled by the Secretary and submitted to the addressee. If the Board of Directors modifies this process, the revised process will be posted on the Company&#146;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_14"></A>Appointment of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s amended and restated certificate of incorporation and amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT>
provide that the number of directors will be set by resolution of the board, but shall be between two and nine. The Company currently has nine directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Company&#146;s amended and restated certificate of incorporation and amended and restated
<FONT STYLE="white-space:nowrap">by-laws,</FONT> directors are to be elected at each annual meeting of stockholders for a term of three years unless the director is removed, retires or the office is vacated earlier. The board is divided into three
classes with respect to the term of office, with the terms of office of one class expiring each successive year. This classified board provision could discourage a third party from making a tender offer for the Company&#146;s shares or attempting to
obtain control of MEI Pharma. It could also delay stockholders who do not agree with the policies of the Board of Directors from removing a majority of the Board of Directors for two years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A director may resign at any time. The resignation is effective upon receipt of notice. Any or all directors may be removed with or without
cause by a resolution of stockholders entitled to vote to elect directors. Vacancies from resignation or removal or expansion of the size of the board may be filled by resolution of a majority of directors then in office or by a sole remaining
director, and any director so appointed shall serve for the remainder of the full term of the class of directors in which the vacancy occurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_15">
</A>Attendance of Directors at Board Meetings and Shareholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended June&nbsp;30, 2020, the Board of
Directors held a total of six meetings, and each director attended at least 75% of the total number of meetings of the Board of Directors and of the meetings of each committee of the Board of Directors on which such director served. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All directors are expected to attend the Company&#146;s annual meetings of stockholders. All directors then in office attended the annual
meeting of stockholders held in December 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_16"></A>Code of Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has adopted a Code of Business Conduct and Ethics that applies to the Company&#146;s directors and employees and the Company has
posted the text of the policy on its website at <U>www</U><U>.</U><U>meipharma.com.</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_17"></A>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s executive officers are appointed by and serve at the discretion of the Board of Directors. Set forth below are the names and
certain biographical information regarding MEI Pharma&#146;s executive officers as of June 30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Daniel P. Gold Ph.D., age 66,
President and Chief Executive Officer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Directors&#148; above for biographical information regarding Dr.&nbsp;Gold. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Brian G. Drazba, age 59, Chief Financial Officer and Secretary </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Drazba has been Chief Financial Officer since April 2017. Mr.&nbsp;Drazba has more than 25 years of financial management experience in
the healthcare industry. Previously, he served as Vice President of Finance and Chief Financial Officer of Heron Therapeutics, Inc., a <FONT STYLE="white-space:nowrap">commercial-stage</FONT> biotechnology company, from October 2013 to March 2017.
From 2009 to 2012, he was Vice President of Finance and Chief Accounting Officer for ISTA Pharmaceuticals, a commercial-stage pharmaceutical company. ISTA Pharmaceuticals was acquired by Bausch + Lomb in June 2012. From 1992 to 2009, Mr.&nbsp;Drazba
held various positions of increasing responsibility within Insight Health Corp., most recently as Senior Vice President and Chief Accounting Officer. He began his career at Arthur Andersen&nbsp;&amp; Co., a public accounting firm. Mr.&nbsp;Drazba is
a licensed Certified Public Accountant (inactive) in California and earned a B.A. degree in Accounting from the University of San Diego. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Robert D. Mass, M.D., age 66, Chief Medical Officer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mass has been Chief Medical Officer since June 2011. Dr.&nbsp;Mass has more than 20 years of experience as a medical oncologist in
both clinical practice and clinical drug development. He held a number of leadership positions at Genentech from 1998 to 2009, most recently as Head of Medical Affairs, BioOncology, a position created to strategically integrate and optimize all of
the non-sponsored clinical programs within the company&#146;s oncology portfolio. He also served on the Executive Development Review Committee at Genentech, which was responsible for the review and approval
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of all sponsored clinical programs across the company&#146;s therapeutic portfolio. Previously he served as clinical science leader for
Herceptin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from 1999 to 2002, Tarceva<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> from 2002 to 2003, and Avastin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>,
currently the leading oncology therapeutic worldwide, from 2003 to 2007. Prior to joining Genentech, he practiced Hematology and Medical Oncology from 1988 to 1998. Dr.&nbsp;Mass earned his bachelor&#146;s degree in Economics from Tufts University
and his medical degree from Oregon Health&nbsp;&amp; Science University. He is certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>David M. Urso, age 56, Chief Operating Officer&nbsp;&amp; General Counsel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Urso has been Chief Operating Officer and General Counsel since July 2018. Prior to July 2018, Mr.&nbsp;Urso had been the
Company&#146;s Senior Vice President of Corporate Development and General Counsel since March 2014. Mr.&nbsp;Urso joined MEI Pharma with more than two decades of experience in the life science industry, most recently as Chief Operating Officer and
General Counsel at Tioga Pharmaceuticals, a privately held drug development company he <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2005. Previously, he was a Principal at Forward Ventures, where he was responsible for identifying and
developing life science venture capital investments. Prior to joining Forward Ventures in 2002, Mr.&nbsp;Urso was Director of Corporate Development and Legal Affairs at DNA Sciences, Inc. Previously, he worked as an attorney in the corporate
securities and licensing groups at Wilson Sonsini Goodrich&nbsp;&amp; Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School. Mr.&nbsp;Urso received
a J.D. from Harvard Law School and a B.A. in Molecular Biology and Philosophy from Reed College. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_18"></A>APPROVAL OF AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(PROPOSAL NO. 2) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEI
Pharma&#146;s Amended and Restated 2008 Stock Omnibus Equity Compensation Plan, which we refer to as the &#147;2008 Equity Plan,&#148; was initially adopted in 2008 as the &#147;MEI Pharma, Inc. 2008 Stock Omnibus Equity Compensation Plan.&#148; The
MEI Pharma Board of Directors believes having stock available for grant to be a significant contributing factor to the continued success of MEI Pharma, by enabling the Company to attract, motivate and retain directors, officers, employees and
advisors who are expected to contribute to its success and achieve its corporate goals, which the Company believes will benefit its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the approval by our stockholders at the Annual Meeting, the MEI Pharma Board of Directors has amended and restated the 2008
Equity Plan (the &#147;Amended Plan&#148;), subject to the approval of our stockholders, to increase the number of shares of our common stock authorized for future grant under the Amended Plan by 9,925,000 shares, so that, together with the
6,437,150 shares that remain available for new awards as of June&nbsp;30, 2020, a total of 16,362,150 shares of our common stock will be available for new awards, subject to the share counting, share recycling and adjustment provisions set forth in
the Amended Plan and described below. The proposed increase represents approximately 8.8% of the Company&#146;s outstanding common stock as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date stockholders approve this amendment and restatement, in addition to the shares subject to outstanding awards as of
June&nbsp;30, 2020 (the &#147;Outstanding Awards&#148;), (i)&nbsp;16,362,150 shares will be available for new awards, less (ii)&nbsp;one share for every one share that was subject to an option or Stock Appreciation Right (&#147;SAR&#148;) granted
after June&nbsp;30, 2020 and 1.25 shares for every one share that was subject to a stock unit, stock award or other stock-based award (&#147;Full Value Award&#148;) granted after June&nbsp;30, 2020. If any shares subject to an award are forfeited,
the award expires or the award is settled in cash, the shares subject to such award, to the extent of such forfeiture, expiration or cash settlement, will be available for awards under the Amended Plan </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are seeking stockholder approval of the Amended Plan (i)&nbsp;in order to meet the published listing requirements of the NASDAQ Capital
Market, (ii)&nbsp;to confirm that the maximum grant date value of shares subject to awards granted to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any calendar year for services provided as a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director, taken together with any cash fees paid or payable to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director for services performed as a
<FONT STYLE="white-space:nowrap">non-employee</FONT> director for such year, is $400,000 and (iii)&nbsp;in order for incentive stock options (&#147;ISOs&#148;) to meet the requirements of the Internal Revenue Code of 1986, as amended (the
&#147;Code&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information about the 2008 Equity Plan as of June&nbsp;30, 2020, and
the potential overhang under the Amended Plan with 9,925,000 additional new shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of shares relating to stock options outstanding as of June&nbsp;30,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,252,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Weighted average remaining term of outstanding options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Weighted average exercise price of outstanding options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of Full Value Awards outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Remaining number of authorized shares as of June&nbsp;30, 2020 for future
grants under the 2008 Equity Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of new shares requested under the Amended Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,925,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Total number of authorized shares under the Amended Plan <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,362,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Total potential overhang under the Amended Plan <SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,615,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Number of shares of common stock outstanding as of June&nbsp;30, 2020</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,513,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Fully-diluted shares of common stock <SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,128,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Potential dilution of 9,925,000 new shares requested under the Amended Plan as
a percentage of fully-diluted shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> The total number of authorized shares for future
grants under the Amended Plan includes (i) 9,925,000 additional shares requested, plus (ii) 6,437,150 shares that remained available for grants under the 2008 Equity Plan as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> The total potential overhang under the under Amended Plan in the foregoing table
consists of 11,252,976 shares subject to stock options outstanding as of June&nbsp;30, 2020, plus shares that remained available for grants under the 2008 Equity Plan as of June&nbsp;30, 2020, plus the number of new shares requested for approval by
stockholders under the Amended Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP> The fully diluted shares of common stock in
the foregoing table consists of the shares of common stock outstanding as of June&nbsp;30, 2020 plus the total potential overhang under the Amended Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The request for stockholders to approve an increase of 9,925,000&nbsp;shares available for new awards under the Amended Plan considers the
Company&#146;s industry, size, volatility, and an estimate of the policies of some influential institutional stockholders and related vote advisory services.&nbsp;The amount of new stock plan dilution incurred by peer companies&#146; stockholders
was reviewed to estimate the equivalent new share amount under the Amended Plan.&nbsp;The proposed total number of shares available for issuance under new awards was then determined at a level expected to be sufficient for between two and four years
of expected new awards, assuming we continue to grant awards consistent with our current practices and historical usage, and further dependent on the price of our shares and hiring activity during the next few years, forfeitures of outstanding
awards, and noting that future circumstances may require us to change our current equity grant practices. We cannot predict our future equity grant practices, the future price of our shares or future hiring activity with any degree of certainty at
this time, and the share reserve under the Amended Plan could last for a shorter or longer time. The Board of Directors was assisted by its independent compensation consultant FW Cook in determining an appropriate increase of the number of
authorized shares under the Amended Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth the following information regarding the stock options granted under
the 2008 Equity Plan: (i)&nbsp;the burn rate for each of the last three fiscal years and (ii)&nbsp;the average burn rate over the last three fiscal years. No Full Value Awards were granted under the 2008 Equity Plan in any of the last three fiscal
years. The burn rate for a year has been calculated as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all stock options granted in the applicable year, divided by </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the weighted average number of shares of common stock outstanding for the applicable fiscal year.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Burn Rate </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Element</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,733,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,119,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted Average Shares of Common Stock Outstanding for the fiscal year ended
June&nbsp;30</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,080,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,139,278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,431,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Burn Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The burn rate means that the Company used an annual average of 5.1% of the weighted average shares outstanding
for awards granted over the past three fiscal years under the 2008 Equity Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Plan is set forth in <U>Annex A</U> to this proxy statement, and the following
description of the Amended Plan is only intended to be a summary of the key provisions of the Amended Plan. Such summary is qualified in its entirety by the actual text of the Amended Plan to which reference is made. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_19"></A>Description of the Amended Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Purpose </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of
the Amended Plan is to provide a means for us to attract, retain, motivate and reward present and prospective employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and advisors by increasing their ownership interests in the
Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Administration of the Amended Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Plan generally will be administered by the Compensation Committee of the Board of Directors, except that the Board of Directors
will perform the Compensation Committee&#146;s functions under the Amended Plan for purposes of grants of awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors, and, to the extent permitted under applicable
law and regulation, may perform any other function of the committee as well. The Compensation Committee (or Board of Directors, as applicable) has the authority, among other things, to: (i)&nbsp;select the directors, officers, employees and advisors
entitled to be granted awards under the Amended Plan; (ii)&nbsp;determine the types and amounts of awards, or combinations thereof, and whether such awards are to operate on a tandem basis or in conjunction with other awards; and
(iii)&nbsp;determine the other terms and conditions of any award, including, without limitation, any restrictions or limitations on transfer, any vesting schedules or the acceleration thereof and any forfeiture provisions or waivers thereof;
provided that no stock option or SAR shall have a term longer than ten years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee&#146;s
authority with respect to awards to employees who are not directors or executive officers may be delegated to our officers or managers, including our Chief Executive Officer. This delegation may be revoked at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October&nbsp;20, 2020, 56 employees, eight <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and one advisor are eligible
to participate in the Amended Plan. However, because awards will be granted at the discretion of the Compensation Committee (or its delegate) or the Board, it is not possible to determine the benefits or amounts that will be received by any
particular person in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Types of Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma&#146;s present and prospective directors, officers, employees, and advisors and those of its subsidiaries and affiliates are
eligible for awards under the Amended Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amended Plan, individual awards may take the form of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock options, the exercise price of which may not be less than 100% of the fair market value of the shares
covered by such grant on the date of grant, measured at the closing market price of the common stock on such date, and the exercise price may be paid in such manner as specified by the Compensation Committee, including in cash, by tendering shares
already owned, through a broker-assisted cashless exercise, through &#147;net exercise&#148; or by such other method as the Compensation Committee shall approve; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">SARs, the base price of which may not be less than 100% of the fair market value of the shares covered by such
grant on the date of grant, measured at the closing market price of the common stock on such date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted stock, consisting of shares of MEI Pharma common stock that may be subject to forfeiture based upon
the failure to satisfy employment-related restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stock units; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deferred stock, representing the right to receive shares of MEI Pharma common stock in the future;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bonus stock and awards in lieu of cash compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other awards, not otherwise provided for, denominated or payable in, or the value of which is based in whole or
in part upon the market or book value of, MEI Pharma stock, including Dividend Equivalents, as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalents.</I> Dividend equivalents consist of a right to receive cash, other awards or other property equal in value to
dividends paid with respect to a specified number of shares of MEI Pharma stock. Dividend equivalents may only be granted in connection with Full Value Awards. Dividends and dividend equivalents related to Full Value Awards will only vest and be
paid if and to the extent that the related Full Value Awards vest and are paid. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Transferability of Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No grant under the Amended Plan and no shares that have not been issued or as to which any applicable restriction, performance or deferral
period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered, except by will or by the laws of descent and distribution or with respect to grants other than ISOs, pursuant to a domestic relations order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, the Compensation Committee may provide, in a grant letter, that a grantee may transfer nonqualified options to
family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws, according to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such terms as the Compensation Committee may determine; provided that the grantee receives no consideration for the transfer and the transferred option will continue to be subject to the same
terms and conditions as were applicable to the option immediately before the transfer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Cancelled, Forfeited and other Terminated
Awards </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and to the extent any stock-based awards are forfeited, terminated, or otherwise not paid in full, the shares subject to
such grants (including grants made under the 2008 Equity Plan prior to the effective date of the Amended Plan) will become available again for purposes of the Amended Plan. Shares of common stock surrendered in payment of the exercise price of an
option (including options granted under the 2008 Equity Plan prior to the effective date of the Amended Plan), or withheld for payment of taxes of any grant (including grants made under the 2008 Equity Plan prior to the effective date of the Amended
Plan), shall not be available for <FONT STYLE="white-space:nowrap">re-issuance</FONT> under the Amended Plan. Upon the exercise of an option through a net exercise procedure, or upon the exercise of a SAR (including options and SARs granted under
the 2008 Equity Plan prior to the effective date of the Amended Plan), both for purposes of calculating the number of shares remaining available for issuance under the Amended Plan and the number of shares remaining available for exercise under such
option or SAR, the number of such shares shall be reduced by the gross number of shares for which the option or SAR is exercised and without regard to any cash settlement of a SAR. Except as provided with respect to cash settlement of SARs, to the
extent that any grants (including grants made under the 2008 Equity Plan prior to the effective date of the Amended Plan) are paid in cash and not in shares of common stock, any shares previously subject to such grants shall again be available for
issuance or transfer under the Amended Plan and shall not count against the share limits for purposes of shares available under the Amended Plan. In addition, shares reacquired by the Company on the open market or otherwise using cash proceeds from
the exercise of options (including options granted under the 2008 Equity Plan prior to the effective date of the Amended Plan) will not be added to the shares available for future grants under the Amended Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Limits on Shares Authorized under the Amended Plan and Size of Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Overall Limit.</I> As noted above, subject to adjustment as provided in Sections 3(b) and 12 of the Amended Plan, and described below, as of
the effective date of the Amended Plan, in addition to the Outstanding Awards made on or prior to June&nbsp;30, 2020, (i)&nbsp;16,362,150 shares, less (ii)&nbsp;one share for every one share that was subject to an option or SAR granted after
June&nbsp;30, 2020 and 1.25 shares for every one share that was subject to a Full Value Award granted after June&nbsp;30, 2020, will be authorized for grants to be made under the Amended Plan. A maximum of 10,000,000 shares may be subject to ISOs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each share that is subject to an option or SAR granted under the Amended Plan, the share limit referred above will be reduced by one
share for every one share that was subject to an option or SAR and for each share that is subject to a Full Value Award granted under the Amended Plan, the limit is reduced by 1.25 shares for every one share that was subject to a Full Value Award.
Any shares that again become available for grants under the Amended Plan as described in &#147;Cancelled, Forfeited and other Terminated Awards&#148; above, are added as (i)&nbsp;one share for every one share subject to options or SARs granted under
the Amended Plan and the 2008 Equity Plan and one share for every one share subject to Full Value Awards granted under the 2008 Equity Plan, and (ii)&nbsp;as 1.25 shares for every one share subject to Full Value Awards granted under the Amended Plan
and the 2008 Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange
for, awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Company subsidiary or with which the Company or any subsidiary combines) will not reduce the shares authorized
for grant under the Amended Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the Amended Plan. Additionally, in the event that a company acquired by the Company or any Company
subsidiary or with which the Company or any subsidiary combines has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the
shares available for grant pursuant to the terms of such <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such
acquisition or combination to determine the consideration payable to the holders of common stock of the entities party to such acquisition or combination) may be used for grants under the Amended Plan and will not reduce the shares authorized for
grant (and shares subject to such grants will not be added to the shares available for grants); provided that grants using such available shares will not be made after the date awards or grants could have been made under the terms of the <FONT
STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and will only be made to individuals who were not employees or directors prior to such acquisition or combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limits per Participant.</I> Notwithstanding any other provision of the Amended Plan to the contrary, subject to adjustments as set forth in
Section&nbsp;12 of the Amended Plan and described below, during any single calendar year, the aggregate grant date fair value (computed as of the date of grant in accordance with applicable financial accounting rules) of all grants to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director plus the sum of all cash payments paid or payable to such director for such year may not exceed $400,000. No other participant will be granted awards with respect to more than 4,000,000 shares
of common stock during any calendar year, subject to adjustments as set forth in Section&nbsp;12 of the Amended Plan and described below. This limitation will be multiplied by two with respect to grants made to an employee during the first calendar
year in which he or she commences employment or service with the Company and its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Adjustments for Changes in Common Stock
and Certain Other Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Compensation Committee determines that any recapitalization, forward or reverse split,
reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase, exchange or issuance of shares or other securities, stock dividend or other special, large and
<FONT STYLE="white-space:nowrap">non-recurring</FONT> dividend or distribution (whether in the form of cash, securities or other property), liquidation, dissolution, or other similar corporate transaction or event, affects our shares such that an
adjustment is appropriate in order to prevent dilution or enlargement of the rights of participants under the Amended Plan, then the Compensation Committee shall, in such manner as it may deem equitable, adjust any or all of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and kind of shares of stock reserved and available for awards under the Amended Plan, including shares
reserved for ISOs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and kind of shares of stock specified in the annual
<FONT STYLE="white-space:nowrap">per-participant</FONT> limitations under the Amended Plan; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and kind of shares that may be issued in respect of outstanding awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the exercise price, grant price or purchase price relating to any award (or, if deemed appropriate, the
Compensation Committee may make provision for a cash payment, including, without limitation, payment based upon the intrinsic (i.e., <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money)</FONT></FONT> value, if any, with
respect to any outstanding award). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Compensation Committee shall make appropriate adjustments in the
terms and conditions of, and the criteria included in, awards (including, without limitation, cancellation of unexercised or outstanding awards, or substitution of awards using stock of a successor or other entity) in recognition of unusual or
nonrecurring events affecting us or our financial statements, or in response to changes in applicable law, regulation, or accounting principles. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
vesting of awards in connection with a change of control or other event will be determined by the terms of the individual award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change in control, the Compensation Committee may take one or more of the following actions with respect to any or all
outstanding grants: (i)&nbsp;require surrender of outstanding vested options and SARs in exchange for payment by the Company, in cash or shares, in an amount equal to the &#147;spread&#148; of each such award; (ii)&nbsp;provide for the cancellation
of unvested grants for no consideration; (iii)&nbsp;provide for the cancellation of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-the-money</FONT></FONT></FONT> grants for no consideration;
(iv)&nbsp;after giving an opportunity to exercise outstanding options and SARs, terminate any or all unexercised awards; or (v)&nbsp;determine that outstanding options and SARs that are not exercised will be assumed by, or replaced with comparable
options or rights by, the surviving corporation, (or a parent or subsidiary of the surviving corporation), and other outstanding grants that remain in effect after the change in control be converted to similar grants of the surviving corporation (or
a parent or subsidiary of the surviving corporation). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Prohibition on Repricing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the Amended Plan to the contrary, and other than pursuant to Section&nbsp;12 of the Amended Plan that addresses
equitable adjustments, the Compensation Committee will not without the approval of the Company&#146;s stockholders (a)&nbsp;lower the exercise price per share of an option (or grant price of a SAR) after it is granted, (b)&nbsp;cancel an option or
SAR in exchange for an option or SAR with a lower exercise price, cash or another grant (other than in connection with a change in control), or (c)&nbsp;take any other action with respect to an option or SAR that would be treated as a repricing
under the rules and regulations of the principal U.S. national securities exchange on which the shares are listed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Clawback and
Recoupment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards under the Amended Plan are subject to the applicable provisions of the MEI Pharma clawback or recoupment policy,
as such policy may be in effect from time to time and are subject to recoupment as may be required by applicable law, regulation or exchange listing requirements. The current MEI Pharma clawback policy may be found on page 6 of the Company&#146;s
Corporate Governance Guidelines under Nominating&nbsp;&amp; Governance Committee Guidelines at https://investor.meipharma.com/corporate-governance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Amendment, Waiver and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Plan may be amended, altered, suspended, discontinued or terminated by the Board of Directors without stockholder approval unless
such approval is required by law or regulation, including, without limitation, under the rules of any stock exchange or automated quotation system on which MEI Pharma&#146;s common stock is then listed or quoted. The Compensation Committee may waive
any conditions or amend, alter, suspend, discontinue or terminate any award under the Amended Plan. No such change to the Amended Plan or any award may, without the participant&#146;s consent, materially impair the rights of the participant under an
outstanding award except as provided in the Amended Plan or applicable award agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Material Federal Income Tax Consequences
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a brief description of the federal income tax consequences generally arising with respect to awards that may be
granted under the Amended Plan. This discussion is intended for the information of MEI Pharma stockholders considering how to vote at the MEI Pharma Annual Meeting and not as tax guidance to individuals who may participate in the Amended Plan. The
summary does not address the effects of other federal taxes or taxes imposed under state, local or foreign laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant of an option
or SAR will create no tax consequences for the participant or MEI Pharma. A participant will not have taxable income upon exercising an ISO (except that the alternative minimum tax may apply), and MEI Pharma will receive no tax deduction at that
time. Upon exercising an option other than an ISO, the participant must generally recognize ordinary income equal to the difference between the exercise price and the fair market value of the freely transferable and
<FONT STYLE="white-space:nowrap">non-forfeitable</FONT> stock received. In each case, MEI Pharma will generally be entitled to a tax deduction equal to the amount recognized as ordinary income by the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant&#146;s disposition of stock acquired upon the exercise of an option or SAR generally will result in capital gain or loss
measured by the difference between the sale price and the participant&#146;s tax basis in such stock (or the exercise price of the option in the case of stock acquired by exercise of an ISO and held for the applicable ISO holding periods).
Generally, there will be no tax consequences to MEI Pharma in connection with a disposition of stock acquired upon the exercise of an option or other award, except that MEI Pharma will generally be entitled to a tax deduction (and the participant
will recognize ordinary taxable income) if stock acquired upon exercise of an ISO is disposed of before the applicable ISO holding periods have been satisfied. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to awards granted under the Amended Plan that may be settled either in cash or
in stock or other property that is either not restricted as to transferability or not subject to a substantial risk of forfeiture, the participant generally must recognize ordinary income equal to the cash or fair market value of stock or other
property received. MEI Pharma will generally be entitled to a tax deduction for the same amount. With respect to awards involving stock or other property that is restricted as to transferability and subject to a substantial risk of forfeiture, the
participant generally must recognize ordinary income equal to the fair market value of the stock or other property received at the first time the stock or other property becomes transferable or not subject to a substantial risk of forfeiture,
whichever occurs earlier. MEI Pharma will generally be entitled to a tax deduction in an amount equal to the ordinary income recognized by the participant. A participant may elect to be taxed at the time of receipt of the stock or other property
rather than upon the lapse of restrictions on transferability or substantial risk of forfeiture, but if the participant subsequently forfeits such stock or property, the participant would not be entitled to any tax deduction, including capital loss,
for the value of the stock or property on which the participant previously paid tax. Such election must be made and filed with the Internal Revenue Service within 30 days after the receipt of the stock or other property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under section 409A of the Code, an award under the Amended Plan may be taxable to the participant at 20 percentage points above ordinary
federal income tax rates at the time the award becomes vested, plus interest and penalties, even if that is prior to the delivery of cash or stock in settlement of the award, if the award constitutes &#147;deferred compensation&#148; under section
409A of the Code and the requirements of section 409A of the Code are not satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Plan provides that MEI Pharma has the
right to require participants under the Amended Plan to pay it an amount necessary for it to satisfy its federal, state, local and foreign tax withholding obligations with respect to such awards. The Amended Plan permits the Company to determine the
tax withholding rates, which comply with withholding requirements then in effect, and which will not cause an adverse accounting consequence or cost to the Company. MEI Pharma may withhold from other amounts payable to such individual an amount
necessary to satisfy these obligations. Unless the Compensation Committee or its designee determines otherwise, a participant may satisfy this withholding obligation by having shares acquired pursuant to the award withheld. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized For Issuance Under Equity Compensation Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below shows, as of June&nbsp;30, 2020, information for all equity compensation plans previously approved by stockholders. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>securities&nbsp;to&nbsp;be<BR>issued upon<BR>exercise of<BR>outstanding<BR>options,<BR>warrants and<BR>rights<BR>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>average<BR>exercise&nbsp;price<BR>of&nbsp;outstanding<BR>options,<BR>warrants and<BR>rights<BR>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>securities<BR>remaining<BR>available for<BR>future&nbsp;issuance<BR>under
equity<BR>compensation<BR>plans&nbsp;(excluding<BR>securities<BR>reflected in<BR>column (a))<BR>(c)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,252,976</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,252,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,437,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of awards with respect to shares of common stock issuable under the 2008 Equity Plan, under which
11,252,976 shares of common stock are authorized for issuance. The 2008 Equity Plan provides for the grant of options, stock units, stock awards and/or other stock-based or stock-denominated awards to the Company&#146;s <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, officers, employees and advisors. As of June&nbsp;30, 2020, all of the awards currently outstanding under the 2008 Equity Plan consist of stock options. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTE REQUIRED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
affirmative vote of the holders of a majority of the outstanding shares of common stock present in person or represented by proxy at the Annual Meeting and entitled to vote is required to approve the amended and restated 2008 Equity Plan.
Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will be counted for the purposes of determining the presence or absence of a quorum. Abstentions will have the effect of a vote &#147;against&#148; the proposal.
Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the outcome of the proposal. A failure to vote by not returning a signed proxy will have no effect on the outcome of the proposal. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECOMMENDATION OF THE BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE AMENDMENT AND RESTATEMENT OF THE MEI PHARMA, INC.
2008 STOCK OMNIBUS COMPENSATION PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE SUBJECT TO AWARDS AND MAKE CERTAIN OTHER CHANGES INCLUDED IN THE PLAN DOCUMENT ATTACHED AS ANNEX A. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_20"></A>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(PROPOSAL NO. 3) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our
2017 annual meeting of stockholders, our stockholders indicated their preference that we solicit a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote on the compensation of the named executive officers, commonly referred to as a
&#147;Say-on-Pay&#148; vote, every year. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy
statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation of our named executive officers subject to the vote is disclosed in the &#147;Compensation Discussion and
Analysis&#151;Compensation Philosophy and Objectives&#148; section and the compensation tables and the related narrative disclosure contained in this proxy statement. As discussed in those disclosures, we believe that our compensation policies and
decisions are focused on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> principles, aligned with our stockholders&#146; interests and consistent with current market practices. Compensation of our
named executive officers is intended to enhance stockholder value by attracting, motivating and retaining qualified individuals to perform at the highest levels and to contribute to our growth and success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We urge stockholders to read the information below under &#147;Compensation Discussion and Analysis&#148;, including the Company&#146;s
Compensation Philosophy and Objectives as well as the related compensation tables and narrative, which describes in more detail how our executive compensation policies and procedures operate and are designed to achieve our compensation objectives.
Our Board of Directors and the Compensation Committee believe that our compensation policies and practices are effective in implementing our compensation philosophy and in helping us achieve our corporate goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, our Board of Directors is asking the stockholders to indicate their support for the compensation of our named executive officers
as described in this proxy statement by casting a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote &#147;FOR&#148; the following resolution: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, that the compensation paid to MEI Pharma, Inc. named executive officers for fiscal 2020, as disclosed pursuant to Item 402 of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> in the Company&#146;s proxy statement for the fiscal year 2020 annual meeting of stockholders, including the discussion under the heading &#147;Compensation Discussion and Analysis&#148;, the
compensation tables and the other narrative discussion </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">is hereby APPROVED.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the vote is advisory, it is not binding on us or our Board of Directors. Nevertheless, the views expressed by our stockholders, whether
through this vote or otherwise, are important to us and our Board of Directors and, accordingly, our Board and the Compensation Committee intend to consider the results of this vote in making determinations in the future regarding executive
compensation arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Advisory approval of this proposal requires a majority of the votes cast by stockholders entitled to vote on
the proposal voting &#147;FOR&#148; approval. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will be counted for the purposes of determining the presence or absence of a quorum. Abstentions will have the effect of
a vote &#147;against&#148; the proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the outcome of the proposal. A failure to vote by not returning a signed proxy will have no effect on the outcome of the
proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; THE APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS,
AS DISCLOSED IN THIS PROXY STATEMENT. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_21"></A>COMPENSATION DISCUSSION AND ANALYSIS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Compensation Discussion and Analysis describes the compensation strategy, policies, programs and practices for the named executive
officers identified in the Summary Compensation Table. For fiscal year 2020, the named executive officers consist of Daniel P. Gold, Ph.D., President, Chief Executive Officer&nbsp;&amp; Director, Brian G. Drazba, Chief Financial Officer, Robert D.
Mass, M.D., Chief Medical Officer, and David M. Urso, Chief Operating Officer and General Counsel, to whom we collectively refer in this Compensation Discussion and Analysis as our &#147;executive officers.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_22"></A>Compensation Philosophy and Objectives </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the performance of our executive officers significantly impacts our ability to achieve our corporate goals. We, therefore,
place considerable importance on the design and administration of our executive officer compensation program. This program is intended to enhance stockholder value by attracting, motivating and retaining qualified individuals to perform at the
highest levels and to contribute to our growth and success. Our executive officer compensation program is designed to provide compensation opportunities that are tied to individual and corporate performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our overall compensation philosophy has been to pay our executive officers an annual base salary and to provide opportunities, through cash
and equity incentives, to deliver higher compensation if certain key performance goals are satisfied or exceeded. The primary principles of our fiscal year 2020 compensation strategy were: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation decisions are driven by a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compensation should reflect individual and corporate performance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Target annual compensation is competitively positioned against a peer group of similar companies.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_23"></A>The Compensation Committee&#146;s Process </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee acts on behalf of the Board with respect to fulfilling the Board&#146;s responsibilities to oversee the
Company&#146;s compensation policies, plans and programs and reviewing and determining, as appropriate, the compensation to be paid to executive officers and directors. To achieve this task, the Compensation Committee (i)&nbsp;reviews and approves
corporate performance goals and objectives that support and reinforce the Company&#146;s long-term strategic goals and compensation plans; (ii)&nbsp;reviews the individual performance of the executive officers; (iii)&nbsp;establishes policies with
respect to equity compensation arrangements, timing and pricing of equity awards for newly hired employees, promotions and annual grants for executive and <FONT STYLE="white-space:nowrap">non-executive</FONT> employees and directors;
(iv)&nbsp;reviews regional and industry-wide compensation practices and trends to assess the propriety, adequacy and competitiveness of the Company&#146;s executive compensation programs among comparable companies in the Company&#146;s industry;
(v)&nbsp;reviews and approves the terms of any employment agreements, severance agreements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> protections and any other compensatory arrangements of the
executive officers; (vi)&nbsp;performs and considers a compensation risk assessment; and (vii)&nbsp;considers stockholder feedback and <FONT STYLE="white-space:nowrap">Say-on-Pay</FONT> voting results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to compensation of our Chief Executive Officer, the Compensation Committee evaluates the Chief Executive Officer&#146;s
performance in light of relevant performance goals and objectives, taking into account the policies of the Compensation Committee and, with respect to long-term incentive compensation, stockholder return and the results of the most recent
stockholder advisory vote on executive compensation. The Compensation Committee reviews and approves (or if appropriate, recommends to the Board for final determination and approval) individual and corporate performance goals and objectives of the
Company&#146;s other executive officers. The Compensation Committee considers the recommendations of the Chief Executive Officer with respect to the compensation of the Company&#146;s other executive officers. The Compensation Committee also makes
recommendations to the Board with respect to this &#147;Compensation Discussion and Analysis&#148; section and recommends that such section be included in any of the Company&#146;s annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT>
registration statements, proxy statements or information statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee meets at least once a year or more
frequently as its members deem necessary or appropriate. Under the charter, the Compensation Committee has the authority, in its sole discretion, to retain or obtain the advice of a compensation consultant, legal counsel or other advisors as the
Compensation Committee may determine to assist in the performance of the Compensation Committee&#146;s duties and responsibilities, only after taking into consideration the factors prescribed by the SEC and NASDAQ that bear upon the adviser&#146;s
independence. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Setting Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee considers peer group analysis as a component of its overall executive compensation decision process, but it does not
attempt to set executive compensation to a specific benchmark level, or percentile at other companies. The Compensation Committee determines the mix of compensation of each executive officer based on its review of such competitive data and an
assessment of the individual&#146;s performance. We believe our approach to compensation does not encourage excessive risk-taking by the Company&#146;s executives as it is not a market outlier and is based on a typical mix of short- and <FONT
STYLE="white-space:nowrap">long-term</FONT> compensation tied to both internal objectives and to shareholder value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our peer group of
companies for fiscal year 2020 consisted of 21 similar publicly-traded drug development companies, all approved by the Compensation Committee, with input from management and our compensation consultant. The peer group is composed of drug development
companies with a similar market cap (all under $700&nbsp;million as of the date for inclusion in the peer group), without material revenue from commercial products, and with emphasis on oncology drug development companies as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Aduro BioTech, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Idera Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Advaxis, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Infinity Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agenus Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Karyopharm Therapeutics Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ArQule, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kura Oncology, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Bellicum Pharmaceuticals, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pieris Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Calithera Biosciences, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Rigel Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Celldex Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stemline Therapeutics, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ChemoCentryx, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tracon Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CytRx Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Verastem, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Five Prime Therapeutics, Inc.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ziopharm Oncology, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Geron Corporation</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that our base compensation, cash incentives and equity programs reward the
achievement of clearly defined corporate goals and objectives. This is critical for ensuring a competitive program that retains our existing executive officers and allows us to hire new executive officers, particularly in light of the competitive
nature of our industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The peer data were used as context for setting fiscal 2020 executive officer compensation. The Compensation
Committee does not set a target benchmark, but in fiscal year 2020, the value of total direct compensation for all named executive officers was near the median, with the CEO at the median. This recognizes that the fiscal year 2019 performance was
above expectation following success in financing activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of Stockholder
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT> Votes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our annual meeting of stockholders
held in December 2019, approximately 99% of the shares voted at the meeting approved, on an advisory basis, the compensation of our named executive officers. The Compensation Committee considers input from stockholders, its compensation consultant
and proxy advisors, when assessing its compensation philosophy and the components of its compensation program, giving further consideration to the level of attainment of corporate goals and to the compensation data of the Company&#146;s peer group
so that compensation decisions are broadly consistent with market practice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elements of Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each executive officer&#146;s compensation has three key elements: (i)&nbsp;base salary, (ii)&nbsp;performance-based cash incentives and
(iii)&nbsp;equity-based compensation. These elements of executive compensation are intended to align the interests of our executive officers with those of our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Base Salary </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Base salaries serve to
provide a fixed amount of compensation to our executive officers for successfully fulfilling their responsibilities. We establish base salaries for our executive officers when they join our Company or upon promotion. Base salaries for executive
officers are reviewed and determined by the Compensation Committee annually, following consultation with our compensation consultant. Dr.&nbsp;Gold was provided a salary increase of 6.6%, Mr.&nbsp;Drazba was provided a salary increase of 5.8%,
Dr.&nbsp;Mass was provided a salary increase of 4% and Mr.&nbsp;Urso was provided a salary increase of 8.0% in fiscal 2020. The increases keep pace with the market and recognize experience and performance. Our Chief Medical Officer currently works a
40% part-time schedule, and his salary is pro-rated accordingly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Performance-based Cash Incentives </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that allocating a meaningful amount of our executive officers&#146; total cash compensation to the
achievement of corporate goals and objectives aligns our executive officers&#146; interests with those of our stockholders. The Compensation Committee establishes annual corporate incentive bonus targets for each of our executive officers. Fiscal
year 2020 bonus targets were set at 60%, 40%, 40% and 45% of base salary for our Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chief Operating Officer and General Counsel, respectively. Our Chief Medical Officer
currently works a 40% part-time schedule, and his bonus is <FONT STYLE="white-space:nowrap">pro-rated</FONT> accordingly. The annual corporate goals and objectives are generally critical path activities or strategic initiatives designed to enhance
shareholder return. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Equity-based Compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee believes that long-term value creation is achieved through an ownership culture that encourages performance by our
executive officers through stock and <FONT STYLE="white-space:nowrap">stock-based</FONT> awards. This potential reward for shareholder value creation is also key to our retention strategy. Under our 2008 Equity Plan, which was amended in 2018, we
may award incentive and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options, stock appreciation rights, restricted stock, restricted stock units, and performance shares and units. Stock options granted before the plan was amended on
December 3, 2014 generally had five-year terms. Those granted after December 3, 2014 expire after 10 years, have an exercise price equal to the fair market value at grant, and typically vest 25% after one year and in equal monthly installments
thereafter over the next 36 months and have a three-month post-termination exercise period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the start of fiscal year 2020, we granted
annual options to the Chief Executive Officer, the Chief Financial Officer, the Chief Medical Officer and the Chief Operating Officer&nbsp;&amp; General Counsel in the amount of 680,000, 230,000, 230,000 and 350,000 options, respectively. All option
awards were granted with an exercise price of $2.52, which was the closing price on the date of grant. The Compensation Committee views options as naturally performance-based because they do not reward the option holder unless the stock price
increases after grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total compensation of each executive officer, which consisted of salary, bonus, and the grant date fair value
of options was below the median of the peer group for all executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Goals for Fiscal Year 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annual performance goals are set by the Compensation Committee, and they are as objective as possible in both their definition and their
scoring at the end of the period, though there is a subjective element to scoring goals to recognize that some achievements are binary but that there is also a higher or lower degree of quality to some achievements. This is consistent with the
multi-year timeline associated with the drug development business, where annual goals are milestones for a long-term development and regulatory approval process that creates value over a long time and investment horizon. The following is a
description of the primary corporate goals for fiscal year 2020, which assisted the Compensation Committee in determining total compensation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conduct the Company&#146;s operations within the approved budget and maintain sufficient capital to fund the
Company&#146;s FY2020 clinical development plan with at least 1 quarter runway beyond topline data from the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ME-401-003</FONT></FONT> study. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose 120 patients in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ME-401-003</FONT></FONT> study by June&nbsp;30, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Complete sufficient enrollment of Voruciclib monotherapy and plus venetoclax dose escalation by June&nbsp;30,
2020 to make go/no go decision on further development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conduct end of Phase II CMC meeting with FDA by December&nbsp;31, 2019 for
<FONT STYLE="white-space:nowrap">ME-401;</FONT> complete manufacturing of registration batches of <FONT STYLE="white-space:nowrap">ME-401</FONT> and ensure NDA enabling nonclinical studies are not on the critical path by June&nbsp;30, 2020.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain Board approval for an <FONT STYLE="white-space:nowrap">ME-401</FONT> development plan for indications
beyond third line follicular lymphoma including inputs from commercial, regulatory and clinical. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation
Committee determined the Company had met 75% of the goals above, and added an additional achievement of 50% for signing the License, Development and Commercialization Agreement with Kyowa Kirin Co., Ltd. (&#148;KKC&#148;) which added
$100&nbsp;million of <FONT STYLE="white-space:nowrap">non-dilutive</FONT> cash to the Company. Therefore, the Company paid 125% of target bonus to each named executive officer, which was 75% of target bonus for achievement of <FONT
STYLE="white-space:nowrap">pre-existing</FONT> goals and 50% of target bonus for solidifying the Company&#146;s <FONT STYLE="white-space:nowrap">mid-term</FONT> future by obtaining from advantageous additional financing with KKC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Benefits and Perquisites </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company offers benefit programs to its employees, including named executive officers, which include paid-time off, health insurance, including a company funded HSA account and a Company sponsored 401(k) plan. Our executive officers generally do not
receive any supplemental retirement benefits or perquisites, and participate in the above listed benefit programs on the same basis as other full-time employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_24"></A>Severance and Change in Control Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Dr.&nbsp;Gold&#146;s, Mr.&nbsp;Drazba&#146;s, Dr.&nbsp;Mass&#146;s and Mr.&nbsp;Urso&#146;s employment agreements provides for certain
severance payments upon the applicable employee&#146;s termination by us other than for cause or by the applicable employee for good reason, as such terms are defined in the respective employment agreement. Upon such a termination of employment, we
will: (i)&nbsp;make a payment to the applicable employee in lieu of notice in an amount equal to twelve months of such employee&#146;s base salary (as in effect at the time of such employee&#146;s termination from employment), and
(ii)&nbsp;accelerate the vesting of the applicable employee&#146;s options so that such employee will be vested in the same number of shares of common stock subject to the options as if such employee had continued to be employed by us for an
additional twelve months. Such payment and additional option vesting will be conditional upon the execution of a customary release of claims in favor of us and our affiliates, in a form prescribed by us. The payment in lieu of notice will be paid to
the applicable employee in a single lump sum payment as soon as administratively practicable after the maximum review and revocation period for the release agreement as may be required under applicable law, if any, or such earlier date as determined
in our sole discretion, but in no event more than 60 days after the applicable employee&#146;s termination of employment. If their employment had been terminated in accordance with the foregoing provisions on June&nbsp;30, 2020, Dr.&nbsp;Gold,
Mr.&nbsp;Drazba, Dr.&nbsp;Mass and Mr.&nbsp;Urso would have been entitled to payments in the amount of $650,000, $402,000, $490,985 (prorated to the current year&#146;s percentage work schedule) and $460,000, respectively, and the vesting of options
to purchase 598,750 shares, 211,458 shares, 204,270 shares, and 290,416&nbsp;shares of our common stock, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a
change in control of MEI Pharma, as defined in the 2008 Equity Plan, unless the Compensation Committee of the Board of Directors determines otherwise, all of the options granted to Dr.&nbsp;Gold, Mr.&nbsp;Drazba, Dr.&nbsp;Mass and Mr.&nbsp;Urso will
accelerate and become fully exercisable effective upon the date of the change in control. As of June&nbsp;30, 2020, the intrinsic value of unvested stock options that would accelerate and become fully exercisable upon a change in control, computed
by multiplying the difference between the closing price per share of our common stock on June&nbsp;30, 2020 of $4.13 and the exercise price of each stock option vested as a result of the termination, by the number of accelerated stock options for
Dr.&nbsp;Gold, Mr.&nbsp;Drazba, Dr.&nbsp;Mass and Mr.&nbsp;Urso, was $1,250,522, $467,280, $425,620 and $616,772, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_25"></A>Tax and Accounting Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The tax and accounting consequences to the Company of certain compensation elements are important considerations for the Compensation Committee
when evaluating and recommending compensation packages for our executive officers. Generally, the Compensation Committee seeks to balance its objective to create an effective compensation program that attracts, retains and rewards executives in
order to maximize the return to stockholders with the need for appropriate tax and accounting consequences of such compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to considering the tax consequences, the Compensation Committee considers the accounting consequences of its decisions, including the impact of expenses being recognized in connection with equity-based awards, in determining the size and
form of different equity-based awards. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_26"></A>CEO Pay Ratio </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEC rules require us to disclose the total annual compensation of our principal executive officer for fiscal 2020, who was Daniel P. Gold, our
President and Chief Executive Officer, the median of the total annual compensation of all employees other than our principal executive officer, as well as their ratio to each other (the &#147;<I>CEO Pay Ratio</I>&#148;). Total annual compensation
for our principal executive officer and for the median of the total annual compensation of all employees is calculated in accordance with SEC rules applicable to the Summary Compensation Table. For fiscal 2020, these amounts were as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our principal executive officer&#146;s total annual compensation: $2,257,537 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our median employee&#146;s total annual compensation: $260,357 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">CEO Pay Ratio: 8.67 to 1 </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the median compensated employee, we chose June 30, 2020 as the determination date. As of this date, we had 50 employees,
excluding our principal executive officer. We annualized compensation of employees who were not employed with us for the full fiscal year. In determining our median compensated employee and calculating the CEO Pay Ratio, we did not use any of the
exemptions permitted under SEC rules, nor did we rely upon any material assumptions, adjustments or estimates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company believes that
the CEO Pay Ratio set forth above is a reasonable estimate for fiscal 2020, determined in a manner consistent with SEC rules. The SEC rules for identifying the median compensated employee and calculating the CEO Pay Ratio based on that
employee&#146;s total annual compensation permit companies to adopt a variety of methodologies, to apply certain exemptions and to make certain assumptions, adjustments or estimates that reflect their compensation policies. Accordingly, the CEO Pay
Ratio may not be comparable to the pay ratios reported by other companies, which may have used different methodologies, assumptions, adjustments or estimates in calculating their pay ratios. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_27"></A>COMPENSATION COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> and contained within this Proxy Statement with management and, based on such review and discussions, our Compensation Committee recommended to our Board that the Compensation Discussion and Analysis be included
in this Proxy Statement and incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended June 30, 2020. Submitted on October&nbsp;27, 2020 by the members of the Compensation Committee of
the Board of Directors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kevan&nbsp;E. Clemens </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Nicholas&nbsp;R. Glover </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Tamar&nbsp;D. Howson </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Thomas&nbsp;C. Reynolds </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This
Section is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be incorporated by reference in any filing of the Company under the Exchange Act or the Securities Act, other than in the Company&#146;s
Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> where it shall be deemed to be furnished, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_28"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_29"></A>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth for the fiscal years ended June 30, 2020, 2019 and 2018, the compensation of our named executive officers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="36%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards</B><br><B>($) (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards</B><br><B>($) (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation</B><br><B>($)&nbsp;(3)&nbsp;(4)&nbsp;(5)&nbsp;(6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus</B><br><B>($) (3) (4)<BR>(5) (6)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($) (8)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,120,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">292,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,257,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">President, Chief Executive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">954,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,854,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Officer&nbsp;&amp; Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,081,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">281,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,985,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,212</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">842,612</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">532,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,015,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert D. Mass</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">673,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical Officer (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">674,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">879,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Urso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">576,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,295,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">161,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,307,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">712,211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,250,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the aggregate grant date fair value of restricted stock unit awards granted in accordance with
Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 718, &#147;Stock Compensation&#148;, calculated based on the closing market price of our common stock on the date of grant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the aggregate grant date fair value of options granted in accordance with ASC Topic&nbsp;718. For
the relevant assumptions used in determining these amounts, refer to Note 8 to our audited financial statements contained in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Gold received a bonus of 75% of his base salary for the fiscal year ended June&nbsp;30, 2020, based
upon the Compensation Committee&#146;s determination to award bonuses at 125% of target levels. Dr.&nbsp;Gold received a bonus of 47.5% of his base salary for the fiscal year ended June&nbsp;30, 2019, based upon the Compensation Committee&#146;s
determination to award bonuses at 95% of target levels. Dr.&nbsp;Gold received a bonus of 47.5% of his base salary for the fiscal year ended June&nbsp;30, 2018 based upon the Compensation Committee&#146;s determination to award bonuses at 95% of
target levels and to provide an additional <FONT STYLE="white-space:nowrap">one-time</FONT> bonus of $30,000. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Drazba received a bonus of 50% of his base salary for the fiscal year ended June&nbsp;30, 2020 based
upon the Compensation Committee&#146;s determination to award bonuses at 125% of target levels. Mr.&nbsp;Drazba received a bonus of 38% of his base salary for the fiscal year ended June&nbsp;30, 2019 based upon the Compensation Committee&#146;s
determination to award bonuses at 95% of target levels. Mr.&nbsp;Drazba received a bonus of 38% of his base salary for the fiscal year ended June&nbsp;30, 2018 based upon the Compensation Committee&#146;s determination to award bonuses at 95% of
target levels. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Mass received a bonus of 50% of his pro-rated base salary for the fiscal year ended June&nbsp;30,
2020, based upon the Compensation Committee&#146;s determination to award bonuses at 125% of target levels. Dr.&nbsp;Mass received a bonus of 38% of his pro-rated base salary for the fiscal year ended June&nbsp;30, 2019 based upon the Compensation
Committee&#146;s determination to award bonuses at 95% of target levels. Dr.&nbsp;Mass received a bonus of 38% of his pro-rated base salary for the fiscal year ended June&nbsp;30, 2018 based upon the Compensation Committee&#146;s determination to
award bonuses at 95% of target levels. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Urso received a bonus of 56.3% of his base salary for the fiscal year ended June&nbsp;30, 2020, based
upon the Compensation Committee&#146;s determination to award bonuses at 125% of target levels. Mr.&nbsp;Urso received a bonus of 42.7% of his base salary for the fiscal year ended June&nbsp;30, 2019, based upon the Compensation Committee&#146;s
determination to award bonuses at 95% of target levels and to provide an additional <FONT STYLE="white-space:nowrap">one-time</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
$20,000 bonus. Mr.&nbsp;Urso received a bonus of 38% of his base salary for the fiscal year ended June&nbsp;30, 2018 based upon the Compensation Committee&#146;s determination to award bonuses at
95% of target levels. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Beginning in fiscal year 2014, Dr.&nbsp;Mass worked a 40% schedule. Amounts reported in the table reflect <FONT
STYLE="white-space:nowrap">pro-ration.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In accordance with SEC rules, the compensation described in this table does not include various health and
welfare or other benefits received by our named executive officers that were generally available to all of our regular, full-time employees, as well as certain perquisites and other benefits received by our named executive officers that, in the
aggregate, were less than $10,000 for any officer. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_30"></A>Employment Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into written employment agreements with each of the named executive officers, which set forth the terms of their respective
employments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement between Daniel P. Gold and MEI Pharma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Dr.&nbsp;Gold&#146;s appointment as President and Chief Executive Officer, we entered into an Employment Letter Agreement,
dated April 23, 2010 with Dr.&nbsp;Gold (the &#147;Gold Employment Letter&#148;). The Gold Employment Letter provided for an annual base salary of $400,000, subject to upward adjustment at the discretion of the Compensation Committee of the Board of
Directors. Pursuant to the terms of the Gold Employment Letter, Dr.&nbsp;Gold was eligible to earn an annual cash bonus in an amount up to a maximum of 40% of the base salary, based on his achievement of milestones established by the Compensation
Committee of the Board of Directors. Beginning in fiscal year 2015, the Compensation Committee established the target amount of Dr.&nbsp;Gold&#146;s annual cash bonus as 50% of his base salary. Beginning in fiscal year 2020, the Compensation
Committee established the target amount of Dr.&nbsp;Gold&#146;s annual cash bonus as 60% of his base salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gold may terminate
his employment at any time and for any reason, upon providing three (3)&nbsp;months advance notice to us. Dr.&nbsp;Gold may terminate his employment with Good Reason (as defined in the Gold Employment Letter) by providing us with notice within sixty
(60)&nbsp;days of the event giving rise to the Good Reason (and we do not cure the Good Reason event within thirty (30)&nbsp;days after receiving notice). We have the right to terminate the Gold Employment Letter with or without Cause (as defined in
the Gold Employment Letter) at any time. If Dr.&nbsp;Gold&#146;s employment is terminated by us without Cause or by Dr.&nbsp;Gold for Good Reason, Dr.&nbsp;Gold will be entitled to (i)&nbsp;a lump sum payment in an amount equal to twelve
(12)&nbsp;months of his base salary and (ii)&nbsp;accelerated vesting of his options such that Dr.&nbsp;Gold will be vested in the same number of options as if he had continued to be employed by us for an additional twelve (12)&nbsp;months. The Gold
Employment Letter contains confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement between Brian G. Drazba and MEI Pharma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Mr.&nbsp;Drazba&#146;s appointment as Chief Financial Officer, we entered into an Employment Letter, dated February 1, 2017,
with Mr.&nbsp;Drazba (the &#147;Drazba Employment Letter&#148;). The Drazba Employment Letter provided for an annual base salary of $350,000, subject to upward adjustment at the discretion of the Compensation Committee of the Board of Directors.
Pursuant to the terms of the Drazba Employment Letter, Mr.&nbsp;Drazba is eligible to earn an annual cash bonus, beginning for the fiscal year starting on July 1, 2017, in an amount up to a maximum of 40% of the base salary, based on his achievement
of milestones established by the Compensation Committee of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Drazba may terminate his employment at any
time other than for Good Reason (as defined in the Drazba Employment Letter), upon providing two (2)&nbsp;months advance notice to us. Mr.&nbsp;Drazba may terminate his employment with Good Reason by providing us with notice within sixty
(60)&nbsp;days of the event giving rise to the Good Reason (and we do not cure the Good Reason event within thirty (30)&nbsp;days after receiving notice). We have the right to terminate the Drazba Employment Letter with or without Cause (as defined
in the Drazba Employment Letter) at any time. If Mr.&nbsp;Drazba&#146;s employment is terminated by us without Cause or by Mr.&nbsp;Drazba for Good Reason, Mr.&nbsp;Drazba will be entitled to (i)&nbsp;a lump sum payment in an amount equal to twelve
(12)&nbsp;months of his base salary and (ii)&nbsp;accelerated vesting of his options such that Mr.&nbsp;Drazba will be vested in the same number of options as if he had continued to be employed by us for an additional twelve (12)&nbsp;months. The
Drazba Employment Letter contains confidentiality provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement between Robert D. Mass and MEI Pharma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Dr.&nbsp;Mass&#146;s appointment as Chief Medical Officer, we entered into an Employment Letter, dated June 1, 2011, with
Dr.&nbsp;Mass (the &#147;Mass Employment Letter&#148;). The Mass Employment Letter provided for an annual base salary of $350,000, subject to upward adjustment at the discretion of the Compensation Committee of the Board of Directors. Pursuant to
the terms of the Mass Employment Letter, Dr.&nbsp;Mass was eligible to earn an annual cash bonus in an amount up to a maximum of 20% of the <FONT STYLE="white-space:nowrap">pro-rated</FONT> base salary based on his achievement of milestones
established by the Compensation Committee of the Board of Directors. Beginning in fiscal year 2015, the Compensation Committee has increased the target amount of Dr.&nbsp;Mass&#146;s annual cash bonus to 40% of his
<FONT STYLE="white-space:nowrap">pro-rated</FONT> base salary. Dr.&nbsp;Mass works a reduced hours schedule and worked a 25% part-time schedule from the commencement of his employment with us on June 1, 2011 through February 2012. Beginning March
2012, Dr.&nbsp;Mass worked a 50% of full-time schedule. Beginning in fiscal year 2014, Dr.&nbsp;Mass worked a 40% part-time schedule. It is anticipated that Dr.&nbsp;Mass will continue to work a 40% part-time schedule in fiscal year 2021. The number
of hours worked by Dr.&nbsp;Mass may vary and his annual base salary and cash bonus paid will vary accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Mass may
terminate his employment at any time other than for Good Reason (as defined in the Mass Employment Letter), upon providing two (2)&nbsp;months advance notice to us. Dr.&nbsp;Mass may terminate his employment with Good Reason by providing us with
notice within sixty (60)&nbsp;days of the event giving rise to the Good Reason (and we do not cure the Good Reason event within thirty (30)&nbsp;days after receiving notice). We have the right to terminate the Mass Employment Letter with or without
Cause (as defined in the Mass Employment Letter) at any time. If Dr.&nbsp;Mass&#146;s employment is terminated by us without Cause or by Dr.&nbsp;Mass for Good Reason, Dr.&nbsp;Mass will be entitled to (i)&nbsp;a lump sum payment in an amount equal
to twelve (12) months of his base salary and (ii)&nbsp;accelerated vesting of his options such that Dr.&nbsp;Mass will be vested in the same number of options as if he had continued to be employed by us for an additional twelve (12)&nbsp;months. The
Mass Employment Letter contains confidentiality provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreement between David M. Urso and MEI Pharma </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Mr.&nbsp;Urso&#146;s appointment as Senior Vice President, Corporate Development and General Counsel, we entered into an
Employment Letter dated March 6, 2014, with Mr.&nbsp;Urso (the &#147;Urso Employment Letter&#148;). The Urso Employment Letter provided for an annual base salary of $300,000. Beginning in fiscal year 2015, the Compensation Committee set the target
amount of Mr.&nbsp;Urso&#146;s annual cash bonus as 35% of his base salary based on his achievement of milestones established by the Compensation Committee of the Board of Directors. Beginning in fiscal year 2017, the Compensation Committee
established the target amount of Mr.&nbsp;Urso&#146;s annual cash bonus as 40% of his base salary. Beginning in fiscal year 2020, the Compensation Committee established the target amount of Mr.&nbsp;Urso&#146;s annual cash bonus as 45% of his base
salary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Urso may terminate his employment at any time other than for Good Reason (as defined in the Urso Employment Letter),
upon providing two (2)&nbsp;months advance notice to us. Mr.&nbsp;Urso may terminate his employment with Good Reason by providing us with notice within sixty (60)&nbsp;days of the event giving rise to the Good Reason (and we do not cure the Good
Reason event within thirty (30)&nbsp;days after receiving notice). We have the right to terminate the Urso Employment Letter with or without Cause (as defined in the Urso Employment Letter) at any time. If Mr.&nbsp;Urso&#146;s employment is
terminated by us without Cause or by Mr.&nbsp;Urso for Good Reason, Mr.&nbsp;Urso will be entitled to (i)&nbsp;a lump sum payment in an amount equal to twelve (12) months of his base salary and (ii)&nbsp;accelerated vesting of his options such that
Mr.&nbsp;Urso will be vested in the same number of options as if he had continued to be employed by us for an additional twelve (12)&nbsp;months. The Urso Employment Letter contains confidentiality provisions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_31"></A>Grants of Plan-Based Awards For Fiscal Year Ended June 30, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Possible</B><br><B>Payouts Under</B><br><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT></B><br><B>Incentive Plan</B><br><B>Awards
(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Possible</B><br><B>Payouts Under</B><br><B>Equity</B><br><B>Incentive&nbsp;Plan</B><br><B>Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;Other<BR>Stock<BR>Awards<BR>Number<BR>of&nbsp;Shares<BR>of Stocks</B><br><B>or Units</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Option<BR>Awards<BR>Number&nbsp;of<BR>Securities<BR>Underlying</B><br><B>Options</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>or Base<BR>Price&nbsp;of<BR>Option</B><br><B>Awards</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date<BR>Fair Value<BR>of Stock<BR>and&nbsp;Option</B><br><B>Awards</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Threshold</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Target</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Maximum</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;1,&nbsp;2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,120,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">487,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">201,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert D. Mass</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">378,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 98,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Urso</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board established single bonus targets and, as disclosed in the Summary Compensation Table, determined to
payout bonuses at 125% of the target levels. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_32"></A>Outstanding Equity Awards at Fiscal
<FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides information on all stock options held by our named
executive officers on June 30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares or<BR>Units of<BR>Stock&nbsp;That<BR>Have Not<BR>Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market</B><br><B>Value of<BR>Shares or<BR>Units&nbsp;of&nbsp;Stock<BR>That Have<BR>Not Vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel P. Gold</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 12, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 22, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">277,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 6, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">372,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;29,&nbsp;2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 28, 2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,083</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;12, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June&nbsp;22,&nbsp;2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 6, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">April 3, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert D. Mass</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July&nbsp;12, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 22, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 6, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 29, 2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 28, 2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Urso</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 1, 2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 12, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">June 22, 2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 6, 2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 29, 2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">July 28, 2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the options vested on July 1, 2020; the
remaining seventy-five percent of the options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the options vested on July 12, 2019; the
remaining seventy-five percent of the options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the options vested on June&nbsp;22, 2019; the
remaining seventy-five percent of the options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the options vested on July 6, 2018; the
remaining seventy-five percent of the options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Twenty-five percent of the options vested on July&nbsp;29, 2017; the remaining seventy-five percent of the
options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the options vested on April 3, 2018; the
remaining seventy-five percent of the options will vest in equal monthly installments over the following 36 months. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The options vested in equal monthly installments over 36 months from the date of grant of July&nbsp;28, 2015.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_33"></A>Option Exercises and Stock Vested </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gold exercised 20,000 options during the fiscal year ended June&nbsp;30, 2020. Mr.&nbsp;Drazba, Dr.&nbsp;Mass, and Mr.&nbsp;Urso did
not exercise any stock options during the fiscal year ended June&nbsp;30, 2020. No RSUs vested during the fiscal year ended June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_34"></A>Compensation of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides details of the fees paid to our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors who served on the
Board for the fiscal year ended June 30, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees Earned or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B><br><B>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine A. White, M.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles V. Baltic III (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59.600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">123,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevan E. Clemens, Ph.D. (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cheryl L. Cohen (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 43,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederick W. Driscoll (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">122,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamar D. Howson (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">97,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas R. Glover, Ph.D. (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">121,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas C. Reynolds, M.D., Ph.D. (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William D. Rueckert (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">64,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 94,536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the fiscal year ended June 30, 2020, each of our <FONT STYLE="white-space:nowrap">non-executive</FONT>
directors received an annual cash retainer of $39,600. In addition to the annual cash retainer, the Chair received additional annual compensation of $30,000, and each Board Committee chair received additional compensation as follows: Audit
Committee: $20,000; Compensation Committee: $12,500; and Nominating&nbsp;&amp; Governance Committee: $10,000. Committee members not receiving compensation as a committee chairperson received additional compensation as follows: Audit Committee:
$10,000; Compensation Committee: $7,500; and Nominating and Governance Committee: $5,000. Such amounts are <FONT STYLE="white-space:nowrap">pro-rated</FONT> for periods of service less than the full fiscal year. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents the aggregate grant date fair value of options granted in accordance with FASB ASC Topic 718. For
the relevant assumptions used in determining these amounts, refer to Note 8 to our audited financial statements included in our Annual Report on Form 10-K. All stock options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
in the fiscal year ended June 30, 2020, were granted under our 2008 Equity Plan, and are ten-year options with an exercise price equal to the closing market price of our common stock on the date of grant. The stock options granted vest ratably each
month over 12 months, subject to continued service on the Board of Directors. During the fiscal year ended June 30, 2020, Dr.&nbsp;White, Mr.&nbsp;Baltic, Dr.&nbsp;Clemens, Mr.&nbsp;Driscoll, Ms.&nbsp;Howson, Dr .Glover, Dr.&nbsp;Reynolds, and
Mr.&nbsp;Rueckert each received an annual grant of 40,000 options at an exercise price of $2.52 per share. Upon joining the Board of Directors during the fiscal year ended June&nbsp;30, 2020, Ms.&nbsp;Howson received a grant of 20,000 options at an
exercise price of $2.52 per share, and Ms.&nbsp;Cohen received a grant of 30,000 options at an exercise price of $1.71 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;White received cash compensation of $30,000 in connection with her service as Chair of the Board, and
$5,000 in connection with her service on the Nominating&nbsp;&amp; Governance Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Baltic received cash compensation of $10,000 in connection with his service on the Audit Committee and
$10,000 in connection with his service as Chair of the Nominating&nbsp;&amp; Governance Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Clemens received cash compensation of $12,500 in connection with his service as Chair of the
Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Cohen received cash compensation of $ 389 in connection with her service on the Audit Committee.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Driscoll received cash compensation of $16,668 in connection with his service as Chair of the Audit
Committee and $1,667 in connection with his service as a member of the Audit Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ms.&nbsp;Howson received cash compensation of $4,375 in connection with her service on the Compensation
Committee and $194 in connection with her service on the Nominating&nbsp;&amp; Governance Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Glover received cash compensation of $10,000 in connection with his service on the Audit Committee and
$7,500 in connection with his service on the Compensation Committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Reynolds received cash compensation of $7,500 in connection with his service on the Compensation
Committee and $5,000 in connection with his service on the Nominating and Governance Committee. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mr.&nbsp;Rueckert received cash compensation of $3,334 in connection with his service as Chair of the Audit
Committee, $3,333 in connection with his service as a member of the Audit Committee and $3,750 in connection with his service on the Compensation Committee. Mr.&nbsp;Rueckert resigned from Board of Directors upon the expiration of his term on
December&nbsp;5, 2019. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Gold, President and Chief Executive Officer of the Company, does not receive any
compensation for performing his duties as a director of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_35"></A>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an indemnification agreement with each of our directors and executive officers. Subject to certain exceptions, the
indemnification agreements provide that an indemnitee will be indemnified for all expenses incurred or paid by the indemnitee in connection with a proceeding to which the indemnitee was or is a party, or is threatened to be made a party, by reason
of the indemnitee&#146;s status with or service to us or to another entity at our request. In connection with proceedings other than those by or in the right of our company and to which the indemnitee was or is a party, or is threatened to be made a
party, by reason of the indemnitee&#146;s status with or service to us or to another entity at our request, the indemnification agreements provide that an indemnitee will also be indemnified for all liabilities incurred or paid by the indemnitee.
The indemnification agreements also provide for advancement of expenses incurred by an indemnitee in connection with an indemnifiable claim, subject to reimbursement in certain circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of each indemnitee are in addition to any other rights provided for under our amended and restated certificate of incorporation,
and our amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> as may be amended from time to time, and under Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_36"></A>RATIFICATION OF APPOINTMENT OF BDO USA, LLP (PROPOSAL NO. 4)
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_37"></A>Background </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected BDO USA, LLP (&#147;BDO USA&#148;) as independent registered public accounting firm to audit the financial
statements and the internal controls over financial reporting of the Company for the fiscal year ending June 30, 2021. The Board of Directors is submitting the appointment of BDO USA to the stockholders for ratification as a matter of good corporate
practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BDO USA has been engaged as the Company&#146;s independent auditor since January 18, 2011. They have performed the
Company&#146;s annual audit of its financial statements for each fiscal year beginning with the fiscal year ended June 30, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Representatives of BDO USA are expected to attend the Annual Meeting. The BDO USA representatives will have an opportunity to make a statement
at the meeting and are expected to be available to respond to appropriate questions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_38"></A>Fees Paid to Auditors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended
June&nbsp;30, 2020, we incurred aggregate audit fees of $359,900 to BDO USA. Audit fees relate to professional services rendered in connection with the audit of our annual financial statements and internal controls, quarterly review of financial
statements included in our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and audit services provided in connection with other statutory and regulatory filings, including providing consents for inclusion of their opinion in
registration statements filed with the Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended June&nbsp;30, 2019, we incurred
aggregate audit fees of $284,500 to BDO USA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Audit-related Fees </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No audit-related fees were paid to BDO USA during the fiscal years ended June 30, 2020 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tax Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended
June&nbsp;30, 2020, we incurred aggregate tax fees of $26,000 to BDO USA. Tax fees comprise fees for professional services related to tax compliance and advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal year ended June&nbsp;30, 2019, we incurred aggregate tax fees of $32,000 to BDO USA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No other fees were paid to
BDO USA during the fiscal years ended June 30, 2020 and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_39"></A><FONT STYLE="white-space:nowrap">Pre-Approval</FONT> Policies
and Procedures </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee has adopted a policy and procedure for <FONT STYLE="white-space:nowrap">pre-approving</FONT> all
audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent auditors. The policy requires <FONT STYLE="white-space:nowrap">pre-approval</FONT> of all services rendered by our independent auditors either as
part of the Audit Committee&#146;s approval of the scope of the engagement of the independent auditors or on a case by case basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>VOTE REQUIRED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ratification of the appointment of BDO USA, LLP as our independent registered public accounting firm for the fiscal year ending June 30,
2021 will require approval by the majority of the votes cast by the holders of the shares of our common stock voting in person or by proxy at the Annual Meeting. Stockholders may vote either for or against or abstain from voting on the proposal to
ratify the selection of BDO USA, LLP as our independent registered public accounting firm. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> if any, will be counted for the purposes of determining the presence or absence of a
quorum. Abstentions will have the effect of a vote &#147;against&#148; the proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the outcome of the proposal. A failure to vote by not returning a signed proxy will
have no effect on the outcome of the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the stockholders fail to ratify the appointment, the Audit Committee
will reconsider its selection of audit firms, but may decide not to change its selection. Even if the appointment is ratified, the Audit Committee may appoint a different independent registered public accounting firm at any time if it determines
that such a change would be in our stockholders&#146; best interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THE AUDIT COMMITTEE AND THE BOARD OF DIRECTORS UNANIMOUSLY
RECOMMEND THAT THE STOCKHOLDERS VOTE &#147;FOR&#148; THE RATIFICATION OF BDO USA, LLP TO ACT AS MEI PHARMA&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING JUNE&nbsp;30, 2021. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_40"></A>AUDIT COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The Audit Committee of the Board of Directors of MEI Pharma has furnished the following report on its activities during the fiscal year
ended June 30, 2020. The report is not deemed to be &#147;soliciting material&#148; or &#147;filed&#148; with the SEC or subject to the SEC&#146;s proxy rules or to the liabilities of Section&nbsp;18 of the Exchange Act, and the report shall not be
deemed to be incorporated by reference into any prior or subsequent filing under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), or the Exchange Act, except to the extent that MEI Pharma specifically incorporates it by
reference into any such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee oversees the financial reporting process on behalf of the Board of Directors.
Management has the primary responsibility for the financial reporting process, principles and internal controls as well as preparation of our financial statements. For the fiscal year ended June 30, 2020, the members of the Audit Committee were
Mr.&nbsp;Driscoll (Committee Chair), Mr.&nbsp;Baltic, Dr.&nbsp;Glover and Ms.&nbsp;Cohen (beginning on June&nbsp;17, 2020), each of whom is an independent director as defined by the applicable NASDAQ and SEC rules. Mr.&nbsp;William Rueckert, a
former member of the Board of Directors, served on the Audit Committee until his retirement from the Board of Directors in December 2019. The Audit Committee met four times during the fiscal year ended June 30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In fulfilling its responsibilities, the Audit Committee appointed independent auditors BDO USA for the fiscal year ended June 30, 2020. The
Audit Committee reviewed and discussed with the independent auditors the overall scope and specific plans for their audit. The Audit Committee also reviewed and discussed with the independent auditors and with management MEI Pharma&#146;s audited
financial statements and the adequacy of its internal controls. The Audit Committee met with the independent auditors, without management present, to discuss the results of our independent auditor&#146;s audits, their evaluations of MEI
Pharma&#146;s internal controls and the overall quality of MEI Pharma&#146;s financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Audit Committee has the
sole authority to appoint the independent auditors, the Audit Committee will continue its practice of recommending that the Board of Directors ask the stockholders, at their annual meeting, to ratify their appointment of the independent auditors for
the fiscal year ending June 30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Audit Committee monitored the independence and performance of the independent auditors. The
Audit Committee discussed with the independent auditors the matters required to be discussed by Public Company Accounting Oversight Board (&#147;PCAOB&#148;) Auditing Standard No.&nbsp;1301&#151;Communications with Audit Committees. MEI
Pharma&#146;s independent auditors have provided the Audit Committee with the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent auditors&#146; communications with the Audit Committee
concerning independence, and the Audit Committee has discussed with the independent auditor the independent auditor&#146;s independence. Based upon the review and discussions referred to above, the Audit Committee recommended to the Board of
Directors that the audited financial statements be included in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June 30, 2020, for filing with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Frederick&nbsp;W. Driscoll </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Charles&nbsp;V. Baltic III </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Cheryl&nbsp;L. Cohen </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Nicholas&nbsp;R. Glover </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_41"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as described below, there were no related party transactions required to be disclosed pursuant to Item 404 of the Regulation <FONT
STYLE="white-space:nowrap">S-K</FONT> during the three years ended June 30, 2020. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_42"></A>SECURITY OWNERSHIP OF
CERTAIN BENEFICIAL OWNERS AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANAGEMENT OF MEI PHARMA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information with respect to the beneficial ownership of shares of our common stock as of October 20, 2020
(except as otherwise indicated below) by (i)&nbsp;each person known to beneficially own more than 5% of our common stock, (ii)&nbsp;each of our officers and directors, and (iii)&nbsp;our officers and directors as a group. Beneficial ownership is
determined in accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or restricted stock
units, exercisable or convertible on or within sixty (60)&nbsp;days of October 20, 2020, are deemed outstanding. Such shares, however, are not deemed outstanding for the purposes of computing the percentage ownership of any other person. The
percentage of beneficial ownership described below is based on 112,521,964 shares of common stock outstanding, plus adjustments to the number of shares of common stock outstanding as described above, as of October 20, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;&amp; Nature of<BR>Beneficial&nbsp;Ownership</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares<BR>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MPM Oncology Impact Management LP (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,137,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.01</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Growth Equity Opportunities Fund V, LLC (2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,533,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.58</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel P. Gold (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,013,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.76</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian G. Drazba (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert D. Mass (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David M. Urso (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christine A. White (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Frederick W. Driscoll (8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cheryl L. Cohen (9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles V. Baltic III (10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas C. Reynolds (11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas R. Glover (12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevan E. Clemens (13)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamar D. Howson (14)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All directors and executive officers as a group<BR>(12 individuals)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,173,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.42</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based upon information contained in the Statement on Schedule 13G filed by the stockholder on February&nbsp;5,
2020 as supplemented by the Report on Form 13F filed by MPM Oncology Impact Management LP on August&nbsp;12, 2020. Shares beneficially owned include 6,250,000 shares of common stock held directly by UBS Oncology Impact Fund L.P. (&#147;UBS&#148;).
Oncology Impact Fund (Cayman) Management, L.P. (&#147;OIF Cayman&#148;), as the general partner of UBS, MPM Oncology Impact Management, LP (&#147;MPM LP&#148;) , as the general partner of OIF Cayman, and MPM Oncology Impact Management GP LLC
(&#147;MPM GP&#148;), as the general partner of MPM LP, may be deemed to indirectly beneficially own the securities held by UBS. Ansbert Gadicke is the sole member of MPM GP. However, all voting and investment decisions are made by an investment
committee comprised of three or more members, including Ansbert Gadicke. Each member of the investment committee expressly disclaims beneficial ownership of the reported securities. The principal address of UBS is c/o MPM Capital LLC, 450 Kendall
Street, Cambridge, MA 02142. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based upon information contained in Amendment No.&nbsp;1 to the Statement on Schedule 13D filed by the
stockholder on December&nbsp;30, 2019, shares beneficially owned consists of 8,533,073 shares of common stock held directly. The shares and are held of record by Growth Equity Opportunities Fund V, LLC. New Enterprise Associates 16, L.P. (&#147;NEA
16&#148;) is the sole member of GEO, NEA Partners 16, L.P. (&#147;NEA Partners 16&#148;), is the sole general partner of NEA 16 and NEA 16 GP, LLC (&#147;NEA 16 LLC&#148; and, together with NEA Partners 16, the &#147;Control Entities&#148;), is the
sole general partner of NEA Partners. Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Joshua Makower, David M. Mott, Chetan Puttagunta, Jon M. Sakoda, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan
(together, the &#147;Managers&#148;) are the Managers of NEA 16 LLC. Each of the Control Entities and the Managers may be deemed to have beneficial ownership of the shares and warrants held of record by GEO. The principal address is c/o New
Enterprise Associates, 1954 Greenspring Drive, Timonium, MD 21093. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 1,639,666 shares issuable to Dr.&nbsp;Gold upon the exercise of stock options that are exercisable
within 60 days of October&nbsp;20, 2020 and 373,632 shares of common stock. Dr.&nbsp;Gold exercises sole voting and investment control with respect to the shares. Dr.&nbsp;Gold&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real,
Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 403,333 shares issuable to Mr.&nbsp;Drazba upon the exercise of stock options that are exercisable
within 60 days of October&nbsp;20, 2020 and 37,500 shares of common stock. Mr.&nbsp;Drazba exercises sole voting and investment control with respect to the shares. Mr.&nbsp;Drazba&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino
Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 585,313 shares issuable to Dr.&nbsp;Mass upon the exercise of stock options that are exercisable
within 60 days of October&nbsp;20, 2020 and 33,661 shares of common stock. Dr.&nbsp;Mass exercises sole voting and investment control with respect to the shares. Dr.&nbsp;Mass&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real,
Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 706,667 shares issuable to Mr.&nbsp;Urso upon the exercise of stock options that are exercisable
within 60 days of October&nbsp;20, 2020 and 24,106 shares of common stock. Mr.&nbsp;Urso exercises sole voting and investment control with respect to the shares. Mr.&nbsp;Urso&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real,
Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 200,833 shares issuable to Dr.&nbsp;White upon the exercise of stock options that are exercisable
within 60 days of October&nbsp;20, 2020 and 15,000 shares of common stock. Dr.&nbsp;White exercised sole voting and investment control with respect to the shares. Dr.&nbsp;White&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real,
Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 133,055 shares issuable to Mr.&nbsp;Driscoll upon the exercise of stock options that are exercisable
within 60 days of October 20, 2020 and 62,500 shares of common stock. Mr.&nbsp;Driscoll exercises sole voting and investment control with respect to the shares. Mr.&nbsp;Driscoll&#146;s business address is c/o MEI Pharma, Inc., 3611 Valley Centre
Drive, Suite 500, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 31,944 shares issuable to Ms.&nbsp;Cohen upon the exercise of stock options that are exercisable
within 60 days of October 20, 2020. Ms.&nbsp;Cohen&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 200,833 shares issuable to Mr.&nbsp;Baltic upon the exercise of stock options that are exercisable
within 60 days of October 20, 2020, as well as 29,600 shares of common stock. Mr.&nbsp;Baltic exercises direct voting and investment control with respect to 24,250 shares of common stock and indirect voting and investment control with respect to
5,350 shares of common stock. Mr.&nbsp;Baltic&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 200,833 shares issuable to Dr.&nbsp;Reynolds upon the exercise of stock options that are exercisable
within 60 days of October 20, 2020 and 10,000 shares of common stock. Dr.&nbsp;Reynolds exercises sole voting and investment control with respect to the shares. Dr.&nbsp;Reynolds&#146; business address is c/o MEI Pharma, Inc., 11455 El Camino Real,
Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 200,833 shares issuable to Dr.&nbsp;Glover upon the exercise of stock options that are exercisable
within 60 days of October 20, 2020. Dr.&nbsp;Glover&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 213,500 shares issuable to Dr.&nbsp;Clemens upon exercise of stock options that are exercisable within
60 days of October 20, 2020. Dr.&nbsp;Clemens&#146;s business address is c/o MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 70,277 shares issuable to Ms.&nbsp;Howson upon exercise of stock options that are exercisable within
60 days of October 20, 2020. Ms.&nbsp;Howson&#146;s business address is c/o MEI Pharma, Inc. 11455 El Camino Real, Suite 250, San Diego, California, 92130. </P></TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_43"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma files annual, quarterly and current reports, proxy statements and other information with the SEC. MEI Pharma&#146;s SEC filings are
available to the public from commercial document retrieval services and on the website maintained by the SEC at http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
you would like to request documents from MEI Pharma, please send a request in writing or by telephone at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MEI
Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11455 El Camino Real, Suite 250 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, CA 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(858) <FONT
STYLE="white-space:nowrap">369-7100</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this document to vote your shares at
the Annual Meeting. MEI Pharma has not authorized anyone to provide you with information that differs from that contained in this document. This document is dated October&nbsp;27, 2020. You should not assume that the information contained in this
document is accurate as of any date other than that date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Information on MEI Pharma&#146;s Website </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information on any MEI Pharma&#146;s website is not part of this document and you should not rely on that information in deciding whether to
approve any of the proposals described in this document unless that information is also in this document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc17046_44"></A>OTHER MATTERS FOR STOCKHOLDERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_45"></A>Stockholder Proposals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who intend to present proposals at the Company&#146;s fiscal 2022 annual meeting of stockholders under SEC Rule <FONT
STYLE="white-space:nowrap">14a-8</FONT> must ensure that such proposals are received by the Secretary of the Company no later than June&nbsp;29, 2021. Such proposals must meet the requirements of the SEC to be eligible for inclusion in the
Company&#146;s fiscal 2022 proxy materials. Notwithstanding the foregoing, in the event the date of annual meeting for fiscal 2022 is changed by more than 30 days from the date of the Annual Meeting for fiscal 2021, all stockholder proposals must be
submitted a reasonable time before a solicitation is made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with our bylaws, stockholder proposals, including stockholder
nominations for candidates for election as directors, that are intended to be presented by stockholders at the fiscal 2022 annual meeting of stockholders but not submitted for inclusion in the proxy statement for our fiscal 2022 annual meeting of
stockholders pursuant to Rule <FONT STYLE="white-space:nowrap">14a-8,</FONT> must be received by us no earlier than August&nbsp;18, 2021 and no later than September 17, 2021, unless we change the date of our fiscal 2022 annual meeting more than 30
days before or more than 60 days after December&nbsp;16, 2021, in which case stockholder proposals must be received by us no earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on
the 90th day prior to such annual meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_46"></A>Communication with the MEI Pharma Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEI Pharma&#146;s stockholders may communicate with the Board of Directors, including <FONT STYLE="white-space:nowrap">non-executive</FONT>
directors or officers, by sending written communications addressed to such person or persons in care of MEI Pharma, Inc., Attn: Secretary, 11455 El Camino Real, Suite 250, San Diego, California, 92130. All communications will be compiled by the
Secretary and submitted to the addressee. If the Board of Directors modifies this process, the revised process will be posted on MEI Pharma&#146;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc17046_47"></A>Householding of Proxy Materials for MEI Pharma Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are MEI Pharma stockholders will be &#147;householding&#148; MEI Pharma&#146;s proxy
materials. A&nbsp;single copy of this proxy statement will be delivered to multiple MEI Pharma stockholders sharing an address unless contrary instructions have been received from the affected MEI Pharma stockholders. This process potentially means
extra convenience for stockholders and cost savings for the Company. Once you have received notice from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you notify
your broker or MEI Pharma that you no longer wish to participate in &#147;householding.&#148; If, at any time, you no longer wish to participate in &#147;householding&#148; and would prefer to receive a separate proxy statement and annual report,
you may (1)&nbsp;notify your broker, (2)&nbsp;direct your written request to: Investor Relations, MEI Pharma, Inc., 11455 El Camino Real, Suite 250, San Diego, California, 92130, or (3)&nbsp;contact MEI Pharma&#146;s Chief Financial Officer, Brian
G. Drazba, at: (858) <FONT STYLE="white-space:nowrap">369-7100.</FONT> Upon a written or oral request to the address or telephone number above, MEI Pharma will promptly deliver a separate copy of the annual report and proxy statement to a MEI Pharma
stockholder at a shared address to which a single copy of the proxy statements was delivered. MEI Pharma stockholders who currently receive multiple copies of the proxy statement at their address and would like to request &#147;householding&#148; of
their communications should contact their broker. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="toc17046_48"></A>Annex&nbsp;A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2008 STOCK OMNIBUS EQUITY COMPENSATION PLAN </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section 1. <U>Purpose</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan authorizes
the Compensation Committee to provide Advisors, Employees and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors that are providing services to the Company or its Affiliates, who are in a position to contribute to the long-term success
of the Company or its Affiliates, with Grants. The Company believes that this incentive program will cause those Advisors, Employees and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors to increase their interest in the welfare of the
Company and its Affiliates, and aid in attracting, retaining and motivating Advisors, Employees and <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors of outstanding ability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan was originally effective as of December 9, 2008 upon approval by the stockholders of the Company. The Plan <FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>has been</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>was</STRIKE></FONT><FONT STYLE="font-family:Times New Roman"> amended and
restated </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>several times since its original effective date, most recently effective as of November</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U></U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>&nbsp;29, 2018. </U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>effective October 21, 2011, but the share increase was effective December 1, 2011 upon approval by the stockholders of the Company. The Plan was amended and restated
effective January 29, 2013, but the share increase was effective March 26, 2013 upon approval by the stockholders of the Company. The Plan was further amended and restated effective December 3, 2014, December 3, 2015 and, December 1, 2016 and
November 29, 2018, in each case upon approval by the stockholders of the Company. </STRIKE></FONT><FONT STYLE="font-family:Times New Roman">This amendment and restatement of the Plan is effective as of the Restatement Effective Date, subject
to</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">approval by the Company&#146;s stockholders; <U>provided, however,</U> that if this amendment and restatement
is not so approved, the prior version of the Plan (as in effect immediately prior to the Board&#146;s approval of this amendment and restatement) shall continue to operate according to its terms. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;2. <U>Definitions</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capitalized
terms used herein shall have the meanings set forth in this Section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;Advisor&#148; shall mean advisors who render bona fide
services to the Company or its subsidiaries where the services are not in connection with the offer and sale of securities in a capital-raising transaction and the Advisors do not directly or indirectly promote or maintain a market for the
Company&#146;s securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;Affiliate&#148; shall mean any Person which is included as a member with the Company in a controlled
group of corporations, within the meaning of Code section 414(b), or which is a trade or business (whether or not incorporated) included with the Company in a group of trades or business under common control, within the meaning of Code section
414(c); provided, however, that in applying Code sections 1563(a)(1), (2) and (3)&nbsp;for purposes of determining a controlled group of corporations under Code section 414(b), the language &#147;at least 20 percent&#148; is used instead of &#147;at
least 80 percent&#148; each place it appears in Code sections 1563(a)(1), (2) and (3), and in applying Treas.<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reg. section <FONT STYLE="white-space:nowrap">1.414(c)-2</FONT> for purposes of determining trades or
businesses (whether or not incorporated) that are under common control for purposes of<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">Code section 414(c), the
language &#147;at least 20 percent&#148; is used instead of &#147;at least 80 percent&#148; each place it appears in Treas. Reg. section <FONT STYLE="white-space:nowrap">1.414(c)-2.</FONT> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE></STRIKE></FONT><FONT STYLE="font-family:Times New Roman">(c) &#147;Board&#148;
 shall mean the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;Cause&#148; shall have the meaning ascribed thereto in any effective
employment or service agreement between the Company and the Grantee, or if no employment agreement is in effect that contains a definition of cause, then Cause shall mean a finding by the Compensation Committee, in its sole and absolute discretion,
that the Grantee has (i)&nbsp;committed a felony or a crime involving moral turpitude, (ii)&nbsp;committed any act of gross negligence or fraud, (iii)&nbsp;failed, refused or neglected to substantially perform his duties (other than by reason of a
physical or mental impairment) or to implement the directives of the Company, (iv)&nbsp;materially violated any policy of the Company, or (v)&nbsp;engaged in conduct that is materially injurious to the Company, monetarily or otherwise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;Change in Control&#148; shall be deemed to have occurred if: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Any &#147;person&#148; (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a &#147;beneficial owner&#148; (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change in Control shall not be
deemed to occur as a result of a transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the
transaction, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the parent corporation would be entitled in the election of directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The consummation of (A)&nbsp;a merger or consolidation of the Company with another corporation where the stockholders of the Company,
immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would
be entitled in the election of directors, or where the members of the Board, immediately prior to the merger or consolidation, would not, immediately after the merger or consolidation, constitute a majority of the board of directors of the surviving
corporation, (B)&nbsp;a sale or other disposition of all or substantially all of the assets of the Company, or (C)&nbsp;a liquidation or dissolution of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Notwithstanding the foregoing, if a Grant constitutes deferred compensation subject to Code section 409A and the Grant provides for payment upon a Change in Control, then, for purposes of such
payment provisions, no Change in Control shall be deemed to have occurred upon an event described in items (i)&nbsp;and (ii<B>) </B>above unless the event would also constitute a change in ownership or effective control of, or a change in the
ownership of a substantial portion of the assets of, the Company under Code section 409A. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;Code&#148; shall mean the Internal
Revenue Code of 1986, as amended and the regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;Company&#148; shall mean MEI Pharma, Inc., a
corporation organized under the laws of the State of Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;Compensation Committee&#148; shall mean the members of the Board
appointed by the Board to serve as the Compensation Committee with responsibility for the administration of the Plan, or if no such members of the Board are appointed, then the Compensation Committee shall consist of all of the members of the Board.
In any case, the Board shall approve and administer all grants made to <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors. The members of the Board appointed to serve as the Compensation Committee, if applicable, should consist of two or
more Persons who are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; as defined under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act. To the extent that the Board or a subcommittee administers
the Plan, references in the Plan to the &#147;Compensation Committee&#148; shall be deemed to refer to the Board or such subcommittee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)
&#147;Disability&#148; or &#147;Disabled&#148; shall mean a Grantee&#146;s becoming disabled within the meaning of Code section 22(e)(3) or as otherwise determined by the Compensation Committee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;Employee&#148; shall mean any individual that is providing, or has agreed to provide, services to the Company or an Affiliate of the
Company as an employee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;Exchange Act&#148; shall mean the Securities Exchange Act of 1934, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;Exercise Price&#148; shall mean the purchase price of a Share subject to an Option, which shall not be less than the Fair Market
Value of a Share as of the date an Option is granted. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;Fair Market Value&#148; of a Share on any given date, unless the
Compensation Committee determines otherwise with respect to a particular Grant, shall mean (i)&nbsp;if the principal trading market for the Shares is a national securities exchange, the last reported sale price during regular trading hours thereof
of a Share on the relevant date or (if there were no trades on that date) the last reported sales price during regular trading hours on<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT
STYLE="font-family:Times New Roman">the latest preceding date upon which a sale was reported, (ii)&nbsp;if the Shares are not principally traded on such exchange, the mean between the last reported &#147;bid&#148; and &#147;asked&#148; prices of a
Share during regular trading hours on the relevant date, as reported on the OTC Bulletin Board, or (iii)&nbsp;if the Shares are not publicly traded or, if publicly traded, are not so reported, the Fair Market Value per share shall be as determined
by the Compensation Committee pursuant to any reasonable valuation method authorized under the Code. </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;Full Value
Award&#148; shall mean a Grant other than an Option or SAR, and which is settled in Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;Grant&#148; shall mean a grant of
Options, SARs, Stock Awards, Stock Units or Other Stock-Based Awards under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;Grant Letter&#148; shall mean a letter,
certificate or other agreement accepted by the Grantee (which may also be in electronic form), evidencing the making of a Grant hereunder and containing such terms and conditions, not inconsistent with the express provisions of the Plan, as the
Compensation Committee shall approve. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;Grantee&#148; shall mean an Advisor, Employee or
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director made a Grant under the Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;ISO&#148; shall mean any Option or
portion thereof that meets the requirements of an incentive stock option under Code section 422 and that is designated by the Compensation Committee to be an ISO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <FONT STYLE="white-space:nowrap">&#147;Non-Employee</FONT> Director&#148; shall mean a member of the Board who is not an Employee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;Nonqualified Option&#148; shall mean any Option or portion thereof that is not an ISO. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#147;Options&#148; shall refer to options issued under and subject to the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;Other Stock-Based Award&#148; shall mean any Grant based on, measured by or payable in Shares (other than those described in Sections
5, 6, 7 and 8 of the Plan), as described in Section&nbsp;9. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;Performance Goals&#148; shall mean objectively determinable
performance goals that may be based on one or more of the following criteria: stock price, earnings per share, net earnings, operating earnings, earnings before income taxes, EBITDA (earnings before income tax expense, interest expense, and
depreciation and amortization expense), return on assets, shareholder return, return on equity, growth in assets, unit volume, sales or market share, or strategic business criteria consisting of one or more objectives based on meeting specified
revenue goals, market penetration goals, geographic business expansion goals, cost targets or goals relating to acquisitions or divestitures; <FONT STYLE="white-space:nowrap">pre-</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> income or
loss (before or after allocation of corporate overhead and bonus);<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">
</FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appreciation in and/or maintenance of the price of the Shares or any other publicly-traded securities of the Company; improvement in or attainment of expense levels or working capital levels,
including cash, inventory and accounts receivable; general and administrative expense savings; <FONT STYLE="white-space:nowrap">year-end</FONT> cash; regulatory achievements (including submitting or filing applications or other documents with
regulatory authorities or receiving approval of any such applications or other documents and passing <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections (whether of the Company or the Company&#146;s third-party manufacturer) and
validation of manufacturing processes (whether the Company&#146;s or the Company&#146;s third-party manufacturer&#146;s); clinical achievements (including initiating clinical studies, initiating enrollment, completing enrollment or enrolling
particular numbers of subjects in clinical studies, completing phases of a clinical study (including the treatment phase), or announcing or presenting preliminary or final data from clinical studies, in each case, whether on particular timelines or
generally); strategic partnerships or transactions (including <FONT STYLE="white-space:nowrap">in-licensing</FONT> and <FONT STYLE="white-space:nowrap">out-licensing</FONT> of intellectual property); establishing relationships with commercial
entities with respect to the marketing, distribution and sale of the Company&#146;s products (including with group purchasing organizations, distributors and other vendors); <FONT STYLE="white-space:nowrap">co-development,</FONT> <FONT
STYLE="white-space:nowrap">co-marketing,</FONT> profit sharing, joint venture or other similar arrangements; financing and other capital raising transactions (including sales of the Company&#146;s equity or debt securities); debt level <FONT
STYLE="white-space:nowrap">year-end</FONT> cash position; competitive market<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">metrics; timely completion of new product
roll-outs; sales or licenses of the Company&#146;s assets (including its intellectual property, whether in a particular jurisdiction or territory or globally, or through partnering transactions); royalty income; implementation, completion or
attainment of measurable objectives with respect to research, development, manufacturing, commercialization, products or projects, acquisitions and divestitures, or such other criteria as the Compensation Committee determines. The business criteria
may relate to the performance of the Company, or the performance of a parent company, a subsidiary, division, business segment or business unit of the Company or a subsidiary, or based upon performance relative to performance of other companies or
upon comparisons or any of the indicators of performance relative to performance of other companies, or any combination of the foregoing. Any performance goals that are financial metrics, may be determined in accordance with U.S. Generally Accepted
Accounting Principles (&#147;GAAP&#148;), in accordance with accounting principles established by the International Accounting Standards Board (&#147;IASB Principles&#148;), or may be adjusted when established to include or exclude any items
otherwise includable or excludable under GAAP or under IASB Principles. The</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">Compensation Committee may provide
for exclusion of the impact of an event or occurrence which the Compensation Committee determines should appropriately be excluded, including (A)&nbsp;restructurings, discontinued operations, and other unusual, infrequently occurring or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> charges,</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">(B) an event either not directly related to the
operations of the Company, Company subsidiary, division, business segment or business unit or not within the reasonable control of management, or (C)&nbsp;the cumulative effects of tax or accounting changes in accordance with U.S. generally accepted
accounting</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">principles. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;Person&#148; shall mean an individual, partnership, corporation, limited liability
company or partnership, trust, unincorporated organization, joint venture, government (or agency or political subdivision thereof) or any other entity of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;Plan&#148; shall mean this Amended and Restated MEI Pharma, Inc. 2008 Omnibus Equity Compensation Plan as set forth herein and as
amended from time to time. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;Restatement Effective Date&#148; shall mean <FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>November 29</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>December</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U></U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>&nbsp;16</U></FONT><FONT STYLE="font-family:Times New Roman">, </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>2018</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>2020</U></FONT><FONT STYLE="font-family:Times New Roman">, provided that
this amendment and restatement of the Plan is approved by the Company&#146;s stockholders on such date. </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;SAR&#148; shall
mean a stock appreciation right with respect to a Share. (bb) &#147;Share&#148; shall mean a share of common stock of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)
&#147;Stock Award&#148; shall mean an award of Shares, with or without restrictions. (dd) &#147;Stock Unit&#148; shall mean a unit that represents a hypothetical Share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) &#147;Substitute Awards&#148; shall mean Grants made or Shares issued by the Company in assumption of, or in substitution or exchange for,
awards previously granted, or the right or obligation to make future awards, in each case by a company acquired by the Company or any Company subsidiary or with which the Company or any subsidiary combines. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;3. <U>Shares Available under the Plan</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Shares Authorized</U>. Subject to adjustments as provided in Sections 3(b) and 12 below, as of the Restatement
Effective Date, (i)<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>11,800,000</STRIKE></FONT><FONT STYLE="font-family:Times New Roman">
</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>16,362,150</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">Shares, less
(ii)&nbsp;one Share for every one Share that was subject to an Option or SAR granted after June&nbsp;30, </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>2018</STRIKE></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>2020</U></FONT><FONT STYLE="font-family:Times New Roman"> and 1.25 Shares for every one Share that was subject to a Full Value Award granted after June&nbsp;30, </FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>2018</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>2020</U></FONT><FONT STYLE="font-family:Times New Roman">, shall be
authorized for Grants made under the Plan. Shares</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">subject to Grants made under the Plan prior to the Restatement
Effective Date will be issued from the Share reserve authorized under the</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">Plan prior to the Restatement
Effective Date. A maximum of </FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE>11,800,000</STRIKE></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>10,000,000</U></FONT><FONT
STYLE="font-family:Times New Roman"> Shares may be subject to ISOs granted under the Plan. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued shares, treasury shares or shares purchased in the open market</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">or otherwise. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp; <U>Share Counting.</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For each Share that is subject to an Option or SAR granted after June&nbsp;30,
<FONT COLOR="#ff4338"><STRIKE>2018</STRIKE></FONT><FONT COLOR="#0011ba"><U>2020</U></FONT>, the Share limit referred above in Section&nbsp;3(a) shall be reduced by one Share for every one Share that was subject to an Option or SAR and for each Share
that is subject to a Full Value Award granted after<FONT COLOR="#0011ba"><U> </U></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
June&nbsp;30, <FONT COLOR="#ff4338"><STRIKE>2018</STRIKE></FONT><FONT COLOR="#0011ba"><U>2020</U></FONT>, the Share limit shall be reduced by 1.25 Shares for every one Share that was subject to a
Full Value Award. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any Shares subject to a Grant are forfeited, a Grant expires or a Grant is settled for cash (in whole or in
part), then the Shares subject to such Grant shall, to the extent of such forfeiture, expiration or cash settlement, be added to the Shares available for Grants under the Plan, subject to the mechanism set forth in Section&nbsp;3(b)(iv). The term
&#147;Grant&#148; as used in this Section&nbsp;3(b)(ii) shall include Grants made under the Plan prior to the Restatement Effective Date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding anything to the contrary contained herein, the following Shares shall not be added to the
Shares that may be subject to Grants under the Plan (including Grants made under the Plan prior to the Restatement Effective Date): (A) Shares tendered by the Grantee or withheld by the Company in payment of the Exercise Price of an Option,
(B)&nbsp;Shares tendered by the Grantee or withheld by the Company to satisfy any tax withholding obligation with respect to Grants, (C)&nbsp;Shares subject to a SAR that are not issued in connection with its stock settlement on exercise thereof,
and (D)&nbsp;Shares reacquired by the Company on the open market or otherwise using cash proceeds from the exercise of Options. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Shares that again become available for Grants under the Plan pursuant to this Section&nbsp;3 shall be added
as (A)&nbsp;one Share for every one Share subject to Options or SARs granted under the Plan, and (B)&nbsp;as 1.25 Shares for every one Share subject to Full Value Awards granted under the Plan. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Substitute Awards</U>. Substitute Awards shall not reduce the Shares authorized for grant under the Plan or
the limitations on grants to a<FONT COLOR="#0011ba"><U> </U></FONT>Grantee under Section&nbsp;3(e), nor shall Shares subject to a Substitute Award be added to the Shares available for issuance or transfer under the Plan as provided in Sections 3(a)
and (b)&nbsp;above. Additionally, in the event that a company acquired by the Company or any Company subsidiary or with which the Company or any subsidiary combines has shares available under a <FONT STYLE="white-space:nowrap">pre-existing</FONT>
plan approved by stockholders and not adopted in contemplation of such acquisition or combination, the shares available for grant pursuant to the terms of such<FONT COLOR="#0011ba"><U> </U></FONT><FONT STYLE="white-space:nowrap">pre-existing</FONT>
plan (as adjusted, to the extent appropriate, using the exchange ratio or other adjustment or valuation ratio or formula used in such acquisition or combination to determine the consideration payable to the holders of common stock of the entities
party to such acquisition or combination) may be used for Grants under the Plan and shall not reduce the Shares authorized for Grants under the Plan (and<FONT COLOR="#0011ba"><U> </U></FONT>Shares subject to such Grants shall not be added to the
Shares available for Grants under the Plan as provided in Sections 3(a) and<FONT COLOR="#0011ba"><U> </U></FONT>(b) above); provided that Grants using such available shares<FONT COLOR="#0011ba"><U> </U></FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
shall not be made after the date awards or grants could have been made under the terms of the <FONT STYLE="white-space:nowrap">pre-existing</FONT> plan, absent the acquisition or combination, and
shall only be made to individuals who were not Employees or directors prior to such acquisition or combination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Individual Limits on Grants to Non-Employee Directors</U><I>. </I>Notwithstanding any other provision of the
Plan to the contrary, including but not limited to Section&nbsp;3(e) below, the aggregate grant date fair value (computed as of the date of grant in accordance with applicable financial accounting rules) of all Grants granted to any <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director during any single calendar year for services provided as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director, plus the sum of all cash payments paid or payable to such director for
services provided as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director during such year (including but not limited to annual retainer and similar fees) shall not exceed $400,000. For the avoidance of doubt, compensation shall be
counted towards this limit for the year in which it is earned, and not a later year in the event it is deferred. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Individual Limits on Grants to Advisors and Employees.</U> Subject to adjustment as provided in
Section&nbsp;12, no Advisor or Employee may be awarded Grants during any calendar year with respect to more than 4,000,000 Shares. The limitation in this Section&nbsp;3(e) shall be multiplied by two with respect to Grants made to an Employee during
the first calendar year in which the Employee commences employment or service with the Company and its subsidiaries. If a Grant is cancelled, the cancelled Grant shall continue to be counted toward the applicable limitation in this
Section&nbsp;3(e). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;4. <U>Administration of the Plan</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Authority of the Compensation Committee.</U> The Plan shall be administered by the Compensation Committee. The Compensation Committee
shall have full and final authority to take the following actions, in each case subject to and consistent with the provisions of the Plan: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) to select the Advisors, Employees and
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors to whom Grants may be made; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;to determine the number of Shares
subject to each such Grant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) to determine the terms and conditions of any Grant made under the Plan; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) to determine whether to accelerate the exercisability of any or all applicable outstanding Grants at any time for any reason; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) to determine the restrictions or conditions related to the delivery, holding and disposition of Shares acquired pursuant to a Grant; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;to prescribe the form of each Grant Letter; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii) to adopt, amend, suspend, waive and rescind such rules and regulations and appoint such agents as the Compensation Committee may deem
necessary or advisable to administer the Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii) to correct any defect or supply any omission or reconcile any inconsistency in the
Plan and to construe and interpret the Plan and any Grant, Grant Letter or other instrument hereunder; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ix) to make all other
decisions and determinations as may be required under the terms of the Plan or as the Compensation Committee may deem necessary or advisable for the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All Grants shall be made conditional upon the Grantee&#146;s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations
of the Compensation Committee shall be final and binding on the Grantee, his or her beneficiaries and any other Person having or claiming an interest under such Grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Manner of Exercise of Compensation Committee Authority.</U> Any action of the Compensation Committee with respect to the Plan shall be
final, conclusive and binding on all Persons, including the Company, its Affiliates, Grantees, or any Person claiming any rights under the Plan from or through any Grantee, except to the extent the Compensation Committee may subsequently modify, or
take further action not inconsistent with, its prior action. If not specified in the Plan, the time at which the Compensation Committee must or may make any determination shall be determined by the Compensation Committee, and any such determination
may thereafter be modified by the Compensation Committee. The express grant of any specific power to the Compensation Committee, and the taking of any action by the Compensation Committee, shall not be construed as limiting any power or authority of
the Compensation Committee. The Compensation Committee may delegate to officers or managers of the Company or any Affiliate of the Company the authority, subject to such terms as the Compensation Committee shall determine, to perform such functions
as the Compensation Committee may determine, to the extent permitted under applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Limitation of Liability.</U> Each member of the Compensation Committee shall be
entitled to, in good faith, rely or act upon any report or other information furnished to him by any officer or other employee of the Company or any of its Affiliates, the Company&#146;s independent certified public accountants or any executive
compensation consultant, legal counsel or other professional retained by the Company to assist in the administration of the Plan. To the fullest extent permitted by applicable law, no member of the Compensation Committee, nor any officer or employee
of the Company acting on behalf of the Compensation Committee, shall be personally liable for any action, determination or interpretation taken or made in good faith with respect to the Plan, and all members of the Compensation Committee and any
officer or employee of the Company acting on its behalf shall, to the extent permitted by law, be fully indemnified and protected by the Company with respect to any such action, determination or interpretation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;5. <U>Options</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation
Committee may grant Options to an Employee, Advisor or member of the Board upon such terms as the Compensation Committee deems appropriate. The following provisions are applicable to Options: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Number of Shares.</U> The Compensation Committee shall determine the number of Shares that will be subject to each Grant of Options to
an Employee, Advisor or member of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Type of Option and Price.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) The Compensation Committee may grant ISOs or Nonqualified Stock Options or any combination of the two, all in accordance with the terms and
conditions set forth herein. ISOs may be granted only to employees of the Company or its parent or subsidiary corporations, as defined in Code section 424. Nonqualified Options may be granted to Employees, Advisors or members of the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) The Exercise Price of Shares subject to an Option shall be determined by the Compensation Committee and may be equal to or greater than
the Fair Market Value of a Share on the date the Option is granted. However, an ISO may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the
Company, or any parent or subsidiary corporation of the Company, as defined in Code section 424, unless the Exercise Price per Share is not less than 110% of the Fair Market Value of a Share on the date of grant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) Each ISO shall provide that, if the aggregate Fair Market Value of the Shares on the date of the grant with respect to which ISOs are
exercisable for the first time by a Grantee during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary of the Company, exceeds $100,000, then the Option, as to the excess, shall be treated as a
Nonqualified Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Term.</U> The Compensation Committee shall determine the term of each Option.
Notwithstanding the foregoing, the term of any Option shall not exceed ten years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Option Termination.</U>
Except as provided below, an Option may only be exercised while the Grantee is employed or engaged by the Company or any Affiliate as an Advisor, Employee or member of the Board. Unless otherwise determined by the Compensation Committee and set
forth in a Grant Letter, Options shall terminate on the earliest of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the date on which the Grantee is no longer employed or engaged by
the Company and any Affiliate on account of the Grantee&#146;s termination for Cause. In addition, notwithstanding any other provisions of this Section&nbsp;5, if the Compensation Committee determines that the Grantee has engaged in conduct that
constitutes Cause at any time while the Grantee is employed or engaged by the Company and any Affiliate or after the Grantee&#146;s termination of employment or engagement, any Option held by the Grantee shall immediately terminate and the Grantee
shall automatically forfeit all Shares underlying any exercised portion of an Option for which the Company has not yet delivered the Share certificates, upon refund by the Company of the Exercise Price paid by the Grantee for such Shares. Upon any
exercise of an Option, the Company may withhold delivery of Share certificates pending resolution of an inquiry that could lead to a finding resulting in a forfeiture; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) the 91st day following the date the Grantee is no longer employed or engaged by the Company and any Affiliate for any reason other than
Cause, death, or Disability; <U>provided,</U> <U>however,</U> that in all cases the portion of any Option that is not vested on the date of termination of employment or engagement shall terminate immediately upon such termination; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii) the first anniversary of the date the Grantee&#146;s employment or engagement by the Company and any Affiliate terminates on account of
the Grantee&#146;s death or Disability; <U>provided,</U> <U>however,</U> that the portion of any Option that is not vested on the date of such termination of employment or engagement shall terminate immediately upon such termination; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv) the tenth anniversary of the date of grant as set forth in the Grant Letter<B>; </B>and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v) cancellation, termination or expiration of the Options pursuant to action taken by the Compensation Committee in accordance with<FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">Section&nbsp;12. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event that on the last business day of the term of an Option (other than an ISO)&nbsp;(i) the exercise
of the Option is prohibited by applicable law or (ii)&nbsp;Shares may not be purchased or sold by certain employees or directors of the Company due to the <FONT STYLE="white-space:nowrap">&#147;black-out</FONT> period&#148; of a Company policy or a <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement undertaken in connection with an issuance of securities by the Company, the term of the<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Option shall be extended for a period of 30 days following the end of the legal prohibition, <FONT STYLE="white-space:nowrap">black-out</FONT> period or
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, to the extent permitted under Code section 409A. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the Plan,
employment or engagement by the Company and any Affiliate shall mean employment or service as an Employee, Advisor or member of the Board (so that, for purposes of exercising Options, a Grantee shall not be considered to have terminated his
employment or engagement until the Grantee ceases to be an Employee, Advisor and member of the Board), unless the Compensation Committee determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Exercise of Options.</U> Only the vested portion of any Option may be exercised. A Grantee may exercise an Option that has become
exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Grantee shall pay the Exercise Price for an Option as specified by the Compensation Committee (i)&nbsp;in cash, (ii)&nbsp;unless the Compensation Committee
determines otherwise, by delivering Shares owned by the Grantee and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (on a form prescribed by the Compensation Committee) to ownership of Shares
having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii)&nbsp;by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, or (iv)&nbsp;by such other method
as the Compensation Committee may approve. In addition, in the event the Compensation Committee so determines, to the extent an Option is at the time exercisable for vested shares of Company Stock, all or any part of that vested portion may be
surrendered to the Company for an appreciation distribution payable in Shares with a Fair Market Value at the time of the Option surrender equal to the dollar amount by which the then Fair Market Value of the Shares subject to the surrendered
portion exceeds the aggregate Exercise Price payable for those Shares. Shares used to exercise an Option shall have been held by the Grantee for the requisite period of time necessary to avoid adverse accounting consequences to the Company with
respect to the Option. Payment for the Shares to be issued or transferred pursuant to the Option, and any applicable withholding taxes, must be received by the Company by the time specified by the Compensation Committee depending on the type of
payment being made, but in all cases prior to the issuance or transfer of such Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a Grant Letter may
provide that if on the last day of the term of an Option the Fair Market Value of one Share exceeds the Exercise Price per Share, the Grantee has not exercised the Option (or a tandem SAR, if applicable) and the Option has not expired, the Option
shall be deemed to have been exercised by the Grantee on such day with payment made by withholding Shares otherwise issuable in connection with the exercise of the Option. In such event, the Company shall deliver to the Grantee the number of Shares
for which the Option was deemed exercised, less the number of Shares required to be withheld for the payment of the total Exercise Price and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
applicable withholding taxes; <U>provided,</U> <U>however,</U> any fractional Share shall be settled in cash. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>(f) </U></FONT><FONT STYLE="font-family:Times New Roman"><U><FONT
STYLE="font-family:Times New Roman" COLOR="#0011ba">Grants to <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees</FONT></U><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>. </U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>Notwithstanding the foregoing, Options granted to persons who are <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees under the Fair Labor Standards Act of 1938, as
amended, may not be exercisable for at least six months after the date of grant (except that such Options may become exercisable, as determined by the Compensation Committee, upon the Grantee</U></FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>&#146;</U></FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>s death, Disability or retirement, or upon a Change in Control or other
circumstances permitted by applicable regulations).</U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;6. <U>Stock
Awards</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may issue or transfer Shares to an Employee, Advisor or member of the Board under a Stock Award,
upon such terms as the Compensation Committee deems appropriate. The following provisions are applicable to Stock Awards: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General
Requirements.</U> Shares issued or transferred pursuant to Stock Awards may be issued or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Compensation Committee. The
Compensation Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse over a period of time or according to such other criteria as the Compensation Committee deems appropriate, including,
without limitation, restrictions based upon the achievement of specific Performance Goals. The period of time during which the Stock Awards will remain subject to restrictions will be designated in the Grant Letter as the &#147;Restriction
Period.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Number of Shares</U>. The Compensation Committee shall determine the number of Shares to be issued or transferred
pursuant to a Stock Award and the restrictions applicable to such Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Requirement of Employment or Service.</U> If the Grantee
is no longer employed or engaged by the Company or any Affiliate during a period designated in the Grant Letter as the Restriction Period, or if other specified conditions are not met, the Stock Award shall terminate as to all Shares covered by the
Grant as to which the restrictions have not lapsed, and those Shares must be immediately returned to the Company. The Compensation Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Restrictions on Transfer and Legend on Stock Certificate.</U> During the Restriction Period, a Grantee may not sell, assign, transfer,
pledge or otherwise dispose of the Shares of a Stock Award except under Section&nbsp;13(b) below. Unless otherwise determined by the Compensation Committee, the Company will retain possession of certificates for Shares of Stock Awards until all
restrictions on such Shares have lapsed. Each certificate for a Stock Award, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the Grant. The Grantee shall be entitled to have the legend removed from
the stock certificate covering the Shares subject to restrictions when all restrictions on such Shares have lapsed. The Compensation Committee may determine that the Company will not issue certificates for Stock Awards until all restrictions on such
Shares have lapsed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Right to Vote and to Receive Dividends</U>. Unless the Compensation Committee determines otherwise, during the
Restriction Period, the Grantee shall have the right to vote Shares of Stock Awards and to receive any dividends or other distributions paid on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Shares, subject to any restrictions deemed appropriate by the Compensation Committee, including, without limitation, the achievement of specific Performance Goals. Notwithstanding the
provisions of this Section, any cash dividends, stock and any other property (other than cash) distributed as a dividend or otherwise with respect to any unvested Stock Award shall either (i)&nbsp;not be paid or credited or (ii)&nbsp;be accumulated
and subject to restrictions and risk of forfeiture to the same extent as the Shares underlying the Stock Award with respect to which such cash, stock or other property has been distributed and shall not be paid unless and until the time such
restrictions and risk of forfeiture lapse. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Lapse of Restrictions.</U> All restrictions imposed on Stock Awards shall lapse upon the
expiration of the applicable Restriction Period and the satisfaction of all conditions, if any, imposed by the Compensation Committee. The Compensation Committee may determine, as to any or all Stock Awards, that the restrictions shall lapse without
regard to any Restriction Period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;7. <U>Stock Units</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may grant Stock Units, each of which shall represent one hypothetical Share, to an Employee, Advisor or member of
the Board, upon such terms and conditions as the Compensation Committee deems appropriate. The following provisions are applicable to Stock Units: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Crediting of Units.</U> Each Stock Unit shall represent the right of the Grantee to receive a Share or an amount of cash based on the
value of a Share, if and when specified conditions are met. All Stock Units shall be credited to bookkeeping accounts established on the Company&#146;s records for purposes of the Plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Terms of Stock Units.</U> The Compensation Committee may grant Stock Units that are payable if specified Performance Goals or other
conditions are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period or other period, or payment may be deferred to a date authorized by the Compensation Committee. The Compensation Committee shall
determine the number of Stock Units to be granted and the requirements applicable to such Stock Units. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Requirement of Employment or
Service.</U> If the Grantee is no longer employed or engaged by the Company or any Affiliate prior to the vesting of Stock Units, or if other conditions established by the Compensation Committee are not met, the Grantee&#146;s Stock Units shall be
forfeited. The Compensation Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Payment With Respect to Stock Units.</U> Payments with respect to Stock Units shall be made in cash, Shares or any combination of the
foregoing, as the Compensation Committee shall determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;8. <U>Stock Appreciation Rights</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions are applicable to SARs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>General Requirements.</U> The Compensation Committee may grant SARs to an Employee, Advisor or member of the Board separately or in
tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted or at any time thereafter while the Option remains outstanding; <U>provided,</U> <U>however</U>, that, in the
case of an ISO, SARs may be granted only at the time of the grant of the ISO. The Compensation Committee shall establish the base amount of the SAR at the time the SAR is granted, which shall be equal to or greater than the Fair Market Value of a
Share as of the date of grant of the SAR. The base amount of each SAR shall be equal to the per Share Exercise Price of the related Option, provided such Exercise Price is equal to or greater than the Fair Market Value of a Share as of the date of
grant of the SAR or, if there is no related Option, an amount equal to or greater than the Fair Market Value of a Share as of the date of grant of the SAR. No SAR shall have a term that is greater than ten years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, in the event that on the last business day of the term of a SAR (x)&nbsp;the exercise of the SAR is prohibited
by applicable law or (y)&nbsp;Shares may not be purchased or sold by certain employees or directors of the Company due to the <FONT STYLE="white-space:nowrap">&#147;black-out</FONT> period&#148; of a Company policy or a <FONT
STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement undertaken in connection with an issuance of securities by the Company, the term shall be extended for a period of 30 days following the end of the legal prohibition, <FONT
STYLE="white-space:nowrap">black-out</FONT> period or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, to the extent permitted under Code section 409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Tandem SARs.</U> In the case of tandem SARs, the number of SARs granted to a Grantee that shall be exercisable during a specified
period shall not exceed the number of Shares that the Grantee may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the Shares covered by such Option shall terminate. Upon the
exercise of SARs, the related Option shall terminate to the extent of an equal number of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercisability.</U> A SAR shall
be exercisable during the period specified by the Compensation Committee in the Grant Letter and shall be subject to such vesting and other restrictions as may be specified in the Grant Letter. SARs may only be exercised while the Grantee is
employed or engaged by the Company or Affiliate or during the applicable period after termination of employment or engagement as described in Section&nbsp;5(c) above. A tandem SAR shall be exercisable only during the period when the Option to which
it is related is also exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Grant Letter may provide that if on the last day of the term of a SAR the Fair Market Value of one
Share exceeds the base amount per Share of the SAR, the Grantee has not exercised the SAR or the tandem Option (if applicable), and the SAR has not<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise expired, the SAR shall be deemed to have been exercised by the Grantee on such day. In such event, the Company shall make payment to the Grantee in accordance with this Section, reduced
by the number of Shares (or cash) for applicable withholding taxes; any fractional Share shall be settled in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Grants to <FONT
STYLE="white-space:nowrap">Non-Exempt</FONT> Employees.</U> Notwithstanding the foregoing, SARs granted to persons who are <FONT STYLE="white-space:nowrap">non-exempt</FONT> employees under the Fair Labor Standards Act of 1938, as amended, may not
be exercisable for at least six months after the date of grant (except that such SARs may become exercisable, as determined by the Compensation Committee, upon the Grantee&#146;s death, Disability or retirement, or upon a Change in Control or other
circumstances permitted by applicable regulations). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Value of SARs.</U> When a Grantee exercises SARs, the Grantee shall receive in
settlement of such SARs an amount equal to the value of the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair Market Value of the underlying Share on the date of exercise of the SAR
exceeds the base amount of the SAR as described in subsection (a)&nbsp;above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Form of Payment.</U> The appreciation in a SAR shall
be paid in Shares, cash or any combination of the foregoing, as the Compensation Committee shall determine. For purposes of calculating the number of Shares to be received, Shares shall be valued at their Fair Market Value on the date of exercise of
the SAR. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;9. <U>Other Stock-Based Awards</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may grant Other Stock-Based Awards to any Employee, Advisor or member of the Board, on such terms and conditions as
the Compensation Committee shall determine. Other Stock-Based Awards may be awarded subject to the achievement of Performance Goals or other conditions and may be payable in cash, Company Stock or any combination of the foregoing, as the
Compensation Committee shall determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;10. <U>Dividend Equivalents</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may grant Dividend Equivalents in connection Stock Units or Other Stock-Based Awards. No Dividend Equivalents or
dividends may be granted in connection with Options or SARs. Dividend Equivalents may be accrued as contingent cash obligations and may be payable in cash or Shares, and upon such terms as the Compensation Committee may establish, including, without
limitation, the achievement of specific Performance Goals. Notwithstanding the foregoing in this Section&nbsp;10, any Dividend Equivalents granted in connection with unvested Stock Units or Other Stock-Based Awards shall be payable only if and to
the extent the underlying Stock Units or Other Stock-Based Awards are payable, as determined by the Compensation Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;11. <U>Deferrals</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may permit or require a Grantee to defer receipt of the payment of cash or the delivery of Shares that would
otherwise be due to such Grantee in connection with any Stock Units or Other Stock-Based Awards. If any such deferral election is permitted or required, the Compensation Committee shall establish rules and procedures for such deferrals and may
provide for interest or other earnings to be paid on such deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of Code section 409A. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;12. <U>Adjustment Upon Changes in Capitalization.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event any recapitalization, forward or reverse split, reorganization, merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase, exchange or issuance of Shares or other securities, any stock dividend or other special and nonrecurring dividend or distribution (whether in the form of cash, securities or
other property other than a regular cash dividend), liquidation, dissolution, or other similar transactions or events, affects the Shares or the value thereof, then the Compensation Committee shall make such adjustment, in such manner as the
Compensation Committee deems appropriate, in order to prevent dilution or enlargement of the rights of Grantees under the Plan, including adjustment in (i)&nbsp;the number and kind of Shares deemed to be available thereafter for Grants under
Section&nbsp;3, (ii) the number and kind of Shares that may be delivered or deliverable in respect of outstanding Grants, and (iii)&nbsp;the price per share or the applicable market value of such Grants. In addition, the Compensation Committee shall
make such<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">adjustments as are appropriate in the terms and conditions of, and the criteria included in, Grants
(including, without limitation, cancellation of Grants in exchange for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money</FONT></FONT> value, if any, of the vested portion thereof, cancellation of unvested Grants for
no consideration, cancellation of</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-the-money</FONT></FONT></FONT> Grants for no consideration, substitution of Grants using securities of a successor or other entity, acceleration of the time that Grants expire, or adjustment of performance targets)
in recognition of unusual or</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nonrecurring events (including, without limitation, a Change in Control or an event described in the preceding sentence) affecting the Company or any Affiliate of the Company or the financial
statements of the Company or any Affiliate of the Company, or in response to changes in applicable laws, regulations or accounting principles. Any adjustments to outstanding Grants shall be consistent with Code section 409A or 424, to the extent
applicable. Any adjustments determined by the Compensation Committee shall be final, binding and conclusive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;13. <U>Restrictions on
Shares.</U> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Restrictions</U><U> </U><U>on</U><U> </U><U>Issuing</U><U> </U><U>Shares.</U> No Shares shall be issued or transferred
under the Plan unless and until all applicable legal requirements have been complied with to the satisfaction of the Compensation Committee. The Compensation Committee shall have the right to condition any Grant on the Grantee&#146;s undertaking in
writing to comply with such restrictions on any subsequent disposition of th<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#ff4338"><STRIKE> </STRIKE></FONT><FONT STYLE="font-family:Times New Roman">e Shares issued or transferred
thereunder as the Compensation Committee shall deem necessary or advisable as a result of any applicable law, regulation or official interpretation thereof. </FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Transfer Restrictions.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) <U>Nontransferability of Grants.</U> Except as provided below, only the Grantee may exercise rights under a Grant during the Grantee&#146;s
lifetime. No Grant under the Plan and no Shares that have not been issued or as to which any applicable restriction, performance or deferral period has not lapsed, may be sold, assigned, transferred, pledged or otherwise encumbered, except
(A)&nbsp;by will or by the laws of descent and distribution or (B) with respect to Grants other than ISOs, pursuant to a domestic relations order. When a Grantee dies, the personal representative or other Person entitled to succeed to the rights of
the Grantee may exercise such rights. Any such successor must furnish proof satisfactory to the Company of his or her right to receive the Grant under the Grantee&#146;s will or under the applicable laws of descent and distribution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii) <U>Transfer of Nonqualified Stock Options.</U> Notwithstanding (i)&nbsp;above, the Compensation Committee may provide, in a Grant Letter,
that a Grantee may transfer Nonqualified Options to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws, according to such terms as the Compensation
Committee may determine; provided that the Grantee receives no consideration for the transfer of the Nonqualified Option and the transferred Nonqualified Option shall continue to be subject to the same terms and conditions as were applicable to the
Nonqualified Option immediately before the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>ISO Notice.</U> A Grantee shall notify the Company of any disposition of
Shares acquired upon exercise of an ISO if such disposition occurs within one year of the date of such exercise or within two years of the date of grant of such ISO. The Company may impose such procedures as it determines may be necessary to ensure
that such notification is made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Requirements for Issuance or Transfer of Shares.</U> No Shares shall be issued or
transferred in connection with any Grant made hereunder unless and until all legal requirements applicable to the issuance or transfer of such Shares have been complied with to the satisfaction of the Compensation Committee. The Compensation
Committee shall have the right to condition any Grant on the Grantee&#146;s undertaking in writing to comply with such restrictions on his or her subsequent disposition of the Shares as the Compensation Committee shall deem necessary or advisable,
and certificates representing such Shares may be legended to reflect any such restrictions. Certificates representing Shares issued or transferred under the Plan may be subject to such stop-transfer orders and other restrictions as the Compensation
Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;14. <U>Withholding of Taxes.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All Grants made under the Plan shall be subject to applicable federal (including FICA), state, local and foreign tax withholding requirements.
The Company may require that the Grantee or other Person receiving or exercising Grants pay to the Company or any Affiliate the amount of any federal, state, local or foreign taxes that the Company or any Affiliate is required to withhold with
respect to such Grants, or the Company or any Affiliate may deduct from other wages paid by the Company or any Affiliate the amount of any withholding taxes due with respect to such Grants. If the Compensation Committee deems it appropriate, the
Compensation Committee shall be authorized to establish procedures that permit or require a Grantee to satisfy the applicable tax withholding obligation with respect to a Grant by having Shares that are otherwise deliverable in connection with a
Grant withheld, subject to such limitations as may be imposed by the Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;15. <U>Consequences of a Change in Control.</U>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee may provide in a Grant Letter or otherwise terms under which Grants may vest and, as applicable, be exercisable
or payable in the event of a Change in Control or in the event of a Grantee&#146;s termination of employment or engagement by the Company and any Affiliate in connection with, upon or within a specified time period after a Change of Control. In
addition, in the event of a Change in Control, the Compensation Committee may take one or more of the following actions with respect to any or all outstanding Grants: the Compensation Committee may (i)&nbsp;require that Grantees surrender their
outstanding vested Options and SARs in exchange for one or more payments by the Company, in cash or Shares as determined by<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT
STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Compensation Committee, in an amount equal to the amount by which the then Fair Market Value of the Shares subject to the Grantee&#146;s unexercised, vested Options and SARs exceeds the
Exercise Price of the vested Options or the base amount of the vested SARs, as applicable, (ii)&nbsp;provide for the cancellation of unvested Grants for no consideration, (iii)&nbsp;provide for the cancellation of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-the-money</FONT></FONT></FONT> Grants for no<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>
</U></FONT><FONT STYLE="font-family:Times New Roman">consideration, (iv)&nbsp;after giving Grantees an opportunity to exercise their outstanding Options and SARs, terminate any or all unexercised Options and</FONT><FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">SARs at such time as the Compensation Committee deems appropriate, or (v)&nbsp;determine that outstanding Options and SARs
that are not exercised shall be assumed by, or replaced with comparable options or rights by, the surviving corporation, (or a parent or subsidiary of the surviving corporation), and other outstanding Grants that remain in effect after the Change in
Control shall be converted to similar grants of the surviving corporation (or a parent or subsidiary of the surviving corporation). Such surrender or termination shall take place as of the date of the Change in Control or such other date as the
Compensation Committee may specify (subject to consummation of the Change in Control). </FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16. <U>General Provisions</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Grant Letter.</U> Each Grant shall be evidenced by a Grant Letter. The terms and provisions of such Grant Letters may vary among
Grantees and among different Grants made to the same Grantee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Right to Employment.</U> The making of a Grant in any year shall
not give the Grantee any right to similar grants in future years, any right to continue such Grantee&#146;s employment relationship with the Company or its Affiliates, or, until Shares are issued, any rights as a stockholder of the Company. All
Grantees shall remain subject to discharge to the same extent as if the Plan were not in effect. For purposes of the Plan, a sale of any Affiliate of the Company that employs or engages a Grantee shall be treated as the termination of such
Grantee&#146;s employment or engagement, unless the Grantee shall otherwise continue to provide services to the Company or another subsidiary of the Company as an employee or director. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>No Fractional Shares</U>. No fractional Shares shall be issued or delivered pursuant to the Plan or any Grant. Except as otherwise
provided under the Plan, the Compensation Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional Shares or whether such fractional Shares or any rights thereto shall be forfeited or
otherwise eliminated. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>No Funding.</U> No Grantee, and no beneficiary or other Persons claiming under or through the Grantee, shall
have any right, title or interest by reason of any Option to any particular assets of the Company or Affiliates of the Company, or any Shares allocated or reserved for the purposes of the Plan or subject to any Grant except as set forth herein. The
Company shall not be required to establish any fund or make any other segregation of assets to assure satisfaction of the Company&#146;s obligations under the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Governing Law; Jurisdiction.</U> The Plan shall be governed by and construed in
accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of Delaware. To the extent the Grantee is a party to an employment agreement with the Company or any of its subsidiaries that provides for binding arbitration of employment disputes, then any disputes between the
Company and such Grantee arising under the Plan shall be arbitrated in accordance with the procedures set forth in such employment agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Compliance with Law.</U> The Plan, the exercise of Options and SARs and the obligations of the Company to issue or transfer Shares under
Grants shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With respect to Persons subject to section 16 of the Exchange Act, it is the intent of the Company that the
Plan and all transactions under the Plan comply<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">with all applicable provisions of Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> or its successors under the Exchange Act. In addition, it is the intent of the Company that ISOs comply with the applicable provisions of Code section 422 and that, to the extent applicable, Grants be
exempt from or comply with the requirements of Code section</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">409A. Notwithstanding the foregoing, the
Compensation Committee makes no representation that the Grants awarded under the Plan shall be exempt</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman">from or
comply with Code section 409A and makes no undertaking to preclude Code section 409A from applying to Grants awarded under the Plan. To the extent that any legal requirement of section 16 of the Exchange Act or Code sections 422 or 409A as set forth
in the Plan ceases to be required under section 16 of the Exchange Act or Code sections 422 or 409A, that Plan provision shall cease to apply. To the extent applicable, if on the date of a Grantee&#146;s &#147;separation from service&#148; (as such
term is defined under Code section 409A), Shares (or shares of any other company required to be aggregated with the Company for purposes of Code section 409A and its corresponding regulations) are publicly-traded on an established securities market
or otherwise and the Grantee is a &#147;specified employee&#148; (as such term is defined in Code section 409A(a)(2)(B)(i) and its corresponding regulations) as determined by the Compensation Committee (or its delegate) in its discretion in
accordance with the requirements of Code sections 409A and 416, then all Grants that are deemed to be deferred compensation subject to the requirements of Code section 409A and payable within six months following such Grantee&#146;s &#147;separation
from service&#148; shall be postponed for a period of six months following the Grantee&#146;s &#147;separation from service&#148;</FONT><FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT
STYLE="font-family:Times New Roman">with the Company, to the extent necessary to avoid the imposition of penalty taxes thereunder. The Compensation Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance
with any valid and mandatory government regulation. The Compensation Committee may, in its sole discretion, agree to limit its authority under this Section </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Grants made in Connection with Corporate Transactions and Otherwise.</U> Nothing
contained in the Plan shall be construed to (i)&nbsp;limit the right of the Compensation Committee to make Grants under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of
any corporation, firm or association, including Grants to employees thereof who become Employees, or (ii)&nbsp;limit the right of the Company to grant stock options or make other awards outside of the Plan. The Compensation Committee may make a
Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company, in substitution for awards made by such
corporation. Notwithstanding anything in the Plan to the contrary, the Compensation Committee may establish such terms and conditions of the new Grants as it deems appropriate, including setting the Exercise Price of Options at a price necessary to
retain for the Grantee the same economic value as the prior options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Application of Company Clawback Policy</U>. All Grants under
the Plan are subject to the applicable provisions of the Company&#146;s clawback or recoupment policy approved by the Board or the Compensation Committee; as such policy may be in effect from time to time, and will be subject to recoupment as may be
required by applicable law, regulation or listing exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;17. <U>Amendment or Termination.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment.</U> The Board may amend or terminate the Plan at any time; <U>provided,</U> <U>however,</U> that the Board shall not amend
the Plan without stockholder approval if such approval is required in order to comply with the Code or other applicable law (including Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act), or to comply with applicable stock
exchange requirements; and further provided that the Board may not, without the approval of the Company&#146;s stockholders<B>, </B>to the extent required by such applicable law, amend the Plan to (a)&nbsp;increase the number of Shares that may be
the subject of Grants under the Plan (except for adjustments pursuant to Section&nbsp;12), (b) expand the types of awards available under the Plan, (c)&nbsp;materially expand the class of persons eligible to participate in the Plan, (d)&nbsp;amend
Section&nbsp;5 and Section&nbsp;8 to eliminate the requirements relating to minimum exercise price, minimum grant price and stockholder approval, (e)&nbsp;increase the maximum permissible term of any Option or the maximum permissible term of a SAR,
(f)&nbsp;increase any of the limitations in Section&nbsp;3, or (g)&nbsp;amend Section&nbsp;17(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Repricing Without Stockholder
Approval</U>. Notwithstanding anything in the Plan to the contrary, and other than pursuant to Section&nbsp;12, the Compensation Committee shall not without the approval of the Company&#146;s stockholders (a)&nbsp;lower the Exercise Price per Share
of an Option (or grant price of a SAR) after it is granted, (b)&nbsp;cancel an Option or SAR in exchange for an Option or SAR with a lower Exercise Price, cash or another Grant (other than in connection with a Change in Control), or<FONT
STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U> </U></FONT><FONT STYLE="font-family:Times New Roman"> </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) take any other action with respect to an Option or SAR that would be treated as a repricing under the
rules and regulations of the principal U.S. national securities exchange on which the Shares are listed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)<U> Termination of Plan.</U>
The Plan shall terminate on November 28, 2028, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders; <U>provided,</U> <U>however,</U> in no event may an ISO be granted more than ten
years after the date of the adoption of the Plan by the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)<U> Termination and Amendment of Outstanding Grants.</U> A termination
or amendment of the Plan that occurs after a Grant is made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Compensation Committee acts under Section&nbsp;16(f) above. The termination of the Plan shall
not impair the power and authority of the Compensation Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section&nbsp;16(f) above or may be amended by
agreement of the Company and the Grantee consistent with the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)<U> Prior Plan.</U> Any Grants made under the Plan prior to the
Restatement Effective Date shall be governed by the terms of the Plan in effect at the time each such Grant was made, including<FONT STYLE="font-family:Times New Roman; font-size:10pt" COLOR="#0011ba"><U>, to the extent applicable, </U></FONT><FONT
STYLE="font-family:Times New Roman">the requirement that the Compensation Committee be composed of &#147;outside directors&#148; as defined under Code section 162(m) and related Treasury Regulations with respect to any action taken after the
Restatement Effective Date with respect to Grants made under the Plan before such date and that are intended to meet the requirements of the performance-based compensation exception for purposes of Code section 162(m), unless further amended in
accordance with the terms of the Grant and such version of the Plan. For the avoidance of doubt, any Grants made under the Plan on or after the Restatement Effective Date shall be subject to the terms of the Plan in effect on and after the
Restatement Effective Date. </FONT></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g17046g14k01.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">MEI pharma IMPORTANT ANNUAL MEETING INFORMATION 000004 ENDORSEMENT LINE SACKPACK MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD
4 ADD 5 ADD 6 Using a black ink pen, mark your votes with an X as shown in this example. Please do not write outside the designated areas. C123456789 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext 000000000.000000 ext
000000000.000000 ext 000000000.000000 ext Electronic Voting Instructions You can vote by Internet or telephone! Available 24 hours a day, 7 days a week! Instead of mailing your proxy, you may choose one of the two voting methods outlined below to
vote your proxy. VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR. Proxies submitted by the Internet or telephone must be received by 1:00 a.m., Pacific Time, on December&nbsp;16, 2020. Vote by Internet Log on to the Internet and go to
www.investorvote.com/MEIP Follow the steps outlined on the secured website. Vote by telephone Call toll free <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-VOTE</FONT></FONT></FONT>
(8683)&nbsp;within the USA, US territories&nbsp;&amp; Canada any time on a touch tone telephone. There is NO CHARGE to you for the call. Follow the instructions provided by the recorded message. Form of Annual Meeting Proxy Cart 1234 5678 9012 345 T
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. T A Proposals The Board of Directors recommends that you vote FOR the listed nominees and FOR proposals
No.&nbsp;2, No.&nbsp;3 and No.&nbsp;4: Proposal No.&nbsp;1 &#150; Election of Directors: For Withhold For Withhold For Withhold 01 &#150; Kevan E. Clemens, Ph.D. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] 02 &#150; Daniel P. Gold, Ph.D.
[&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] 03 &#150; Tamar D. Howson [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] For Against Abstain Proposal No.&nbsp;2 &#150; To approve the Amended and Restated MEI Pharma, Inc. 2008 Omnibus
Equity Compensation Plan to increase the number of shares of common stock that may be subject to award and make certain other changes to the plan terms. [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] Proposal
No.&nbsp;3 &#150; To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers <FONT STYLE="white-space:nowrap">(Say-on-Pay</FONT> vote). [&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;]
[&nbsp;&nbsp;&nbsp;&nbsp;] Proposal No.&nbsp;4 &#150; Ratification of appointment of BDO USA, LLP, as MEI Pharma, Inc.&#146;s independent registered public accounting firm for the fiscal year ending June 30, 2021. [&nbsp;&nbsp;&nbsp;&nbsp;]
[&nbsp;&nbsp;&nbsp;&nbsp;] [&nbsp;&nbsp;&nbsp;&nbsp;] B Non-Voting Items Change of Address &#151; Please print your new address below. Comments &#151; Please print your comments below. C Authorized Signatures &#151; This section must be completed
for your vote to be counted. &#151; Date and Sign Below NOTE: Please sign your name(s) EXACTLY as your name(s) appear(s) on this proxy. All joint holders must sign. When signing as attorney, trustee, executor, administrator, guardian or corporate
officer, please provide your FULL title. Date (mm/dd/yyyy) &#151; Please print date below. Signature 1 &#151; Please keep signature within the box. Signature 2 &#151; Please keep signature within the box. </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g17046g16r28.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">C 1234567890 JNT 1UPX 3481111 MR A SAMPLE THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS MR A SAMPLE AND MR A SAMLE AND MR A SAMPLE
AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g17046g23q00.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">T IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE. T Proxy &#151; MEI PHARMA, INC. FORM OF PROXY SOLICITED BY BOARD OF DIRECTORS FOR ANNUAL MEETING December 16, 2020 Please sign, date and return promptly in the enclosed envelope. The undersigned hereby appoints Daniel P. Gold and Brian G.
Drazba, and each of them, as proxies, with full power of substitution in each of them, for and on behalf of the undersigned to vote as proxies, as directed and permitted herein, to vote your shares of MEI Pharma, Inc. Common Stock at the Annual
Meeting of Stockholders of MEI Pharma, Inc. to be held via live webcast on December 16, 2020, at 9:00 a.m. (Pacific Time), and at any adjournments thereof upon matters set forth in the Proxy Statement, and, in their judgment and discretion, upon
such other business as may properly come before the meeting. You will be able to attend the annual meeting remotely, vote and submit questions during the annual meeting by visiting www.meetingcenter.io/291997584 and using the password MEIP2020 and
entering your control number. This proxy, when properly executed, will be voted in the manner directed on the reverse hereof by the stockholder. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED (I)&nbsp;FOR THE LISTED NOMINEES FOR DIRECTOR,
(II)&nbsp;FOR APPROVAL OF THE AMENDED AND RESTATED MEI PHARMA, INC. 2008 OMNIBUS EQUITY COMPENSATION PLAN, (III)&nbsp;FOR APPROVAL, ON AN ADVISORY BASIS, OF THE COMPENSATION OF MEI PHARMA, INC.&#146;S NAMED EXECUTIVE OFFICERS <FONT
STYLE="white-space:nowrap">(&#147;SAY-ON-PAY</FONT> VOTE&#148;) AND (IV)&nbsp;FOR RATIFICATION OF BDO USA, LLP AS THE COMPANY&#146;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR FISCAL YEAR ENDING JUNE 30, 2021. NOTE: In their discretion, the
proxies are authorized to vote on such other matters as may properly come before the meeting or any adjournment or postponement thereof, including procedural and other matters relating to the conduct of the meeting. Each of the foregoing proposals
is more fully described in the accompanying proxy statement. This proxy will be voted as specified above. If no direction is made, this proxy will be voted FOR all nominees listed above and as recommended by the Board on the other items listed
above. Important Notice Regarding Internet Availability of Proxy Materials for the Annual Meeting to be Held on December 16, 2020. MEI Pharma, Inc.&#146;s Proxy Statement and 2020 Annual Report are available at http://www.edocumentview.com/MEIP.
</FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g17046dsp2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046dsp2a.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0B@4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              &@   *H    & &< -0 V
M '0 .  R     0                         !              "J
M&@                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !@0    !    <    !$
M  %0   64   !>@ &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  1 ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M 0((  D1%!(3%38X)#0U918Y(F15%S=8&0HA(S-4E;569G;65V<8:!H1 0
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MAED5E U?X'RC'!&;F)"&"E*-Y603TQB$E]P3<#CEY#,T2WVV&*P*6DK]7O\
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78_K_ /E/_>/YCP''^ > > > > >!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g17046g03v42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g03v42.jpg
M_]C_X  02D9)1@ ! 0$ ;@!N  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M<OKU<:SK=S<J3S#;*+:/'H=I+'\6K7M=*L+*W-O;VD4<3?>4(/F^OK^-7**
M/._&6@W5YJ%CI^C^&K.2VD8R75UA(E&/NHQ W8)Y..H&*Z'PMX6C\/132O+Y
MU[<D-/(JA$XZ*B#A5'8?G71T4 )BN/\ B1A= LRWW!J=H6^GFK78UQWQ0MI;
MCP!J+09\VW"7"X'/R.&_I0!)J!_XN9HH ZV%P<_\"2NM'2N,GD6?QUX9N5.1
M+I\Y'T_=FNSH **** "BBB@ HHHH **** "D(!'-+10 S STHH/6B@!]%%%
M!1110 4444 %%%% !5>^M([ZRN+24 QS1M&P/H1BK%(10!Y3X2OI[C7_  S8
MWA'VS3[.[@F _P!AU0']*]7KCM(\$+IGC_5O$IN%D%[&JQ1;<&(_Q?7) -=C
?0 4444 %%%% !1110 4444 %%%% ##UHH/6B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g17046g1017042551817.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g1017042551817.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& $8# 2(  A$! Q$!_\0
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2=%%>I&*BK([$DM$%%%%4,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g17046g1017042551988.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g1017042551988.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  0  P# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g17046g1017042552129.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g1017042552129.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4  P# 2(  A$! Q$!_\0
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)Q/'H!110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g17046g1017042552487.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g1017042552487.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ,  P# 2(  A$! Q$!_\0
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-B4L<G:CLJ_H!0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g17046g14k01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g14k01.jpg
M_]C_X1I)17AI9@  24DJ  @    -   ! P !    - ,   $! P !    )00
M  (! P #    J@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    L    !L!!0 !    N    "@! P !     @   #$! @ >
M    P    #(! @ 4    W@   #L! @ )    \@   &F'!  !    _    #0!
M   (  @ " " _ H $"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R,#HQ,#HR,B Q,CHU-#HP.0!R<C(Y,S<T.0  !   D <
M!    # R,C$!H ,  0   /__   "H 0  0   .H"   #H 0  0   '<#
M       &  ,! P !    !@   !H!!0 !    @@$  !L!!0 !    B@$  "@!
M P !     @    $"!  !    D@$   ("!  !    KQ@       !(     0
M $@    !    _]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M *  AP,!(@ "$0$#$0'_W0 $  G_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&
M!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /55E_6'
MZR=+^KN$,SJ+W!KCMJJK&ZQ[HW[:VRUOM:WW/L?74S]]:BXC_&3C]5J;B=7P
M&VOJQ:LBC)] 38QM_HN]9HVV?HOU=S,BS8_9_HTE+87^-3 S,W%Q!TS,J^V7
MUX]=M@8&!UCVTR7;_P QS_?M7<+R#ZNYW5OK1UG#9158^K$R*;LG+=.QM=5W
M[0<VYP+JOM%MS7>CZ?Z6W_"_07KZ2E))))*4DDDDII]5Q,G,PW48UYQK201:
M"X$?]MN8Y9?[!ZSOW?M)\;MT;K>-NS;_ #G[WO6UE9>-ATF_)>*ZAH7&?^^J
MK^W^D3M^TMF8B'<QO_=_=3XF0&@T\F?%/,(U"-Q_N<?XN<WH/61MGJ3S&R?=
M;^;]/_"?GIC]7^M;8_:;YVQ.ZWG=OG^=_=]BT1]8.CF(R6ZQ&COSOH?FI?\
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MMW/&W[08:2 Y\-AS/?M:YRH?LZ"9;A#:?=H_3_P1.B:&],N*?#&N,Q\ 9?\
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MD,7&&TBE@V?0AHTC]W3VI57/>\M=2^L#\Y^V#_F/>BI*1LHIK#@RMK _Z0:
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M_P!+U#_MO%_](I*==)8^[J.]GIOS2)=ZGJ,Q@-NRSW-VUM_2>IZ?I_\ "?\
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M4;VN'4,85O=M:W;KK #2[UE*KJ%=SQLS\=S='%NV#'YVIN_[ZG^T],_T#_\
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ !(     0 " $@    !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  -W   "Z@    8 9P Q #0 :P P #$    !
M  $              NH   -W                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   -W     %)G:'1L;VYG   "Z@    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #=P    !29VAT;&]N9P   NH    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     $X0DE-! P     &,L    !    AP   *
M  &8  #_    &*\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( *  AP,!(@ "$0$#$0'_W0 $  G_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M1]GL/M%%#!]&H_1V;-G^#_FTE,J!TG$L;DT7XM3'. W,:>'_ *1_N]8M9O\
MW]B-^TZ@#NZGB^V).V.?H_X=%^T=,F?L[Y\?LMO_ *12^T]-_P! _P#]A;?_
M $BDI@>J4;VN'4,85O=M:W;KK #2[UE*KJ%=SQLS\=S='%NV#'YVIN_[ZG^T
M],_T#_\ V%M_](I'(Z6><=Y_]!;?_2*2DM5Q]-['9=-EFT['M $$ DO<WU';
MMJ2IY#\"RS']'&?[+=S_ -6L'M%=N_FD>.W_ ,#224__V0 X0DE-!"$
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M8G(S)!:"DI"BLD-38W,E<, T-:#B@\/S1-3_V@ , P$! A$#$0   /W\
M                   'BFK:RMP[7%&9WB7L?IL)WNY3?9ZM"5YN,XVFL0I<
M;9-5EI\'7N[3Y;<XQ\O.GY"8SF^/>3Z#/F,YK &4Z7D!B.8P!ENF3QB><0;G
M-YF?%ZG#N1V69;+5X=FVG9CJ/GB<,;KP
M     IUQ=_E$[Q]$L-=N]+9NZMQ[ /:.L["<#Q[7_D>][#,%QC O+>B\[K/@
M&!^1[9G_ (KS!KYROKS8AJGE+7!N?J;85KWD'7!M7J_9+I/E'6ULOJ+8YJOE
MW7GOGHK.G5.%X*;%U[/+ \LP3SO6_P!9'!?E3G+J?*@
M               !3;FZ_*#V_P"AV'>S>DLX-?XK@-LO:,_L1QC 6^[?L&P'
M*,#LGW_._'<%P'R_:=AF'\UZ[\EZNV)8GR]K?V+TIL+P?E/7/FO5>QG7/)^N
MC/\ J#8AA_,FOG9._P"=V#XA@CG.RYVZWR3!G8NL_K$X+\M\Y=;Y8
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M89(Z2I:_]J>-G60               <'(    !P<G!R<'(
M  !P?R*5;>LDJ*?R(;)T/SD1FS=2_EMEN?[4\;*L@
M                      X/XZ*MFE&IC)+/D?&ALP4YOC-IW-5DMQ_:3C9U
M(               'R?1P<@    "!$!\@^@  ?!]'(           /D_F?KC
M7C"OT1M\C3%:%QX4,@XRW2?U4%EVH@              =)]'PARD^U0=1\2.
MV6/P#KGI]DTW;"/1,^X4_I4Y2$_)P?(I.448?=23X3]27M1ZDG:G[D0
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MC2ZYI>*-/LFN_B>E\RTOB,O,MW]+7F:;A+S"OVRU?A;=\U7E2]%.X^IINP
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M^I[?%'-=(RDPFB11<[!>4F(AN]W#(C$Z!3Z]WWT;.,<AL&5&$Y]%%]LDL6N
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M+=]0!TRRX+[/WC!_9>[YAZ_Q"QKO)PYE-\HTV7G7#<VV9:GYKK-&@
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M']K;&-(\P;U.:>!?3-,!U00+E-OQ@SO899Q&CR=;:M.^/U
M   86&(Y2SJ+C)0,:2T3+XHA'9,I%Q>ID68HEP%GD\&)9)Q+YCZ9%&.):Q.)
MUDP&-Y2B]BP"P"JF8)#IBF9#%%/&2<7V2X9H'(!IEZ3[?T^].]T;)]&\H[[>
M0_.+T*@'5"7"/8^RXF['VB><+RV<K#4<J,'S0                1H81$K$
M2G47B6P2(9@GH*R6Z7$44X*V<E)*B=H    !\%$*\       <&G;?_8VH[?_
M &QL8T_RQO9Y=X$]4]0#K0PTSW7L<,WU"2;'0Y[QFI9-8?G8
M    ZRS#J+:*B6.2,6L3(=X                  !T3S]<:GW"3T24P!\H4
M&M?VC6R%8IVE8DH5ZE9@               "!2-"]C#<RR,;BHF0YB<30>,K
M),YB$7R2<082\48CDNTC8E,LPF<Q>,KS#@SN,7"HDCEF'09*DV@
M                   '@,;RR"UR6BURLEYD)$QD.%\EV$5%P%Q%FE[E-+7+
MN+)/4702.0 9"F+YEL084@O M0HY/!,YR
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M\F81Y#ML_4>58ZR]GCRXV#._&<3S6M>%<&J\S&.\@$R?,,2:R0#QEC&91R
M                                 "T+O.?BFWK[(>B7([2,9X;F"XQ^
MMS+=)RFM;S53=^L_T8:)\^-O>+\:\&!!KT)I.HF PY.#N/:4$_0@<@
M                             MVME/S"[M]*[@H6^;D/.^E.]]P9&R<9
MS!Q^FV)4S&RK6_/>P^Q\Z"B$9ET%2*&=I'Q[BM%2.#V%IEW'P7D>\
M                          HRY_*9N?T6NV;&8VY;><\\'R[4+L7KJZ65
MLBK=?K'YK\J,_P"SX3P0T048PDVEW%&(3)F(N/ 2X1Z7V8[F7!D"2N
M                           6A=YG\2W3/LOL#PGD::<3C?1>7NK'.^QI
MRQ^D;)\7Y*R!PNE;6,=YH'!AT6*2H8[DZ%EGF+I+L+/*4041D6L;KBZ@
M                            "VJV5_.EM7LRDY._P]N>V5VG?8?7O;<T
M+7BUS2:C^A[1OG_EU8<_ QI*:6R1H2>6*7B=0+6+>)U(G*X9T@
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M,53/HUV$X'06<6,;%3& ]1N,*V   #"<\AG$<@
M   'A.DB@EP[CSG:#M.#Q'N!Y3V'F/LZST'C/4"+RJ%]'!]'R?)ZCL
M !B08FE*,KC!@SB([,5S(8QG,P"/S)\RT
M             .#7,88F4Y8)=A6"#C DSG*$1N9WFS$
M
M          $,EYFJ<HY>I%!4#.HQ2,2#+THY<IVEDDJF+I1"?R>#!,KQ/A>9
MC6=9F:8T$O$9$:ER&5IBH2T0P6&9A$ &2YA69MF+9F@9K@
M          '6:XSV$SD6$KF/)?9'!(IEH:YB924"(3%(F(Q\,PC6"9EF;1Z2
MQ#X+4.XF4M8L(V"   % *J>H                           &+Q1242-"
M3"PBP"ZSDR1("/&2:>LLHO,B@J99I528CR%C'O.LKP+'+J,@CD
M                     $1'G)D+'+X*<>H[RCE9 *>6P64366.7P<@LL%Z
M                                  HY%QAN8^$E$@E*+"+7*B5LL$F0
MMHKQ%Y,)5"*B1"@'G(W,IC$$F(BLR#-G)R
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M7E%)^)),@B.2[36N9R'!!Q+9>ACD>4C\SG(6)N,<SM(U+B/T"&KHW %>
M            !A$>8               L@Z2WRGEY%0*&704$LHK!YR^BTCD
M]112IGV5$NXATJQ]'I*Z4LD<               X)T)S.")CY*@
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MH*X< @ QY!FP74?)]GT=9\GP=AV')TD:&)1P2T94D6$IG(.3DHA63D'T=)V
M[ <@               ATB@DP]I8A8YEN6H1*?1]%TE_F*1<)+!;Y>I*@ ,:
M3@E Q@+$+7,NB%#/DY             ,("4S(<U;%Z'<2\>\RG       ,,R
M02;S6^2N0N9%%<,ICD $.D-F*9,Y(!:YDH4@M,@,N8L$R&*61@5<H1,YEB<@
M&-9"1DT48PQ(V+F+H-I!R             8JF*YM/,#R,2"B7R=S.
M Q2,8#:,8-%&,1C$\V\&>AR "%R'#*<PE)**2>8DDA(NHX,G34X94&89=(
M!8)BX9P'(-=IL+.\  X,*B13K(>+H+%)?(H+9)O(;*L;!0    #'<\IDD"%R
M+3+DY .#"HO@J1'YWGA)",3S(@JA6#(TQQ/@R1!P:LC\V!^I@V"@ %FD=DP&
M+Y<Y#!/)7".2+B\B62)"O&1Y6P  "R3%$SC.3@UY&P@[@ #@AP^3TD&%")8)
MF,:SP$A'R> R0*B    #'H\AD@"'B)#+P '!#A6SDQ^+>)*+](?*F>XX,HC'
M,X,C@ :=S/@R0
M
M                     .#3:5$VFEZ&JPC MPJ9NL-?AB$2N6(9(&QL
M                                   $,D7F5YW&)AB^3<7299%@&.Y>
MA')(YDZ
M 8GF.A;A>Y<)B^;)2B$='!$!&!*Q*1B>9VF&!73Z+$)U(;/*7"5THI<AC*2\
M7*6<7"4@S',<S.LU1$2FS$PS+V.LR6,<2JG43^0F> \I?!8A[CUE',DS-P
M                %AG21$2>>H^R,B8SK+=(6+E*X?!<)6RQ"C%Z'L.PIY2B
MA%QEN%['M*">4KI&Q<A4BF$AGB+!)=(1+G*.2@6F182 2<0@4LNXK!ZCV'P6
MR>@F8M$KY5 >@^@"Q2*#) Y!AZ9>G: 0J>HF         QZ(6,#2;3S$ID,D
MCD;D;DG$SE>,6RL%\GP9"&%)9!-9=Q:Y:IE 85&6AAZ;!3"<RK,;2F&8!C^7
M*646B9 &+QDD8P&4IY"/"-C+HQ++Y,BS&<QE,M"= 8G$W&/AEN8^%JFV,F0
MQR(=,[P#5 ;3BH@&(1P9?
M
M   &'AC,6F7T7 8TFS@L(H1Z3$LNDN@GH@HJ1[#&HE4Z#+TUP$KF5Q@,9HD"
M%B%\%HE<,@"PS&$R@*H8V%T$_DF&$A<99YE*0D> D\N8P\)K/(328LF4Y#I3
MRZ3(DQ&,C#.\  M,USFT,Y.#6F9O$G@&*9:)FT        > \9'A()]GT=A[
M3RG81.<DJ%(/6#K/LY!1RKG2?9YRM%$+!+_/6=9ZCK.D]ITD3$IEN%[E".#U
MGH.@Y.\[2D'J.D^#M/">DJA9Q?Y22DEX@ 'C,43+DY!B69/E5 (R+.)^
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MPE4 B0LLR/        ,33!LM(SL,/2;B "+S.TPF)Z/69%&M<FPW %3
M                                   *&5P %O%P@'R?0
M
M              *0?@-,@C]IQ;)+Q8I;1+)9I?)#),!W
M                        %K'\F\V*G]"$T1E%,]C&DQZ,7#+4K)63"0WR
MFU                                        \AH")2-VIR  ",233D
M
M                            QC,F3[!%Q=!%1/P!8!02704\[ST@ $8%
MY%=+)!>P         ++.PO '4><]I#!>1>H*>>@]  !P=!9Y]EZ@
M   '4?G=(W,-C<J0,5TP2,L2^#:&0*8?GR>\^3SEZD&&5A"!-!C@=Q,)02Q2
M=38J>H       ^R>"S#6F0R:\P789QF;)CH8D'V2,1T3P0T58D4QB*^=AD88
MXDADFFQ4          %[DLF-9^>$V4@                    T[GZZS\^I
ME0<                     '!KP/U-&-1A&;<0                    :
M%S> :'3]!0                     !^? _0>1<?G4)Y
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M0*              ?GS/T%F*QB8;70    :\38<  #7Z9\'J    /S\@_0,
M             ?GY.#] X             !^? _0>8JF)AM=    !KJ-BH
M-=AL3    !^?D'Z!@             #\_)P?H'              /SX'Z#S%
M0PW-JP   !1RAEZ  '!&I)8   !R:$RGF_L              T)'G-^H
M         .#0*?H8+ /RH'(             /T FBLM<Z@             ;
MD3&XP$.H             &R WF'_V@ ( 0(  04 _#Z+ &:_HH;M=R.J[=P^
MP+MDY<CH2_#+"NV[M<?]@L?8O[6NB/A&T;8M9<M5']863#&N6"M; $"MYEC1
M:N,"\%-;/-6^%H\$R%YE56AICX:Z3;)_;#8C>JY:/L@;-RF.1$LH,2X4I^AK
MX6%,A6GF/R(3#J:[FS^_4;-%M45KH5.I4LVA/+-JB@T-JS4GN4+- C0%M.50
M[U'[%FI-5Z+8(ENT7N)5-JFXE]J_26O7ZKG$2BD2I^BS2>(6[0VEZF@+B5:M
MU%5^BQ2;+@%Y"<]046J*Q$D\;E%2I^1"8=35B_;JO&E(K=OFKUBZLWE$K>OG
MS-DQ>+FRP$W 9+WTT#I?]@I'[%"?8-E_XE0-6KJ?0>L4$K5\O^U+'RU96B]8
MNVT]3L4$S1BQ69*'RU%"E47O7":B6M65*\7,W[9XK;(+INS>J+GBP%G?V:U+
M\B=:PX"J= !5U'H*H?'@+"ET_EU 1%84!MW%!1NEJE8^)>XI'[MBI84 +@I'
MNYK53HA_)G>6U=0MC;4U"FFTK*-H*E,Y570K*%(7E0_< %=1IIJ4U&OE*NJ!
M:,*)Z_;%:4 INWKM^O\  PX'X(/:X 5<$*N?[^55U@-/;ZUC6%5KM]/L.GX4
M'_AK^G/\\Z?+_K^'AU_!Q^'7Y X'X154-/.V/.V/.V/ 'J'.OZ@'7@@(?/5<
M ![8\"L>OW[I^#  B(D3X\_CC]074U0HY<3%.BU6GJ%(W$Y0HMUD#EJFI+.C
M4"69 *T@UW-:6HTE*4PZ%@21VFQ_&FJ> 3-4C^P/7 J)'>W0E*%7+J>=MA4E
M*E7+B:>M4UII_NC"0?M4 D&N[N)1VW2"8H5<_BC]-(IAT0_BSW8_BSHA<M7;
M57WGI\.G.GWCI^G3]/B(= _S\A$.IRP3*6JZTDM9-*-HO:OWR5BLNL%+)03*
M>4JLN4@6+VP3"M*:JI92REER5@$PS;*U(]A-L5)U1 M2F6D\L)>Z3+4"63"U
M=DPGEK9@H4L54J]BU1<2"Y81<)0MVK:64$BJD"=LI;3RH%EPD3M(Z>1M"GG[
M!8$1/3K/[&_8LBD(9"F_8=0!95.=!'@@(?B-NW5<KNHY^S0*0<IM5))VFBE)
M."%M*/W;?[:^' K"OY" ")VLK>N'SEHS2;4BET3 %;X6',7,7+RG8J JY[55
MVU<H[Q%<-/\ ^B)5D+B-<HK$A:M7*D^Y8,_Q0$KMLO?MFAO$RU=-D_;JJ,)Q
M6\%E7L5=ZED[@V5TM=IOER]X;"T5,#19*7A)+Q4Q2CDBEX4-1L&*$@HGU5E[
MUF__  "!V2Y!W]FM7M4VJKG[,I0-DB4JJH0[%^J\V2]%5]!*VKMINE+UI;3[
M) ?N CTYU'H ]?B%(CP _7L@'!Z<$>G 'K]C0 U\J :1X'7Y2(#^Z_\ SE%F
MW4-G@57:PHKJN&.AFJTD*"7=$S313?\ C8O56+U+K,A5=?)J[R^]38UB^+X%
MC3Y-7+AM[7;A<V\+QBQ6\*_VQEWWC-DL]+UJU:>-P2U;QO4E@>)H;7UT8&BI
MTFQNV7O>HMW71>NW;;Y,VP-.V]?&P][]FF^]3E=P'J<"LX\S%P+KX.TECKU,
MWBU+U,_M#;QOUV;+Y-47;;PO5E;+RN6+9XY6?-6ZQMU5*(U46U/L5"N7J>7%
M\Q75<6[]VLDY#-!<\HW3X_;_ *!RGLUT]FYU[%? MUU#W=?:[-70+5P>#1?$
M0MW* Z#SL5B%5J\ !UZ?.%NNJFD;@\[%73LUCS_?VQMUA4/Z#UJ ;YLV8MU'
MC55JDX;"W^^,A30=-4V[(W*.5=!'X@/3@B(B(U4@-8]0JJJH[8]H1Z\_00IM
MC4%JW72% 5!RFD*:+85<Z!35U_4>O ZAP!YU'@U5<ZCRFD:A_6@:JAK"KI33
MT&O@"/*Z*:P"L YVAI&D*A'MAUJ[(@  /PZ@/!$1#ONT(4TTA_@/L$-$OK8_
M1!WM+#=N)%H.HA\1'L@W^Y$U9N)YJN[;3+(DJD_K1;3:KIJM+IO!;3: *BEF
M+RE67&DB5M?MK5A('CAJ*6:*K5X.=Q=ZC9O@/[<QU$N9#G[>]SN+W0;-T.(=
M1;L_LB0A8$G5=_<IEBF]01N4VQLC8.6;G?!8, (6+P\"Q<YW%WG<7>!8NB%=
MN[3S]>GQLTA5<*HUF[9J22M04H!>KE"*6MC_  Q.JNA&)71,)1>URBW;_<@C
MV1"INVJ:[B(5HHMI-NL3J97;,4MLQ7PPCC8IO %/+57:I^%%/:X02:;U(I1&
MX%*-8#G\ 5N<%$+V@!)* -Q*+]W62MC>M(-FJFI**45THI6T-Q*M#4J)ENS9
MLM\Q=M_P=PO5?MTV[E 54U_91Y=II$#E@+K\OVZB 5]JGXB(4\ME[X6AN71M
MDT50-%S-%XE<O%S96P9+FB8DRQX[:/%#1,Y03N"7M!=-U6D\_>42MLY6<OJ!
M^U?_ 'QZN[6GJULK9-G+EVX*G2HFA/%S1 HI&[=PY<HO&R!@M8($31VX82CM
MH+E-T1MEC %1NW!X!F[; %,^//Y Y7P3EWI^\N#P#EP. =N\K,5U@(B(_&R-
M--VTX"12W2L%J+=#B+VPI<1*[S^92PJH<! O9OK1*_034"?[SZ@M6PNKI:]=
MJ5$\:@5RMJ@ZLV/W .4I9H4%2B]RY7W@TTTT_&LQ3:K35:Q9MT+I6U54O$::
M!72U/ 6BHUTK9*W<LJ1+LWCB8"J76R1<:E<G=+_SA0:ZUTH(J*K8O6Z'$7M%
MU%9LG!,W:>\&D!#[)@=B[S]E:"Z^+04)H=.GQKI[5*347NI8M\EW:563*I]]
M%)F#"D1*GK*N1)G[9$N41RZN3*JIZXFERI$HCD2MT@6*?OD\N5+J%U$+7KME
MOD[?+@V+Q0JDE;)F^7(U+!],LGE5)KLIY(40F9.FB"><)I)$L0J,W+!BU:;A
M0>&[)<FF5!UYU_3X= 'G0.=D.  !\UNGMU"V+AVT"$/4$#O!H0+84_P90 ^G
M"]^U6A4V:+2;5</_ ,'5<&MKTTUUMPMV;C>I&VKHE5J^;135%?\ #7@*54A1
M5\;Y?O+A)$ U8%OA="IN57*Z6Z(<K1:ZJKK=KOT_P@5TWD(I4J6VS15<I1J;
M? 0Z2W/X*D:5!-[H:DPUW5"3?M >M" AU[/V/3C&J-= _?A<>-VK^.I#I3\0
MY;KJH#MW::N]N].\K#@W*QYWESI7<O#4%R^%--VX(!>N]@+E=(45W* [R]P+
MMT.=[= 0N5!RF]>I'O+G:HN7Z:^W5T"]<ZA<K#G>5CRBY=H"NN[6'VI>JFW>
M*KY<I;K42M!45<G114IDK]=PTG]X74R9:BX?(WK98T7H,BKE[--U<)WJZE4C
MWEE3*TTWSMJHW;5B06E4Y;N45=.U\;=WMBDF;%CG[ZQ9N_O"M%JA1*=+2D5M
MF"BZ6+WK9\M9IO&20*ME9*6*JCUB\0,JY4Q7_+%@XI&2MRW<4R%%I34BIFV8
MIHJ-@ !7]B/(\IL5AV$WOGY79K30_P ?)T#G0!X(@(55!33UHIHZ@-%KMU (
M=/C_ *_>Z0&NH&V9NVOX8U<NEVV:NUVVX:NVA;)S@MHY532WCP6RJ9= U<0K
MU8?39BW;H0+]0TH=\*SY"\5O 3- -1,UTJI[-7Q[%--1)OFU&@6Z;JY_ ':A
MK;IS@MXV-J\@WJ:+C?O7@O(!@5.EN'**Z$.]V_I^_;K_ (,QT/)UXK:HL&[G
M+1,Q5<JMU4G>STJ^Q'C#))]P!2"_>O,I;L)E(CW7QJ_X40A9-A?1TVS:))A>
MXGIJ.6,$*T$CV#2<FE+%A-I[N_2%-S[\5J"@PG+!6V<L*!6NS0HEKE%]4*FC
M%J^3I/D#Y,B(';%9%.,%[*K2HEJ2ZBK$S-^X;+!?*F2=L*S1>I2N*1&]6K'+
M5=H?\_"K_(=CHB&[!3A0X2LB7O$[:50:)UTE3!*P>)**<1-ES1.R7NUEOY\N
MIDBY<#Y6I*,J):_?K/%ZJU>[8#@JI$"BD?LWBYP>M5K_ (/LF#?MT#4;H"X^
M3PWDX [5'Q#B<7-W>5I1\.7T54+<_CU.BFDBKU<,)RC< 22I^W+HY\P9/IQH
MK7]/'PJN(QBW5<MUVJ_OG40YU$>?XYVJOAVAZ<$1'@"(<"H0YVJNG!'KP1$?
MG_TZCSJ/3@"(?'J(? !$.=>?ZB(CSJ(_:L&T?K $]4JN/6Q<I(=.GR#335Q)
M4"16@5VS508<A.JBVYRML:W%1=X"[1UI<- 62B[07&^LUF#(NCMTW%FF_<.7
M0O7_ ,E1X:OVJJEHQ3<?9R^93!$>S\>@#Q$)V+XTE"UJZM62]-]3L6+5SX]>
M!^G _P!H] #\F1^6*W0%-2QNO@G383.@5T_$ ZBEI1@S<J13'5021H.J).@L
M8_*/^C%N5T<$RHU7'K;.5IU(#33\?TXFFS!4+BX=KH.J%VX94C=9N[^4H[/B
M7M@MVPNOA1MF$OJ A\>@#Q)H+4@-97NU80$XN4T47_RDP2A&Z'\,1KNOA/HL
M)G^GQZU!Q,3_ .1'Z:2J.'$FC]PK$[9.]^41_P ,(V%-7\G8"X[SH5I] ]:/
MB(=0)FS%D*CRU<HO7SXFE&\9O7?RCUXP+=^Z(@-NX_*+(I]--73XCUZ(I@@7
MKN*"/1=.'$T5%>,%KQC\H_ZL;][0%!M1HO/&\:N)H!4%OXAUXB)ED[<OI";3
M>,I9$3*T6)ES'Y2IKKHYWMT>55UU?-08OVP_?G.5FS%RN[>NWZO_ "5K-'>7
M12Q[VZDUVKPD+_>ET:Y=NJ:/>)A0FW*PH1+P4&K 6*_RJ1 !.6JPMBIF:+E=
M=BJD$>J]687#%NY18I"S>-G;-RPJ54C>_*I<1IOA?KM6?W%PWRCO^U0G#=J-
M%1M\O*-Z\8NW;Y>@_?IOWORJ%?8J+TC>+6K=5B_1<I&Q6J7+!@F=LF!OEB]D
MRH"3NESMGNKWY5(" ':C)6DK_#@; K;,TW;Y&BQ4GT4V;-^W=,F+Z=?HN*5N
MFW?_ "J7$>^,%;HV2UN\)8F9+@-5FY0H&37=4VQM6*C]_P#51NA=,?E4E0-9
MSN>U29L#9K**=5-1T:Z@I*V[E-9 C5=-IU%=M0L5%S'Y5)5!2<OGRP4W#]J[
M>H_:6;M"IU$3%JYPY6-L?YBLM6IW_P!R8_*W>5\[ROG:JYVAYU'G:JYU$>"(
MC_\ <$QZAP*:N57:*>47J+@\_3G;IYV@X-RG@7*!'X  CSH/4:OUKN#354%5
M(=L I[VWP*J:OM^[YW?.[YW?Z?<::.H=WP0Z#^"=!$0"Y5PQW-%1D2I>S78N
M6PII[57:H#@&+%05=FCG?6P$;E=7*Z;E--RU?M6_^;59KL54V N4#R_;,5!3
M53W?9*@';LUU?;=L>=L>=L>#74/VWZ?(%0ASMCP1ZC\P4!]]I"D>)U):E05"
M:<EJ"@03+!1=3"5X',B_Q9='MTF5!02"]N\NV4I)IO4H=@NZ$L@534C]K>,W
M6L5NDE),)7+!Y)($TN];3C*3;$*ZT^VEJ227;-)-+5$XD62#@VZKGSA1UI^\
MC]F'^!_S]Z$!#@?Y)4 9I[9%3-J9=.-";<*6C6'@O654JF=+"A2L6D^XO+J4
M%HZ9*@ON953SB20H"DW6YBUE,5E,D7L5F2IQ+6_X\PA6:Q$L5N(R:CE'@0,M
MVRL$4TH8[-=[YP_X/E[%/3X=BG@TT]/B =1[%/*J0 /F#X=?C312(=W1RH
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M>R(1/QN\R*77%[ZI2"<<O4VF)\>/15+5(BP%BD!I^0AVQ4+O>5+:T6"P0?\
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M0E)Y1VA/5YQ=<2&R1JBM#<:NXFXANYM,9O)#43UE4('TZ[%B-:!73$MN12(
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M:\@6B9%L2'9*K+%>(G3+?ED4I&8#C<9AS,XPU[U<7.RU6,5N<*CA2^0-?>A
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MVPG:/>[H*0UW=6248@-27 ]OL35%M(A=QRJ"J28M&JA5QR#M31&-=-1^ O\
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MM"6S6TA7[#*;!!0!F->E3OLULWE(\RVTHGZR=J];+6^YM?&]T[(54=L*[=5
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M<DMEBR^(2RCSB#'N?HMVB/UU41GM37'T#<<C==Z)]A/F*SVER7('Q*>$33:
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MDS+'UMSNVGMC%K_F*()6?."DNNV0XZP]RH>=L[K6G*Z9LZ_YJ!;JQ&FR%L0
MU_3>K*UW6'.J3%T18[3(Q62T-?>3: FJV DS/ N.O/*;^1HU@S^ALC%&&Y_:
MF3AO79-M*HTL ,BFE)$OX*RA(,U58'/-9Q>7-=V1IIPM1$K;37XE$,@&4H0F
MSEN/XI^!!.GUF+4),Y?8,8?&9FJ['4VBZ'-SLD?[CG48DXMB(FS#F##R#DI-
M>:#QCB99!GQGKR;E7L&O$%V:\R4W$M7R.SR= ,&?\\HJC?&'*&3Y4?;*DS/N
M (PCS)C.ET/;--HY**4D8NK[M)L$\W<J3B<XBCXJ9"8JEU7\HC^O+S;;IEP?
M(@-)J-7Y II"K_PL<"E6C(47>KQV+3B5Q"]53EU.6?DE27'\.,5L3["KWOAR
M3I/CR&&$B3]"[ENWS!<M1'$G1U,#3'_!;(>#CDU%S%@W8_*+X_Z*T6-TVMXR
M3P<+*OJ0,KR]1[&XO@GGI@TJR,2VB*"U@&E9]S%B+B1C!L5QJUP29"NQ:7G.
MMIFY,GCHA95RJX]H>=>.64\D;"(.8^QULN!O7-V#?B?"X<W2&6/Y//DBRD1]
MKCI!$(.].QJ'QPF /F'E$,110Y0_\,G?F=BLP4ZW<HNV_A(,V1'%"W:>[/O/
M-;RFQX;;3^,D2@PHC;\8SU#LSF_@IJ99)+7396S?^5<F6-&VX&PY4)YMKC2D
M5F/I2;\C,ITNW[I($BL2*6JS'\SY")?"]=M6+2:I)RRG#R0\AH3B9SQY(C,E
M5I_"ZIEK2G0:*W#/RCPJ9+'2T<20R9<9C'D5ER24^\WKMJQ:-8X1DEZT&SC<
M\D-96\8ID@^&\?D=I1Y'L 0"RHNGN9HL29#R9=VNVMWQ H8S-,]>84/%6;+J
MW.F/2NJ9*NJ&)?A5U0+ Q"0T6,ZB+B>IYNQGKU3HO9",X<8XF8L13$O%XE>T
MF/''\J9;N5%N,Y9=%N#XS68ZG\HPY0QH<D'(#@?#.@]JH#>C-N-]D2-+,:,!
MT2D<A%FB>;#/AEFSN2RMQI$G_:S%WG]K,7>?VLQ=Y_:S%WG]K,7>?VLQ=Y_:
MS%WG]K,7>?VLQ=Y_:S%WG]K,7>?VLQ=Y_:S%WG]K,7>?VLQ=Y:RGQBOW0X^Y
M(CR+4;-=P8L92MB?ZV3-LZ0]B(:C2IJ8E.-IIZMB4T%J8<%R<2XL.89_QG'D
MWF\.9ZGML1RST4N682:FM7*%XQ"\DP8\8A-#Q/OXX8^DV,V(P46_!;1C2.).
M>9R-7'(J_#R1<3?H(@+@1XW9Z<?PKN0=BXHD(7BI ::*S8CM/W&^N$,?G.&9
M.(7/[DXA<_N3B%S^Y.(7/[DXA<_N3B%S^Y.(7/[DXA<_N3B%S^Y.(7/[DXA<
M_N3B%S^Y.(7/[DXA<_N3B%S^Y.(7/[DXA<_N3B%S^Y.(7/[DXA<_N3B%S^Y.
M(7&%/<%RJJ_KS,X1IP]T[:6=6,^:P/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM
M^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K
M3/SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS
M\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/
M;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_-^VGC65B]J49 B+,]28RVK),"A
MZ?S31SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>W
MZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M
M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/
MSV_6F?GM^M,_/;]:9^>WZTS\]OUIGY[?K3/SV_6F?GM^M,_/;]:9^>WZTS\]
MOUIGY[?K3/SV_6F?@^GZTS<P_P 2<;\,/4B<S/\ ^SS0O_[.GX5ZG'_V.F1_
MT7ZA7_\ KG\-;O\ \HKDX1Z8ER%L7\$_4*XBX^>$'J6^>$'J6^>$'J6^>$'J
M6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J
M6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J
M6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J
M6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^>$'J6^9CZY-_.>..
M*&F_PR+MZP2F[/:$? SU)@AX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX
M%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX
M%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX
M%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX
M%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I/YX%^I.Y@[KSV",/8U^G%
MA1MHZ07];;BZ<,QQZR+'209@_7A<Z2-U\;SM:KM >$UY#/JO$YXM%7<%^0F"
M5N%C)<X7^9V/EDL0HCSI"+B.?SR&*X'PN7+=JVBK2.XTGY%%W-1(7/D7G:U6
MO<#X-AXM%[$FX[6J\"WV#A=S4:0?*Y7,VV:AE#14^5X['DT&$BM=YL][D?BZ
M7:U6.B++G;;<3"3H;2DIAQX2&P(^M-QS-MX([?=K5=@_>7Q_T7J/14ZSK\B2
M1<H7;D'*LBHT1QQ""OF)BOEJN92[4LCL5<8Y%SNQMS7_ +I;:KJ%-,W9NXM3
M%8R5VGD)'U$'YLD'/&78KS(@Z/(BSNR*<>7>+.P[;,;CR'94VF3%+R%L)VW*
MF.=R6=D[2S&UZS1FU(^*_P!?9I<RP1E=X84EH=>Z9@M&&2.R:17/.62^>0:S
MY,S"V[A>EE=RB=^36*62FT)JP+K#RZV'27E9,&6&QM$SG<VQ3=.3QHV"S1L[
M=,5;.X\DY:R.QGR8VS2!-4I33EU7L.N9H[?+L72!L0VEQO%<PR/G'.)5YS#M
M)G_#^0,O]M*<@:XF4^FKAIARY<^<3,4M8+QR\FM&MS!M>8..>2>:&V]CLK#"
M8L]Y[R_7%K8:V\]I<G3:U,^(&"<T9Q2IDE&TC[!XTE_+(GF3D]JY1\H=NAP[
ME1,V4J+G(\<S-V9C&4_FMLB<:D8R<VZJ8[")8SXD;&3%"6E!9@/Z^S1'FXDE
M,$D:='.&4L0Y8U3CM??KFPHG'*UZ88-7.S;,XKN3^1^SO++6)L!AV19EC^G)
M_-;&TQ).>VS"F.MS5EZREC-C>Z-AV.!Z.W]FK TNO>;M\;6MQ\C.5O,?[NMI
M]"LC,+TX6JI.1C/IXM?,,2JV<LF*Z))F7(U@0BCP=E;"N0J(2?#*4[=+M:M:
M"4DEGW0ID%A5-\U(3!(7"TAL$\?586PY-O:Y(C M*"S,D=(SC;\L,=S/*YL(
MA:S":MEM#3;CUPY+QTANVK/:);5;SRVC1BR,=7T)+/"]&;^RM23'5_B2_6,O
M&2LC1Z?M)LBQ\L&*9MC*\YFO*S(==-4F1Q147?+)-VWC/</,9KJLQ,-$7U1Y
ML]$.9,58V25 <"RM#"M#9Y\,M*L6I%CZ_=+2Y%)VE<<"2W6^Z\^,>D=BQ:T(
M1Q>95$ELRE5<V4L*MQF2[D1%\,L-.R(BQ1EE/?;&5S)F0V 242TB1^<MMB5H
MS>;,*R:R;A5&7D)QDT3/N$5Y5BW(B+Y79B.ZFNX;H2@RA,JDIL8@6\2HZ_9G
M7(WDXS=>K-L()/(F!E%X7Y5B\K4:D%A$;B@\V@E-1\K6+<_,QCCC/!2L0=K5
M5C"X[6JUZ23[8ZG7;E*,[U+=F>(7<W/Y]#_A'MD9%#!=YF4F+311*+(,WRDY
M0R?<=4WPV"NGNQK*RFN/EDMDS<D6/[53RRDB5G/LY)$>)XJ2^A(QBT_F)>03
MS_8B979D^-#";XAL'^18LKQE)Z3+$]Q7"[8BC+".)?43<B, A:+&"YPO\!X\
M-9\'O&_*.#%B7FW>Q! <DIQQ>29[1G#K79SBEU)U8Q,7;2M@\V5W&!R:X7E3
M+\1X+HN/,!6M?D5NE)QRP49<%3FZ=731DA:4=5C:/J;'UN,QL50+B,9AN1XF
MP&,Q+&Q;72E'H0AC&)QPZYEC!HPI)JUC.INN7LF<.$G)5]+^&)ILXFN#67%Z
MPL8L82I&+JRU]1*"VDI.U -8L@VM:*.63DK#N_<:K\U0/2\U@U=M5;6"&K-(
M:Q.Q@E:L/G(O6^S,B5K^E92N+FCJ?;39*SG@HYI)XDZR&,FE4K77:9EQ_1HN
M2&S535T6-(4JXC.*;LFSVH9G6R9["E,N0BW-2;3;D7*.IQF*3TC#7TUXS6YA
MUBI4LOPIJ\:Q%Q+."375<:'+K(=*I(>+6+QK&%-.:^HD-Y'G]33:5W7C_@DD
MP*XW?K+7&LT2FI B91)&U5+U*=-V%Q>?.7]?C>N8N6-6[0*D">KQEI3A*ZN$
MN-HSMP6:/Q*?U1M%58KLU?L]UF&+KY)1*_9OPY0IFF='U,QVG)MO7"E7U@YJ
M(8)J*WW$+FDR+%+3\T34?7M71:M^L[4FUVL0MZP6]9=38U<-9H&\<<*K&*1[
M(3 =:R-R(D'4LBR/7)VK1N2*HOS4P@/IP2_A@W)G6"F"*:F8S*NLIAGUR&]8
M9HRWD_58QTA'QOUY,G'*1W]K?;#S<KCULT.!5=NKICNI;:1!T)I3X7*Z;=$;
MD=@N1T1W&YL[_FL;$S.R[+<'N#83-B@Q&+L5.6Y#A?92_;*T:R'9>$S[9FS@
MZ4Q>1,Q0F9B8*2:CPJE0=)[%RRPJ84G0X61X5S^(K&$<69L0G<_*#+S\EYG(
MJ1MD6% MDCF"XH,EE7W*HB0*+L)L/%,A'8K,SZ2UW-MZQB#IS8EAE&X7G]Z/
MJ?AELR Y=RSDR5R"BC:"J(;5';RW:6U/.<:E!Z>E[.[JDM0!L6OR]!:-M+?#
M%LXPYDG,DWMCULZ?(1CCSL2D5:8^+^;*=DDK!]B(=>-C-V4VY*)7<>B7TMP;
M:UJD_?VJHUE<F?(!XHV,;H?-ULJ&6$XNIDX<'<TLA,<Y3.[7R"4I1KF??R'B
M2"MK%;HB1 VJWG!7D-G*F1+*BYN!34= =NTM7J?9?;&DF[BMETX$C&IX[)7I
M90FSM.4V*TS.>JNX,6&+M,56.A3ME[(4#Y3$-H/[HTEJJ6MD?F'KS(O,R5X+
MFR_M )"\&IMRN2R:0=N11>)IF2Z;(N)\%2@^#&/"&^;CENQ=G+EDU(CHVEV*
M7#CMGXEY&2U'>T(RUVJI[4+]I4E;-$O'95O;84@PC*6WZXO))7:!>/2I$.9R
M_-^,RYLG4%IL-G9^YD9,QUSIM9#F8LVRN%O6)XS$E)E-!P[1#B<WHPD-N2@R
M/GR<D)?B/&S#QX^HJR[Q>JB/U+U=*E WJ15A:\$?4FB-N'O4M6;-,2>I?INW
M\3/48&["OBEZC==I2X+]24BJ7AIZF[E43>IBN&:8?]2S115$'J6JZ7!BWZC1
MT215"WJ41 O$_J82E-N(?4MV>6(I]3$7J")/4O!38B+U+I:JJ+/4S5<\-/4W
M<\-/4W<\-/4W<\-/4W<\-/4W<\-/4W<\-/4W<\-/4V\TI9BY!9OX:X@Y+>H%
MS_9AJ&/4J'[3(Q2]1/'J73$?J7J "'O4L!R_$_J835KPT]3=PQ%GJ9C=FN(/
M4M7::XB]2Y=J\*/4Q!3:A_U+5@;^*OJ+C$I7XC]2Z:J8^)OJ(X[(41)ZEZT-
M$0>I:MUVXL]3+8LW8D]2_?N#"?J3JALQ'ZETO9IAGU*EOE<6^IFN7JH<]2O7
M1:B_U--BWX:>INYX:>INYX:>INYX:>INX,:>INYJ-RZS?G*;,L<K-K#YVN78
MC]2]?NM3$SU$3+-VX@]2U9IIB'U+E%VJ(?4N5DR\6>IF*6*XQ]37<HMQ!ZEN
MU13$'J6Z*;43^IBL5A#7J5@![8J^HOD)P7XI]3&:J1<3?41M]P6X>]2Q:"J(
M?4N5W+,6>IF+TW(H]3%> 85]2A4)6(/4MD:PAOU*M%=44>IBKLUQ'ZEVY<*Q
M1ZF,E;\-/4W<\-/4W<\-/4W<\-/4W<\-/4W<P9RSV=INU'J/,ZA"G"/1AT\H
M#[(:@I^<1   0$/L!YZ;8::L"O3=B X.??!YJD&D=HT?=/<Y??6]53[H3F=G
M_9#HO_\ 9_\ L1Y+5V[,^P$/FV.J*BY(5)$RB<3^Q]-G_P!A'IN?^QO[[JC_
M /=(C[_Y.OWUN_\ RBN9V?\ 9#HO_P#9_P#LM>_23RORCUXD?_SCLI#[+TV?
M_81Z;G_L;^^ZH_\ W2(^_P#DZ_?6[_\ **YG9_V0Z-U]"*:A/JAL\^J&SSZH
M;//JAL\^J&SSZH;//JAL\^J&SSZH;/' =9CE08X1HJB6/OJAL\^J&SSZH;//
MJAL\^J&SP70V>1RRX<B@Q]4-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4-GGU0V>?5
M#9Y2YFW6/IL:J:\!O3B+*0GX/?5#9Y]4-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4
M-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4-GGU
M0V>?5#9Y]4-GGU0V>?5#9Y]4-GGU0V>?5#9Y]4-GFIZ]9,;1&2?(I_J<?JAL
M\^J&SSZH;//JAL\^J&SSZH;//JAL\^J&SSZH;//JAL\^J&SSZH;//JAL\^J&
MSSZH;//JAL\^J&SSZH;//JAL\^J&SSZH;//JAL\^J&SSZH;//JAL\^J&SSZH
M;//JAL\%T-GC3.DS_JA>2PDQ\OQ;3K?]'_V?+?\ 2 <\M_T@'/+?](!SRW_2
M <\M_P!(!SRW_2 <\M_T@'/+?](!SRW_ $@'/+?](!SRW_2 <\M_T@'/+?\
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MI2K72J>/YA6SHNH1*?036UW87RPX=]%L?OGQ>A*VIL?^8Z^;[ %J0/)\QK9
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M.E,:5L9^>M1@( !Q^NFED!(TDKPPIK9&H4_M4FE^)JX?%MQ@A>!CVD"K2![
MKF8KWUH$3=.E<NT4YODM3NJW8(FZ2A.%0$0-P8Y.\!14(,05R'ES_=6V-:T
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M@#E2-.(S2BUH1IH#@/T")4OE2!H;S!-,;^(;XNPT)I;MCU.0SI2$/Q%2A'*
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M/UU!<-O02R=@([%6I]S\\&1EUEP(!Y]OT4ZZ-V$DE(]!P!6K&W-R'.BO9,<
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MX=-<M:K%PPPPPX9GNJSA-P&.U .'%,SW+SJ&UV^]#8F,"A<3]9PP-&>*X(9
M4T\2T'%>=-W"#<&O,D:OB' X8I5VRYM0W4UVD\N53NO]UULDC:&Q]S5\/;DM
M2W+,&2.) Y#]Z_J1P^(GP*/C95E\7$E:XT@^ &LJ('P!/@4YUF:S-9FLS69K
M,UF:S-9FLS69K,UF:S-9FLS69K,UF:S-9FLS69K,UF:S-:/L_ %+@!R/S_10
MC#W!HY%#4;W%"W)'(/2*G8<?, #NYJIIXC.HXP<&*B]_K2F2.*%H05)&2H=@
M2<2G8>%%K1J)"*<2G9RH9$C@<1]5.F9X7OP/(=PX'MHNC)!.9''Z^TUJ+B"G
MV?IY_1Z:#=;BB\3Q[:<<UKRP?#1?I"(F 0'L(XU+$,!(""!]'("I+9SW>0YN
MDA>&&7(X9U'!(&NC8  4QP[:<0N*9E<J.%8J*S-9FLS69K,T@)3XR+\.=9_%
MP-8G]0P-8GXN=9FLS69K,UF:S-9FLS69K,UF:S-9FLS69K,UF:S-9FLS69K,
MUF:S-9FL3^L8&LS69K,UF:Q/_P DP?_:  @! P(&/P#^SXX2_3J(QK9XV[LQ
MIO'L "<'@GZ*A9_58R3(& IV<ZV7;9=TCU7$PC&"C4X*._/T5:W+]W862S%@
MP5,B/G] 2MLMKC<XRZYE:S+(.P]/T5=[H=X8YD$C&N5N0<T$)VH1V5M$DVZ1
M:MQGBB:$S,KM ]-;YNC=Y8EE=MMR PXD@.'=R]"UT]?NW4#\5>P0@:#G*[35
M]>_UINF%[01H*J]?;V<J.Y2;H- EB9BQ "]P:H/VE7YZZGW3^L1ENV0PRDEN
M)$VD $<,T'.KC=)-UC2%\+"-./WSM/U?/6]RNW:,NL&QEQT_^*T.&'>OSTV]
M=N3/%*UKL,5<X-'?4L_]888VVPE]W%"G#GC4ET[<XSY;D*A$*ICVG#YZ9,-X
M;I=9LF"-P1X_C\C4TDV\1>'/#F4J.4;K&=3(W9<),J=Y^[1H"&G#GA0NF[M'
MH&D'#'Q98<*EGEW*-&DM.'8I]G[Z.Y1;O&&1V8E. &8/#T'$9>FIMJN;T23-
M8,DX_L+:J 1YC<^2BORW;;PZ6&ZM@5"*K2/2*>PPA6[DGIT_)*_+)C8@C[Z)
M>_16Q1FW*.W.0#CDUJ^RNA8HV -=<QDX?WFI74,!C U74&)YZ(Z_+:!S6^:W
M>;'21DGFIC7YESG2#_7H3A_Z3?KKH(AS3_[]8##LE!-=5Q,("7D!&"9 Y^VI
MH2YI>+ZV(XX>>U5-?FTU\8+'V&TZBF0T0K_"M\>R,>6;G;TP3#SF@>PY5^9<
M?E-U2MM$P_\ *%.C>T(;R!$_]5OJJ_TP$QG9VY'CX3E6[2.MV^8V0=^;5]:5
M"XVY#!T[:IXL5T<JNG&!HD)9EVO'R-6_@:C;2U!]579$97S&_P#:!IQ\D(D!
MY8 X]_=QJY,<0TNG)*YII/R2MRTQ-TC8FJO/2_*MP<8D>&-^;]A;72%/F-]2
MU^7#X7(T7%N3S\*DK4LC)@OXPGTHM=!7+) 8X+V(GO#:VC7,-;=PE<.[2!72
M,T3P61742]B$8_56]")P.JZB(7DUC0OK!K\O)V,!T[S9JG#3+J-?F/&U"'[W
M$YH"*@C:M=!2NC:AZ@LB@S#1(U3]==6W# TR27D!9Z0<#]-6X9$WSC>P*>&$
M[3ZN5?FE'%.T.?8[6T#@K61+[6UO+@]7?B+ @#,@3-^HUU].R<8MM2!Q/W9'
MI2K"</QENX2!Q"2A5X>WG5PT7 1VV,:/0T*M7=O&\&1UPIY(7"HHFS@,_HMO
M&!_>: *W!C)!K$B>J0>SE4;'/Q_"VZ?\*+\]2"&0G4]I'+ A:+6SM#@R,>D.
M-7<<,S2UKR[T $'YZW2)MU&KMC8@U8X-?@.WE6X@IIT-R[A_8&JL*P''X3_8
M#2)'-((*M*'"K60;O=?<N!:DCL$R3MJ1LG4%T6N<7)YAP/!>WV5;7@WRYUQ$
M$+([/L]M",;]=:&%?\QW'.FSOWNX<6Y+([ C%11@DW^[+'8D"1V>0.=6\$N_
M7;FQO#@LCL'!4*<$^FIK,=2WH;+,V5X\QR.+0AXU:P7._P!ZZ*%[7M^\<@<U
M-/'F*EM#U!>^4\@G[QV) 0<:_!R[W=NB+@Y-;CB"OSU>P.ZANS%/H#UD>=08
M @^JO*_K=UH5I*R.7PE1\]70FW^Z+)@ _P"\=CI]WV+3+=V]71:TJ!YCL,5K
M2>H+HX!O^8[W?X40_>[DPN8A:9'9ZEP]E:7[_=H!I_S'>ZTX5)')O5QXG!V,
MCN8)H-'45VGEM">8[[/[DIHNMZNB0AQD/-:?#_7KK0XX 2/IXNMZN7M<>,CC
MZQR%-ACWZ9K- 8?$1X 3@G<<*EOK^ZDEN')BXDE!S]/Z\@%>(4#P^#$U@:9Z
M:=_8*45H84YR9T*/Z$(<:4G&LJU+Q^# _!G0*_V 2BT2 E(J&O>-8E:--IQX
M?LN5H@5B:34F%>^%KWOFIH6B. '[+D"@7"EHNX"A6=#&G#L_9<CG1%(!1#A@
MM)6% @940?[#4\*</T""@?A+3\!"TOQB: ^#MHFDK']8!H#XH7/^P8V@*7.
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M*R;(QA<F3WIIP"G$HBU+NMWLTK+.-"]R!6M/,*H'HH[VW8ISMXB\TO0'[O\
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MHWV13RXAF<!J*Y95';PVQ+&.*8G#UUO.NP?YG]#CSP&3_75U#_3OO/+?BO\
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M=W8F(!3%@"+@#GRPK88)K:/3;W\,Z=L9U!2BX$=W.MP@;9Q!LT^H($5S2$.
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MU_!)-$4*-:W@,>T+]%;I:0WDHOK%[ _P(W2A).'$IA\V51;VVZF'3L,,QEU
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M2:D,31%6Q1)2**:@4P%^UB(A]EH/AQN?*H4Y%#;?=P"1 %,PB<IK'7"")1
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MB'!#%=&1)"-I%G$I(5B(138,Y@!+*-FQ"->E)!\!S=PH: ;EKP$E'T6ILG9
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M:[6W0$/;EEE$@(J)UNHC;J!)(@<S"!2$, %#4=" 0Q2 !2Z*Z&Z12 PZ$ /
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MX/JZ!KQ8\8,A8169*0HM=L(6IZ0ND=<V;8=89ZX*!%4XFT)%\JXT-H43$/\
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MM$4VS,! %3#R*8>8APV0;Y*I#CS42>;;E;6&/5,>)(<2&E$Q*I]M9 < )U%
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M@0%, *H'25<RAM3?[HCR$/#C"90'G_4SMJ9A,]7.Y P7 Q@()@4YD;].@*&
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M)@ >HP=6O3ZHCJ/(."CW T-KS$!\ *(^L ?8\_W> -W"B EZ@$ 'G\/UM.
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MLJLH;D4B:91$1UTT#A:IX^RQ5;18DV3R2&+8.E"N%8^/,*;MRV\PB@1VDW,
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MH.I7M <-.+[)4QIN'8S5JW&M:/B9_<9*>N^1FV+D+,V=/+G&3,I7X>UEK<M
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MD"W *FF@"8!$OK<Q'T< 0F_W%?6'2 )CMHC%%! N@@H?6V")NH==0#I+IZ>
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MU\# )M>72 \]> ,0X'Y&,';T,!BAXF+TB)1+\ ^'+EP   @ CR,'(HZ% Q0
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M?7Y^N//@14*)@(4!T !T ? @E$=1-X:<N":)@  4NA@$0-IS 1, FY@'4.G
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M#H <P !#T#IX:@.O,/\  <_#BMFMD-9)3XS*2";+XOMXUR*!XXJ)E/-@^DF
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M:BZQM.H"I) J)SF. :@ <^-=.GX0'QU].OZQR]-_PV:2CE;37J[*"9E%1(
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M\0GO:=WA5S(@"AH 40 S(QA$0,;I\ X9E<@)'*B#<KI$3 ?M.!2*9=(3@'K
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M2.@\]=-?'0=0YAR$1TXU]73QT#J\/1XB/'@'UP]/[G'[^H_[0X]'[@_O\?\
M)_R\?\G_ "\>@?KAK_MX]'[0:?[1_6KN7!^V@U3.Y6/J(="2)#'4,!@UT$I
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MGK\/U?J?J?5UY#\'AKZ0X#0H=9B_[R@@ \PY!XZ:CRXL$4A0@DL9TBR5^G9
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M7UA'33ETZ\:Z=0Z (Z:!J81$/5 3#H&I==1Y<"( 0  ^AC'U)J \^6IAYA\
M\ 4PE#_? /J>MZOP>MZ/1QH0.O[(>G340Z>G4HAJ',?1Z.-0 @@.@!R,82CR
M]00*8.HWCS =..L *!/5U,)BZ%U'01$=0 >>O+X>.L0$QO0 %Y@'4("70# (
MF*(AKR#D/!M#?8Z /(0'4=>1@'X!#T<>C7TCIIKP.IAY_6Y:CSTU^'@ U$-/
MK<P#X>7 AJ/,=?1^YQ]8/K:_7Y?4X\1_T?O<::?M^G_1IQXC_H_>X^'X '3]
MWPX\1^R$WH\?W.!'J'F&GH_V 'AP :C_ *.-/'Z_!?J!I_HTXT^'CGK^P?\
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M%@;VV<NTFQ1JYC()6=]:734BWG"ZBBE/5" ;^;U\1!8YM/\ =X*'I 0U_=Y
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MV"O73(U/=U)O5\&1<-674XPM60T9^=BYAU#V"00*P;!&(.U07$>L ,*2:QR
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MLBQ+R^0EMJ^3K#6XVS/S.XY,DFG,Q#0 :)RKA)-L#>I;;U]S+6PY%I>Z-UG
MUKEVUU3J.0<5FW(3F:&VWBY(,K$A:(^BEITTG7 38.@:I-X]NF5L+/K:#A^
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MC(LK<L2(9?0K$O)6=-P+DV;CL#71::9DC$F#WRX1+,L6BFDBUC2-2%12 HG
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M6%:R,$L#T0AGZ)'34".2$5#(,!=X"3NZ^5K=C.\9$M%BFGAK=:)[#<U79[&
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M'&,462;D9S#9HDFJJ<I"\C!S'GP\V#%RW@U4N0;9!V/">28"28$A8^BTAZT
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M5GYTB12@B51^+?I\JD@@G4Y&?I*\@XQV>%7QCWK!/"GB]] XEN&#X^2H! D
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M8LQ/?<LP^5E,P8]MZ.&,:85L<<>5B[^_I3S%<DECE.RM4C0RLRVEG)T3.%1
MC\EWHJL5BX<+7?)^X7,D>2GK34>[H#S(M^KEBI-%AX9Q&1T*I&%9R4^K(BW0
M;IE>%253T[ZA.+=+PCO;["3<W*;@IR(G&\99T)B,G<G;ZZ)NSQC.FD$JX=X6
M8Q!4J[*P$<Y34[S1U,++-#H(*+HK5G)F4Y;;A=ZHWS=0<IVJBL:#,P]<>MZ/
M [O*HY-$U1RWEZVC*VJ,W$P;MXFLF<IGU:U6<.C'3<$OD#DJS8VR3%VDSF?B
MK1$1DH.1JX\D[3:IN3Q@6;D(9H>>P[%)2Z;VOLUSE=1$@\DDA\RBNB=&JVNI
M-XN$I%/SU;;!B/!>;<9/ZG#K[3+'4,MQ[# .2*H9 UCBDZ9D[.U@L5<%^S.=
MHTC(9HX9%40*Y2E,<UW-.-+17G%'DHPUGR94[4]O]BMMA]W8OL/G7T_+1LRN
M@@S.ZBHBU)O!!\^5.B9HL!E$47I\78LQX%!Q)D?"=BQQDW$-KA*8TDJCCS+-
M,E4I.;GHNL)$@BOHZXMI*;CY$!\NN]:3;DZ@@LH8W%V;1&08*OXXFY&-EZ00
MD X-<Z!"M-HMMVJRV#D#HJIP\OA*UN)U&V2#/5KW9):12.W55=(OVMC)>[KA
M^?AW^.L?1E-FJL3,M$RKBNR15*PI2KQ1L>W".NSVF1N*%G.&T9^#,ZJSU="4
M<@C(,7S4JQ7.WO$ETN]9G,G8*EJ!(DR2?'L''PTZV:0[W'68(CXDQ)&$-&,<
MG86MMB@%$6:;5DBO()N2M2$1(U+C3%4=DBDRR]0PWNXP;.W^U5A]\89BD9=P
M0?;Y@-JYCXXRB$ZOC&A5VM)3:CMRF,HZBE72((J+])('<G+/,*L5B9/N5NL_
MQ.C[&SL+JDV/:!@_;S'X[BW;N*1 *_%7[#_QA*T77%H":Z(%3\RCWAM.3I.T
MX!DZG.9%IL\%17IUD@!EZG2-UV"-QL-\:B1H2,7,7CXM8UFJL[D'"3H7R4OY
M@QDT3G8)P.UR/=8@EGQIFYU.TC)MIU2AM\%W[)=MF9NL5>"5A'0#+Q6+K(6"
MBV;IO[(;KI%.=,[5,&A]PFS"-R?CJV8?;GRY7-CJ]R@K#=9C$6(\@,[$>I8I
MS:UF%V2.4(''4I, BV63<$7=PYO)+B8$4U3XSN#[+-/CUJ-G?(^4G$=68Z7D
M:XZH>4+K&Y LN*U:=:F;VO* UG$%0AIZ*)7):$7T<)G69KN8=3+]QJ>0:G$5
M[+41CF)L%'MZ$K/P4S\1[UM_M*<H07$9(3-&ESQ6(7\<\3AGY(*?;/6 O(I-
MZQ4D7?LQUDND5ZKK65V_KD33HJ9;N,"L(+?=?=W]+DL#.%&[%G 3,M3+R2CS
MC86[1IY:%CG"1U6B1XHUYE8&X4AW1;'1\R8^C,4OJ(DTK"-4=6>ZW/:S!/7:
M*[U5+^KY+YHO+('B;=55Y$OXM$B:1HE,5<\XPG)#%\G%Y5QEARIQ<766LXU@
M%;51]KU,P-?;#:FCR,1!;X_V&G%E%UTDUW:K=P)')EED^X?!.3I&?PT^F\62
MNV#XP6.+0M9+9,US"NR2];4+[$1<D[AR+MT+Y.V2.FRMU%P;F;Q"*#H%EB)+
MIY7F6JV#9.DY+SG9<W*P=SK,NK(GD+#[OJR;,THBQ%1CI:(G4H6X23:T-5C)
M%,4A5D@*"XD7"Q(K9;I4%;96VX$NT9=(@D_.F0L^+MJM!VZ6]];ZE:X:0J>1
MX.YNZ@X>.8N3;"LNS>$%O(1DFW2D@_62\[4<J62BX*Q'B*HY S9&T>IXOG+L
MQKEHLF4H^9R?"+9'IEP1FV>.F%$0<R4"V*W>OHLSE1@*[])!D\K,W,9@G\E;
M<\QX2ON0\)A=*GC&"N<]%TVV8<CHW*;X<>4:F#7H.]1^17!XJ#>E6D4(]-)P
M_*U>+'8-/]'[G[NOZ[F "'UM>!^T(\QU_P"$3F/I'PYCQR12#ZR9 _V<?\,G
M_P @7][CDFF&G,-"%#0?A\.! 2$$!\0Z2Z"/U>7/C7MIZZ::]!?#X-=.!$"%
MU'QY!ST^'ESX'H(4NHZCT@ :C\(Z!S'_ "/^SX.+=G6BU; <W$4JYQ$/:L1)
M7ZTRN?Z6S9QF3%,R5"]X_9PS$:QE3;XQI*=LFHE14SR0J+*8519MU&T<K*6R
M!I2VWK+;2 H 3C6PQ-^F:Y!.+-&2VSU)\T*[<I33N3CKA5MSSJ;@SLVZL<HP
MB$>W*/E%7Y(UQ RM.VWNY#XYW_'R3]MDJT1T6P?XE]X7B'8_<[A,D7B)%=&!
MEXC,[*S,&0&*HT"*=HKNU"*D51LV6<L/8*LL6>WBC4^SP'XPK"IMPJSE'W@.
M9=MO];4"2ZS8:[B&R5Z'8S"TVL@@)8EPS1=/_*(A(!"2]GGL9HW%Q0:[8<B1
M6*LDN+76:\VML0Z?1D[ VU2/J5A+4K-%M59"%E%F;$7++1= YR%!8=A^Y*S9
MWODQC/+=TV-5*/J:&9[-?KKE[*;2=SFKEV:E)*4>()(1N3JLZA(;XI ^?L7\
MK% [6;LW*'6Y99]CB;<K"VGW$G-U*J5G)ECF)V0B:ACNFW7)^++89Y 04#CW
M-^+Y"Q.F4O%NI%U)I-VZ;@(<51<LVMEJSVJXJI4X.5++CRDWK+%Y<UK;R]!*
M+R?-8J&5SG6PMU84<YP2QR=A%H 5G/1LP1ZQ=P@ND(]"6MF.86REPS=LA[9<
ML99K62E[;8:<X3LN+Y;%Y%<9XRLL2XK4P]R8\979Q*%;EZ5S1$2Y$[%9 [D6
MJ-$_%^P8U&9B-RCL7+)X^-<\3S.W7/,+AR.K^88ER06C%SG"OSY+16CH^7U8
M-'!"$>MP(_,M#VJC8D8H3TY'0D#/U&Y3EIAL?QI-^%^V4V+(&4%'32".M1(T
MU;CYT'2 QZ*2STK)RNBDH#Y+(-5O["FT*+A\$4:X56@M&CQS,S<XAN$W1X5N
M&4ZW87\FS>VK$MQ;8=A)>&,$:W%"/G&0**F44[SC)%:M6)\?PUNQWC#,=I<.
MG+>]1E!=7O:Q8,@1NXZH.[6LXD58R&3@38^F*U*^563>,;J8136-'N"A4';\
MV%J1/W)7W8=DM,Y%V^\7>IEPMN_R3G**/!$J5CFJ_7:1:XH(!DR^,+4J@S1I
M1$JH?:XY-ON,SQ'4BH6ACAJA2UPC<08ON,K9LYQ-UJ]?NLE<-O67Z6YK;<M!
MS/"S-30CT&(JJ/'2S[4[!LD1NJ^LEF<4W$;^IL<?9*M%-R8WG+$GCO(UJBMG
M+7=51*%6G[ETW56M*<DRD:[*L"*+/'*9F;YL1%91>-0D65B9T>[UN7W?3F(D
MGM,;IGG,7XTE6F "8N?6&DMK6[O%EB[*;,'?=66,CY D?WF:[B.2BG2S^,VM
M0\%)&Q7,Q6>=J5]G*O Y?O=IM&:*Y>MS69\:7FFXYLDW.M97*=$BGN/DXV90
MDB.V9'DRW;*HL"M6(N-U.Z+&;O"(S>.L+W7(&+7-+L<WDUO7K-"86-?'V/\
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M5)R.6MR%(&YY:=XXH^ [_'8WC:A9*S:+!3=UDTVKFW3)/EK-%1KAIBG(DNZ
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M9!FQ9,T$VS1FS:I%0;-&K9$I$6[=NBF4A"$ "E*     !_EEY"(81I80DA4
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M8M_@_)MD_P!'C_\ 2EQ]+)L'_P!C;)_^RH\?2R;?-ME#Y(\<MV+<?K8VR?\
MN#K4>/I8(?-KD_Y(\?2P0^;7)_R1XY[L4 _^QMD_Y(\#KNP0+RU];&V3P_\
MK1X^EDV#T\\;90^2(\?2S;?-ME#Y(\?2R;#];&V4/DCQSW9-@#TB.-\G!T__
M !W_ %2]/'+=@@(#X"&-<GB'[H5'3@0_K8MP$-/LL:Y0#QU\-:CS\..6[%N/
MUL;9/'3_ /Q'CZ5Z/S:Y/^2/'TKT?FUR?\D>/I7H_-KD_P"2/'TKT?FUR?\
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M&+"!C (@;0.YKT%#3]L>.>R_#H<A\(M;Q^#_ (GP\!KLNP[KZ=(M;E\'^^/
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M74X']EE)T".H!H(G^$ \.#=?N6=DFA3"///9B]0E]<I$P-%?;CF3#EIXCRX
M1]RYLF(!AYJ&SR<I3:Z:&(4T6!]":@!@T$1-J!0Y<!_\19V3& QP(40ST<.>
MO241'V48H%4 0Z2ZB8 #0VG+CJ+[EK9(8H";4?Q]*>J <B&*(17,IC%T'P'Z
MOCP)B^Y<V2E'734,]G433$0 W;.8D5TG4$!Y% >?P\N(Q#?![HRA[?Z9-23:
M)99SHLG^-O#D*_>KD;M$[_*Q!4Y.CM72QR@#IR@#8@F+W%"AS%J_8;.L+R$?
M)-&LC&/VK0'K!_'O4P6:/8]XW4,BZ:.D#%.50H])@']OC0=EN'0'_O6KH(>
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M+B-JM(A=UN[QC +*@6:QI,VQI7T*W8DDB'35:F8G,X%(>G1, ,/AQM@ F/\
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M&O&XJWR=-L^RJBY/B\8Q36G2,:V4?SMFI;L[B6G7M=8&,Q)$OY$A#@N  90
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MA>PVZW[:C[M\1A"[>ZJ[@<^8/;P_M^0GL%VD:XE7<D3\3#_QEW!LG/MI!O\
M;3-02^V<9-P37]I5:>Y$PQ9L&57*T67:]4C-Z,_W'0"=GQ2\E7B40J1W"2L
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M':Y2G0,0JA\B;A:IDFNR&)MPNWG$]2W#X^EP<KVF?W(8A]J1\%FVLR4/6JU
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M0815@D 8PZ$R0J*R*0+*';")B 589?9FYO\ BR%R1(X VT[>B78K6W+48(;
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M>(E:YZE347N.WH9;W2TYE3B3*7Q-KV3(:F0K.ARX2K%DD\>UQK2D=';<").
M7$ 23!,!/_D7==@S;QE(JN.MO%@]W9DZ5IEU)CTE#B<+Y0KF;Y/<I22)EIK[
M)%@N&3VE(C$ZN=-ZBG"RP=]1XV9"JW<>Z>SU)WA[:,J;^-YU\P%N*VW,JY78
M^-Q3CMRCGD+B6C1K6OHWNF6'9T3&$>,F^DW3Q1XH#WVL!C.6@-=O>*\O[D+S
M77&3-E^?<DW"<N=8Q'$R^<;? [L[7C2CWS:1)5FD+03:4PO2:<XB[_'2Z:!D
MQE(UTA#*]:DJ3?GNTA-UV1V.5<#^\-RYMFQ\Y^+^'WL1&8W@/>$8TPA5D7,8
M\QJY:/YF&Q/+OXP72Y55'@O?-KBHZ117)[X[,$9D-SCN]>[OS-C3'6VG!LA6
M*W,1>2*H:D8EM58F\BQ[N(6N5\=[N;!>'\-%J1SR/%H1)!.*!-^BY66JL9D6
MY7ZT;/MYN?,1XHQU8:E TE7(6Q3<6>TTI62P+D*8CJH=&U8+SC#/).+:3TBW
M<RL%.I%9&72*Y:KCL P/4,LVBFXASGMXW\6K*-/A6]/!&;L>#J?BZ3QM849F
M9K$O/0SROO;X_6,5JZ2:/#)(@Y1632$AH+9IO(NULOUWHV&;QN Q3N&@*K4J
MQC#>1MYMTMCJ,K,[=HROP*475<[X"LMM-!3D5$#&LG:+MG)D2717(IQ ;1T]
MRF466'K'L,R!NL7@6;#&";MKD*+W?TJJ149'/G&/W,BE48[&TVXKH-#**&4:
MF!VHH:0*#L/=30EWSGDA]%;CM^'O/,.Y@F5X_#31ADK&NV]EGE?$%5:(PE52
MFZXI5%\:1I'#MFUBW<@)5^^Y< X((5+)&XO+%^F9]Y:-RE&KSRU+8B:U3/A:
MAN/R]48Y_5*U3:W"S<#.8,H^*6+%\<OE"2'ME1PZ;*"9JZ-[PK"MWS!D>.P?
MM\W-8*@\=V,CS$492Z?$WS 6([BK@.<;.*XE<[(ZR_>LEO20[XRAWT>HP3;H
M/BJBDW7M&)<[R-ZW+3+#!FXW>ILFRM4:S482$W9X\IN%+';76TK-,?3:LV;1
MV9L.9$?0:#!Y!$8#9H)X@Z,!ERN$EI7?=6=YLT\S-)>[9RINE5/ UK$(U1]E
M=3![7)<,^HT \J4FM7:[AJ[ $7[.5/(D=,CF;S'F7@@Y+[KZOU+()4+QNNRW
MLEQ_N0S.]:5J3M6,L89YJ\Q(R^0"1BT,>G5N8RQ?ZS\4X63>QOLIF_DS%;MS
M.$T"%W>X3PS%FW)TW:[O I59KS"'MV.<6;A,YX>LFT=/+N:,/X6N%IK:^,KQ
MF':=D"R14P[8N&S>2FZ^8L:X<@[*JJXJM+KF>\V*[:KW[L'9YNM&]S-;PEC"
M4Q#8,@W#+3>[9NRE4YRK.%FC*Q0^-XZ-EZZV4>PT>\DU5VHM6W2Z)D1[&Y7F
M<HIQ'_N0:Q]W97L&SM>HSEA.;6;SBNC6F?CX-Q!U6*M[>U83]OR%H;SRCY8Y
M8R/51EC.&WKI;",$XFMF2!QYG_"6[^0R1CO'SG&T7)NI?&2^$6M0R6SGKO79
M22CAQFSR/*RSQHS55+*MV943,G1B@09++\)F^V9^V&Y%@\58 N\[0ZWC=;)6
MUC,=SHF/WV*]V]/EX>J.V-MPUENX6])A;(UZD_;P:CYL^CRE9&4;EW4;"<D9
MBRC+QEU982W?;3,G-(6EM'=-VQMY@:KN"Q,\EX_'YH!V_JV4H%*(;KRR;R9=
MQ5R:*^8*HT*KQOVE\E9TR:P2P'NH]Y)AW#EW>.,*L*S=(S$,CD""Q?BB+@6U
M22FW%[PS!5A*R^TUT2JRJ*9@=>T6Y'8([&L_(Y-9SNYC<;3=F[_+68+-$5)Z
M_P 9T7/62L74W-NXMQ1XZ(B:@A"8X#)*3=J96/)!QCUZR,[2613415]Y7B_%
MN7K1(5[:_!>[7O\ C;,"D)C][;Z/<MR^X>OXQRMM^M<E(U12H6M.SXW7+88W
MS;%*6ATY?K,X% S$4-D. \H9/MEKC]R,W[S*93QQBU?$+6[(8'QO)8?=;7I2
M^7:2H[.'=92PU5\@RDG8#P"9FTPV;(-5$I5RD=9PWKE7S%"9,LE<J5886&Z0
MLG4I2<6?S-:0=0UUFH:O@:&BW%P;?]+M$P;),7**H';D%N)>,'[,_P"LAEN0
MQ%9?=T9FS=:$7BF/$K1.Y<I.<L/X]@KNK-LZ"W7C50KUKDNN.9$;Q"BQP.+4
M>V4"U^"EK%*6^3AH6+BY"USB$6VFK,]8,D6KF?EV\&PBH5&4EUDA<."M&K9L
M"RANTDF3I('^0GT9);_-EC"1C'KN-D6#W='A!J]82#!PHT?,7K5:\$7:O&;I
M$Z2J1RE.FH02F ! 0#](/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX
M_2#[(_SJL&?+KC](/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[
M(_SJL&?+KC](/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[(_SJ
ML&?+KC](/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[(_SJL&?+
MKC](/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[(_SJL&?+KC](
M/LC_ #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[(_SJL&?+KC](/LC_
M #JL&?+KC](/LC_.JP9\NN/T@^R/\ZK!GRZX_2#[(_SJL&?+KC](/LC_ #JL
M&?+KC](/LC_.JP9\NN.7O!]D8_\ _56#/EUQ9,BP6\?W=T)D&Y-6+*WWN)S_
M +;HZY6IC%E*6-:62SL[8C-SC6.*0 03=+JD2   @!Q+V=MO ]W.WLUA1E&L
M_84,][:TIR;;39&Y)I"7ET[25_)H2Y&B0.BK*'*X!,@* ;I+I20JNYOW8]8+
MC5_8)3'(5_,.UF&"@REL1!M:9&E>SK"V"JR%E0*"<@LP["CT@=*PG#B7Q\;<
M1[K<U"G[)\<IZD#E;:B-0G+=W2./C5+5OV[[%D[(+@A3^>71.Z$Y0-UZAKQ#
M661WA^[I?V.N(Q;>O6![GW;8[FX%"$55<0J,-*N+4=_&(Q"ZYU&I4%"%0.<Q
MB 41$1ET87>K[OF'1L-E/=)Y*+W$;=8]*;N"KMI(*VV8(TMR1)*RJ/F""YGZ
MX'="JBF<5.HA1"*N5TW:^[=M]NA(B4K\):K1G/;-/V2&@)Q!=M-0D7-RUG=R
M<?$S#=PHFZ;)*$1<$4,50I@,(#!Q\#ODV"PD?5XD8&M,8?<EM\C6==@^VS2&
M&@FK*Y(HQ,4*4<W*+=N5-'1NF'3ZA0 F47>[_P!W,ZR:E!+U9/(KG/>VI>])
M5ESU>8KB=N4M1[ 6!<"J/6T!P#<_4.I?'BM##[@?=91(TR7F+!3QC<H;3F'Q
M5GK%TA8)NMBUFTO8<O.](><<M>TLZT^V&-Q'R6.MSWNRJ!(P[698Q4A2LR;7
M*J^C&-B=MW]@9Q[N"L3!=DUG7S5)9ZFF8I'2R1#J 8Q2B$E<#;E?=A#;9JRL
M[G,6D<O;5_C%+7".*8D=:Y*;]O\ M-]96!3""#Y54SI(!]50->*_ U7>S[ON
MM0=3251JL+7]Q>W:'B:R@NDLBLC7XZ-M[=G#)+(.5"'*W(F!BJ&*(:"(<6>M
MN=TONT'-<NR;Q*Y0"^:-KZL+;DI%^63?I6>*4L9F,\F]E"@Y6!TFJ"BX=PVI
M^?$["PFZ7W:$/$6>)A(&S145FC:_'QMAA*T+KXN0TZQ9V-)I+14 +U;R39P5
M1%KWC]HI0.;6.K3O=A[MES789_(2L1 .<X;9%X6*E);O^U)&.BE;,9BRD)/S
M2OF%4TRJ+=PW6(]0ZO['8MR7NP)^PRD/$5V3GIK+FU:4F9&OU\430,$_DW\^
MN^>0\(+=,6;50YD&W;**92](<2%PIVZKW:=2MLM)RTU*VFM9KVPP5CDYB>(F
ME.RLA-Q=D:R;V3FDT"%=KJ*&5< 0H*&,  '$?:+_ +K/=K7FS1$3(5^*L5PS
M=MBLT[&0,L!PE82/F)JRO9!E#R8',#ALFH5%<!'K*;7B985C>#[N>ML;$VAV
M-A9P.>]M<.TG65>B&\! ,YEO'6ILC*-8.!9HLF::X*%:LTB(I@5,H% LV._;
M8H,RFP4BTY8=SV!!E"1BSA)VM&E?C=?-E8JNFY%#(@;MF4(4PAU  @Y&-W!^
MZRCQ>N+*[=^2REM/:"[>7..<Q-R=.10G">8<6R*>+-I,YNHSYNJ=-<5"&,47
M#.H;G/=D51F\JIZ*[:5O,>UN#:NJ0HH*QZ:X0C+"T26JIUC"<8XP"S$PB(IZ
MCKP[Q[+[H/=ERE!?3+:P/J1)9FVN/J>\GV?EQ:3CJM.K$K#.9=L+1+MN3H"N
M3MEZ3!TETAI^[[J?=IW*>KD,]KM>FK5FO;#89>!K\FD*,C!0LC+61V]BX=^D
M82+M4#IH*E$0.40U#A^O1MY?N\*8M+,:W&2BM3W![<*ZK)1U-A$*U48^04A[
M8S.[8U2NM4H^-24ZB,6294$2D3*! :97>[L_=NO<I1[7R+')3O.6V9Q?V+$
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M/T@^R/\ .JP9\NN/T@^R/\ZK!GRZX_2#[(_SJL&?+KCE[P?9'^=7@L.7I_\
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M(0Q9M=]2*@]7LCB/=V)9W6H9RK/NXE,Z44YFU%F1SRB\8D<2MSKBH9$HB!!
M!X5D7>+,<NI!>63G5G[BD5E=ZM.)22TRC,JNE(PZYY9&7<J.BN1,*Q7*AE0,
M!S"(DBZ]#Q4%&IJ++)QT-'M(QBFLY5.NX5(S9(H-R*N%SF.<P% 3G$1'4?\
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M)@,0@@B3T_M_Y $!#4!#00'T@/B'';\HU[8&U GETN@!Z2D$0+T].O20 ^L
M!Z.-$R$3 /5 "% H &HFT "\@#J$1_;X%=-JW37,04Q6(@F144S'ZS)]TI0.
M)!/ZVFNFO/C0B29 %0RVA4R% 53B(G5T H!W#B81$WB.O @5%(H&4!4P%3(
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M->$SG(0YDC"=$QB%,9(QBB0QDS" B0QBF$-0TY#IQJ<A3<C%]8H#ZINGJ#F
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MNPVZ4:Y,MV I?*((1$0NKEFAX-KFX.17L-$9)(C U&=Q]8 *SET%#(+RR0(
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M'L+7EIEJ>#>UBK7%:%CGK90C5LNU17(T*@)FH8]4M-@PM<;#3*/G:I6"TRM
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M8(LM.P#A]%K]P&,_6)=Y7[+7Y-LH5-W%3]=G8YPR?LG*:3IFZ1.DJF0Y1*'
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M':.4U2E/H84U"FTT, CP# 7+?SPMS.P9=Y/S1FI5"HF= WZN\+8JQP()^GI
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MR=IV'%/11()VPL?9SNCDO=KQ:S1PGBRV*YRIEOR[:Z[4,MQV9LUSMP@<.(9
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M^/T?."_Y/;/E/Q^CYP7_ ">V?*?C]'S@O^3VSY3\?H^<%_R>V?*?C]'S@O\
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M,.@!KQCK#2NR'</5+#D+)%-QLFO8+A1FQ8.3N-BB:\B[DV!D$GW1'FEB+*)
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M1-JQ;KN$E\K6N4FJKCL<N0F&H:W3,&[]C6F?L=UBZ#!V6LN8X9'VECF2L$H
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M?"3U3<9[H$[U IB(O#88W&F=(IF P&32<&U53(8#FU !T]8?AX!,NX7W/92
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MV>0"8?'+"PAS,(CR#0/VOAU_QWT_O?7X_P#<@0 (!1#<]M9$3 (ZF =OST
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MK_CW_N0-_P"<]M8_\0#_ (W"?^QXQ;_Z48_X]D;_ -BM3O\ TOW?ZF\CE_\
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M_P"Z./PB@OOO'_=''X107WWC_NCC\(H+[[Q_W1Q^$4%]]X_[HX_"*"^^\?\
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MG?\ :BX_*SL(_O/G?]J+C\K.PC^\^=_VHN/RL["/[SYW_:BX_*SL(_O/G?\
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6._!HB!5S))"J'= AO]'B/A\/U^/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g17046g16r28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g16r28.jpg
M_]C_X1/\17AI9@  24DJ  @    -   ! P !    - ,   $! P !    )00
M  (! P #    J@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    L    !L!!0 !    N    "@! P !     @   #$! @ >
M    P    #(! @ 4    W@   #L! @ )    \@   &F'!  !    _    #0!
M   (  @ " " _ H $"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R,#HQ,#HR,B Q,CHU-CHQ-@!R<C(Y,S<T.0  !   D <
M!    # R,C$!H ,  0   /__   "H 0  0   -D"   #H 0  0   #8
M       &  ,! P !    !@   !H!!0 !    @@$  !L!!0 !    B@$  "@!
M P !     @    $"!  !    D@$   ("!  !    8A(       !(     0
M $@    !    _]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M         0  ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MI?YK^M_61W]7ZJW*:QN78&G'K?'M^D:\9[G?1_>L>EE=7ZJW+N8W*L:UM;"
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M[5M&.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      !  2     $  @!(     0 ".$))300F       .
M             #^    X0DE-! T       0    >.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      -!    !@
M            -@   MD    & &< ,0 V '( ,@ X     0
M           !              +9    -@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    -@    !29VAT;&]N9P   MD    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   #8     4F=H=&QO;F<   +9     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    !.$))300,     !)^     0
M *     ,   !X   %H   !)B !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M3__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
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M970@96YD/2)W(C\^_^X (4%D;V)E &1      0, $ ," P8
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MI.G>^>=\]',W.@4\=)V2-G.Z(7:I=@_CI-$'LY_!D>0)[XM@3Z=6VDGV.IX
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M2M6+U8!NE0'WQ:.Q3)/5DL3*IQ1ZJNUC6.(IB4A;31'L*R( %'YJ!"GZ.FF
M* !3=,N??((/^8-8?XY,J_QM[%C^]M.\_8[NO[,B[C 'W9MN1'[M#DH?:/>^
M/N>:6^S2_5#^%ZN@'V)Q1A^W3QAE <PX@$1W9FQ -AW1@^S_ "5P.]&X?/VL
M;EB(9<DO:&S@?\.68O[@%C$1T+J@#\5+[,8-N/2Z$ 'H  /E  #Y.>!$>?E'
M\PB'=38>%L8V!FE%S&-:+]<9*_0#.JVS%549VB3RG3T:@:'2:/G.4ZA&4EM#
MD*^D<JTZ$I[*/1,^E\G5"&J<?&F.]=Y#I496ZDF*H  B(<<C3WML0)-_7U=M
M\2M;H[>7R,Q"1<9"L?3^1G3(Q,]?FK1W*7)5JC*Y#39 [M2JC"4N0%2?9* _
MOET8].']E&4+*Y&%G&OKL$A.FO!2"_MSEVPG\CJN)$V0[ V?S5G5C(][D!O#
M6)Y<G#4 5[_D_/T("'R(F$#&4$>E@^ETR_;(%0!S#J^"@;RY8X^^QL:(%VTL
M @&'MUC=^0]Q.X=9MN"_NTK' N1+U[=0=*C)_<QU,, ZOUL.["<48I,Y^,
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MW__:  @! 0 !!0#Y1Y %5@221VAP$O7Y_+F.JO0XG;+7:>I,1MAKO/4I//\
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MOH]?V#Z?#T/'7]_$/3YZ_]H " $" @8_ /N.P%=%N*=J2*GH6'6="F778^3
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MMT=7AD8*GP97%8#1A!0E(*>'""&"$ E!7"  )^&8CXH (*Q,%>:$(0I&4#9
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M5\<\(MCJC:@K(W(NZ2),PP7U.N+"7-R8$Q1%6E6%BHRIAT3.,E@\&E57(?\
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MC%1!M0+'<IIMPUSF6).4)@:3=F\1W-KV] ,J/JVF$L',^'3&F<9BAO<K.UJ
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M%2BHT2D)%5*)[DI2*ZS#*F^6<%5CG'UU58\VO*;_  E0,8O"7Q&^&WIY+A3
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MC$83%VN+<&7Y?E36D@-MJ(+73J030=NEJE\AXFR$7-VT*!NK2E_$HY D1 A
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MT2@&JTW%NO6E:5TZGW-RN#,U*DA*$A24QYH&X)2*T'37XA-&VTC^C]#0 &T
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MJO5CC3]WO. VOFZ!@WJ&Q*+(?EMM8<Y:H2;5F]O@!+I$W%'9>Z0TR!NCJWJ
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M)FYJ<::#$E9=;.Y0#@"95@DLX19X")SF2M9#;I4AEV3/EL-!>/.0DV\/1[3
M6BK#H>6"A(JA*JTEY8_D.*LWN_6J?9,IGH3(6JY6JYM6R/<&T-AIX "#;$>&
M=Q4M-.M:ZQR#!QWCNX?(MR;N4.=-G/E6>^+(2Z+5?E.6:2B+%B((0@E;RSM&
MU([Q>Y]VQA45<.]VEG$_!\W:;7:,C+LJ;;H<A^$RLB%<70ILAM*5[14=VGK[
MY"R.XM)M5OB-R8=QC11;9$"&W&D);M"+('GER'S4E,E**=:>WZ!U'45*>T&M
M*5IH4KUH*]/J]G^;K[-4[#TJ.WH:5_0=7 =QBR?JHRL:_%DKW>I>10=W_M=
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MJBPNWK"F"#%QB>D-.,I9@]0TL-AQH*5M4*UUQWQ'\,N4+#.,<HQ[+;#$M[R
MN;?\:G?$H3MT=*%JG5EU6^I8_E"BJO4UU&Q?,X\^.+;>8F266[V68[!R#%<B
M@K4[;[]8YP"_+S6U'H!5*15)%*ZY&A7^9DO(%YY7Q\8UF.=Y;>Y,S+Y=CCA0
MA6B'<8X8=@-07#XC1:"2AT;JUT[F+]_SGDK*58Z<,@W?D.Z?')-AQ!2D@V.W
M%;:"W&?"1XJS5QXBJRK6/Y1#O6;W>P89D5SR3 >.;Q=S,PC";Y=_&,RX6: I
MI+RE-"4X&$N+<2P%G93I3=N"B>E$G=04Z@D ;23V_P"=K:5)W>RHKH[2DT'M
MK^@'LU0$$]]3MI^?7=]1K^?V:Z$$BH^GJ/J]FB2OK^JFM#]'<0:^S6.JR:ZY
M;C=]PNY.W?%<FP>^/67(K1)E1UPY09E,!6Z-(844K0I*DJIU[-0N/<&1=W+7
M&N%PNL^==Y"[A=[M=KJX7IUPNDUP>)*F2GU%15TZGI0=-<N/Q+:J6US3D4G)
M<V@SMLB#+FR[:W;GX_@.)4 VJ,V/<-1NZ]=+XUXL@S86,+OMVR-B+,F.2GHL
M^\RE3);#;CB4_L@XL[$4HD=-<6<IWF//<R;AYZ]SL2VRG(\(OY#'\K<O/M(&
MU>UL51NZ5[CI![/='V>G;]'LTL]0">E#VTK^_K'IN#SI<-YO*;4+RU"@,S7;
MQ9BK9-MQ"QN9:6@G]J*%/;[=,Q,IAYS82YR5<F+!99]H,>'=;6N[%#D*1):;
M=4W;+59Z+9>4XA*TD +/9J3&L5[RZ?F/WA-Q+QA-PC+1B,3%O..MPIZ;D;?6
M-"DP@@J<;<*BO[774A#MJS1,;X#<\0<5:;<\F.G.Y,U4NWW")-\LN:B"U&2F
M*I\M*;/1735OB&TYK(8Q>XWZ#FEM=A"]-19%W>:A8C'5<UQ0]>C;HY7<4O,@
MH;W!IRM-8K<,6Y#Y;GOLW=",B+\,PD?$W8+[\ZWK2[ :D/1(DYO86A1M"OL]
M#35FEXQ,S*]7B"J[S<J;;R"6W*@>"ZTA,A4:1:F6YDOW5D6UJB5] %5ZF2+E
MD.5WQL7_ !Z(X+A$>A6:4S<Y7@.P6;#(@QY5IEQFEDI*75I?;!) '360XI:+
MCEKL>!R%D3\.:BT+MB+ICMRGK;QJPLW=J$J/ CVY#+@5(*"0DI42:C6'1$VK
M-)><6K,I5URL1H8EW"WXS8IB52+4]-D--MW=JX(6GPGVT5?3U"1360?+TO-Y
MKF0XU$8QC';3:7&V<>N%XA,JB+N4&5!=@3TQYPW^:*TK0[[BB$UU-L;3F>1)
MKMHQZ*Y(^!L'X-?L2N"7,LDNRQ'\K-<R5EUIM+36]JA5X8![+1,Y'ON20;;F
M>%9DNPV^2)>47")D<:!&<@J3)3!+4*0^XM88@O)5L4BB?HN<K'9.8WCDZ\WR
MVVN*?'<N]RLDATJ>DR@F?!AIL\1<>.4NA0*$>)1)J!JX*N4GD2UX[D-PNDNW
MW"!C2FY6.0;7\&M\ZSR:17=WE7DO.L/.I0'DK.W=MUQY>\6N6;7RVQ,^RR'(
M??LCIR#)\!3:_(V1VXL^384S(9O$I2TK*$A3;8('>+',SN5E5RL"6+Q$N5QD
MJ48EQ?M]O7*AV)['4P6V;<5OI]V?N*U$!.[N/(SN7.9;BU\A9':[]9[S+M[S
M4AS#,@G.O_+J),2$XNWLQ8<4)=E);+J%.BH'<J3B[?(T*WSL:MUELMVF6=4J
M4C*H<]NX2KBIJ/%COHCW&VCP \MM*%!?;NKJ5+M%RRC'[2S&E7IAZ>XFQ0L;
M@--V\BWHM;MN><R&6^^V^I22H%._ITUQ$GY@R%NS2L9C1;U&V76QP)N4M22Q
M-1,;7;B' EQ"ZH)2E7ZM!364,XM;\K@VR;E@N&'BX65<F"]9,6B/-918& $J
M<AO7SPPY#<>H%$>[]%I5>+GG:%W*<';SB6265^';[5BDBV%P5D*B(+,Q-S0$
M>ZZJOLTA#:"E'5"!V42.@)ZUK]>NH'2G8._Z]?U]5J*>WZ?X/W;)"YSYIXZX
MGE9(S*DV!G.\FMN/+N\>(ZEF0[;_ (@\R)2&5J][;H;_ %D>GL$J":?>5C?;
M2O=._J&K-@O'_JDX5S#+LCE&#8L<L.>66;=;M, .Z';XS,LKDO\ N]4I!.@2
MD CH*&O3LIJ?_J65_<EZ_%E_REY'_P 70-1/YK.+/_5.O7)]'(V+G\R(NO6I
M_.KA)_/+L>O2!_D8QC^:Q$_P:]4A_P#K_P I'_7$Q.KN#WVGG,_G+PUEW^H^
M>_[I<]7\=?\ _0:9V_[MG-6W_)%Q7]$1W^OJV#V6SB@_GNC>N-!W'#^$B3]/
MCQ#^;7J2'\7T$R*?^C7=?AZ?Y7CY_P#>)[7!O^[>.3]5@</\.O20?;S)F'Y]
M\\'ZM?ANT_Y6UDI[2?G%LZ_%TKW\%)_P-,[#V:>^C@_-TCZH\S].OQ"4^S@2
M,?K#E]&OQ$?Y@G?[J_K\$G_MMU_V3<_ZVOQ)/IY+M%/92MQK^]I\?_L=<C^>
M+7^#3 ]GJ-=5_KEZFOQGOYR,:_P@G7X0G\R4;_ J#_!I7Y?X#^X"*4_6KW=F
MB" >Q5!0GNI2M*#ITU6J:$UJ5$$J*>H _55M[NW015( /1"B 1VU"3^3I_T]
M%/>1U*E'J.\T/;4?5HT"0=NW[2>RO7ITIJIV[0=NXD"A2:  @U )'7K^?54N
M;U;*_:'7J$FA/N@5U0*"E]U%!1 K4TZ]X_/H@=IH37]8UZ$CLJ"-5 ZTI])
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M+GC5YG68F%\XVN4&$.1DY*RTF6J,XD>"I:D"G<#VU Z^W1%:5Z5]E>FBD@+
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MM\&O;[U-=:5Z4]O;T^GMT]XU UX;GBUK]C:=]:55]FO9KGD1I'"0XE.:K_I
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MZMI'FJ;]O4C[5._17;Y?!9]3OS>X0TTD?.HS+:?%"3Y8?WT*:[J*K3251)/
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2"M-"FVNX_9I]JAK6G?3]S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g17046g23q00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g17046g23q00.jpg
M_]C_X2/'17AI9@  24DJ  @    -   ! P !    - ,   $! P !    )00
M  (! P #    J@    8! P !     @   !(! P !     0   !4! P !
M P   !H!!0 !    L    !L!!0 !    N    "@! P !     @   #$! @ >
M    P    #(! @ 4    W@   #L! @ )    \@   &F'!  !    _    #0!
M   (  @ " " _ H $"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C R,#HQ,#HR,B Q,CHU.#HP, !R<C(Y,S<T.0  !   D <
M!    # R,C$!H ,  0   /__   "H 0  0   .L"   #H 0  0   %L"
M       &  ,! P !    !@   !H!!0 !    @@$  !L!!0 !    B@$  "@!
M P !     @    $"!  !    D@$   ("!  !    +2(       !(     0
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M:7V?ZR_]S\'_ -@K?_DFHL^J_2&8PQ6LL] .L?L-CS/JM]*YKRYQ<]CF_O\
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M;^K.N%'KVM<8&]V(-H+O%_K;'?V/H?GK7H9D,=8;K1:'.FL!NW:V/H?2=O\
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M?[/<G'4K9?.);#6AS2'5&2=FZO\ G?YVMUFW^PN;K^S59C\-U?3&Y&2_T[*
MS(:7^BY[::S<6.;^CI^T4^MZ>RO^<_F_T"DU_0J;/0R/L8P(>YE+*[VOVV.J
MOJ#MPL9;ZE-.-D/;L_G:O9[$E/1'J5DN Q;) =!+JMLM:7[7.%SMN[;L3'J=
M^V6X5K3$GU'5- T+]CB+7[7NV[/H_P#@?Z1<U3;1ZWKVNZ8T['V5N-60WW_I
M&O>[UOT?T/M['_H_IJ.S$%C:JF=+^TML;74UV/D- +C^AG]QKKMWZ/\ F?\
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M7-< YI!!X(U"YC'Z1;F8K'XM'3G418&;J[CLL)]+)KVO=58W<_']*W^:L_\
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M36_FLWJ Z%T@<8M8CP$<K.IMZFX"NR_/=._W?9JJSM?6&U[W1].FS]-6^O\
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ !(     0 " $@    !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      T$    &
M  );   "ZP    8 9P R #, <0 P #     !
M  $              NL   );                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   );     %)G:'1L;VYG   "ZP    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   "6P    !29VAT;&]N9P   NL    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
M 0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E
M9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '
M9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y
M<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T
M;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S
M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     $X0DE-! P     (DD    !    H    ($
M  '@  #QX   (BT &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( ($ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M%NYGJ-G)P1+/=^E;^N_S?Z.SW_\ !I*;XO=K/4J3(T]K-#I_PB1O<7-/[1H
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MT7N]VQ,Z^PMAO4J 9F=K3I#?;_._O;_\]0_:74/_ "DR?^W,3_WK2_:74/\
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MTOL_UF_[GX/_ +!6_P#R339/U9Z3E&PWUN)N_G2U[F3[:JO\#Z>S^CU_S?\
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M[68=@#FL_G&4VN]C_4^@S:HC*S7-EN9:#6"^TG!L]T'Z%8_=]S&[&;[/T?\
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M;NFMQ-IQW--5Y]N][RSVG_NQ@NV/I_3V6V_I/TE22GHSU.W_ +AW 03JZH3
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M$76^O3N;94_Z'V?Z=EG\U^@9OKN6T>H8 <&')JW. <!O;)!V[7<_G;V)'J&
M"0<FH$3(+V]OI?G?FI*<47]0M]6ST^IL;818*=M#2W<:YJJ?.[]#]FL^F_\
M[56_SN^CT6HNZ@QKSLZF\AX:/4;1/Z-U-C[*_P#@<SU?1]WZ1E5-WI_9;/TB
MW79F(WZ5];=0-7M&KAZC1S^<SWIG9^"TP[(J:2 Z"]HT/T7<_G)*<7&&<+:/
M?U+](TN#;&U;6G:YGI9#MC_TFZO?[O\ #9/\]957Z= O\H.94P6=58Y]\%VR
MGVM>,=@]21[,:C?9=_A+OT63ZEEGZ/U=\9V$6EXR*MK3M<[>V ?W9E,>HX
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MRJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_V0 X0DE-!"$
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M(" @(" @(" @(" @(#P_>'!A8VME="!E;F0](G<B/S[_[@ A061O8F4 9$
M   ! P 0 P(#!@               /_; (0  0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,#
M P$! 0$! 0$! 0$! @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,#_\( $0@"6P+K P$1  (1 0,1 ?_$ -,
M 0 " P # 0$!           '" 4&"0$#! H""P$!
M !   @(" 00" 0($!0,% 0  !P@&"00% P ! @H9&A4@$1 P4!A@<!(6%T A
M0< Q$Q0Y*A$  04! 0  !0("!0D#! $E!0(#! 8' 0@1$A,4"0 5%A<AD2(C
MV#&5UC<8.)@Y"B#P)!!!46%Q@3!08'"AL3(G2,'1,R4F5AGA\30H6+C(0(!"
M0T14=3:WUW@IF1(!                    P/_:  P# 0$"$0,1    _?P
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M/)X/(/ !Y               /!<TGX\@
M
M     T@_(J?T                                            #O:=
M,C^#F@=##9@  "G9.15$^4W$GLJ^;&?06$-0( -E)<-@/L)/*5'@G$AHFTEX
M                             '@\G@_!\7@+#'S$@&$.MQ7@D\KT<%B,
MSIB1&=MS\WQ(9M!"ITN/S[G<XYN'=DXQ'[9S\BI)9&I94_0^;R
M                    #UG,PVHW<AHALF0Z='D\%?B("J1EC;RWAKI6,QY8
M I.;"7>*U&TFJF!-B+>&#*N&P'2D                              $>
MGX_S^@                                            ?H-.F8
M
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M7D*G$TD!$ZE>2.CH@0R47+*$1$[&SF9-@*3G1LLN
M  4R.&AWV,2?P0\4K.E!\1+1SQ-R.F!P"/J/29T_0&
M                    45/STECC=B+RO!&1()/Y^H _.40@=ZSCT:^;,?,?
MIA                                           !Z3VGD
M
M           %6RLQT&/@,N>30C8R2"H)*1(!Y/@(")F,.;T8 RI_1\!ZC6B/
M2SA"YNI!Q8X]9\I I8 P)#18TQIE2N!8,^8R9M(
M   !SF(C.?(+(DWG/(UH_12?G#+&DY&GE'SK*48/C/4;F3D4C)&-L*"'7 M*
M<J2WQ Y+A\)08Z+E.#Z#XCHJ4!+H%1#?CG@=ZCIT
M        1V;Z?V>P    &D&[@^,P -H/[      !\AKIMH
M                                             !B3FD2Z64,.?,5J
M)_,8?<9LA,_@E\^LJR6^-C(<,^?4:$9TU,T L 8<BTVX]9Y-G-0, 6(,40^5
M'+D$P'UE9BX!08DPG0JH7 )%(.(Y)4/4?,:02^5L(V+JD?EC2.CZR+C[#?2*
MR53:#6"HQ.Q!))9]QNA]1FB/23"KY90KJ2\1R2$?T:R;Z9(^ G, \'/4Y5G5
M Y='N/<3@?R<RCH2:"= CGX2>?812=<S\Y9,Q8HA\M&2T8HHR6$(7.FI80K*
M4D-8+0D)$*G3\Y:EBS3BS9@"WQ6H@TC,FX@ ZL'-(B OZ4T+3'SFC%\CF*?(
M;@74**G1,X(G20SQ7@L07N*;%42Y)#I\A/YRN+LF!-Z+,E=3?SF66U-*)#/F
M(X-'.NA1([Q@'@J<>L@XMN54-9+0FC$ND0@DPU<AXLP1::L;25=+V'/ Z $*
MD>%CB6R$"#RRAJID#6272MY,I)QJI%A,A]!]A!)_))!K)L)/!7PEXYN%BR1R
M+342TQIQ!9*YFR-C^#YR6R'#$$EF>(N+RE6243Y2,B0SYS1S/&^E,RQYJA-A
MKY QJ)4DL6=7   8(X6F")-+:D"&!(]/G+,D\G,0Z1E%2#3HN0<9DC@U,ETR
M!G"92NA#1?$I80 6;/O((,\2$9P^HN>4N,42>8<D\YN%O2/#Z3?"X1S%.@)3
MDQQ/93\D\F8THQ!#!+!)!6<L"1 74*FF-+$D)EW2G1>HH\>LFTBD@0DLOX<U
M3T$KDVD*ET2K1!98 Z]@  ]1^=8M$3J?R9(OV<8BW1<,YJDND9&^'N-1-E->
M-G(D+WE8R2"IY>PJZ;N1T3L0F84T4ETCPGLV$^<C0@0G,WXKB;">LPQ(9.QA
M"-"-BDI9(LV4(.BIIIL1-I"A]A+YX-**GEMRMA(I30Z[E6RT!S[++F^D8&BD
M=$VFY&T$-DP',HO$?>1H1L2R3*?(1(=+@#U%)2@A+AD2MAV/.;!\AU4*D%=#
M4S;SUD:G6,YWD:&^EQRG1<0YXG4DHP?<1$;D;H2D08>3VF8(5)J+8$!$3GI,
M>:Z2X0@2J3,1L6L*]$0$T$TGN.:A9,TT_HM^5#)R)8*S'UFXD?'T%6#JL5N)
M0(2/G+NE"C:""3;#/$ND2EDBMYJ!M)\Q]AK9>4\E43J,; #YSA666(,+\&KD
M8'R$#FYEOS3"1#R<>SHH98I6=,"DINYESY#HF<^393 &JEM2NI,Q])4,^PE(
MU4SYK!F#4RYARN+UD;'@V S!%)N9-96PF@KZ;<6(,&5X)I(!,J;<?(3Z<W2_
M14T^<GLF(PA1DMN1^;.:H;X3D8(@<^$LZ1"5C+.$$'44D8   'SG- V<SQN!
M7<M48DT\^HB ]QL9)AD#G27%(Y)8)"*[&G&<+6'.TD0G<K&6B*\$RF#(3,&;
MH2:?"0R6%([+$%6"633#Z2VY1L@XMD2H5Y,^:F2H;X1T8<M>4>)V/::<3:5#
M)R)L(5/65].H!0\UH]IMQ%9*YO)I!&A]Q=8K4>32#*G4@R(   /6<="O9>\@
M<D8T<M^54*T'70Y$%Q3T&N']$7G;4Y8D=&]$^$;G\D!EDRE)8DG(I,3X8<U0
MWLG,])EBNQ@"R!&Y'9])\9#!?$D K<8(P)OQ'Y&!*98@I"6")R(&/4>T@,L^
M=*CA\60-N-;/J*H']EX#W'+,M06M-8/F*QDR$=&WD9%O36"M18(C@L(7Y  -
M'.8QKYZR9##&>)+(M(=+N$"FDE@"-3ZC6"YQ1,T0LL2V5W,2289 PI'!<<B$
MC8RYH1OQM!AR22-R "RY 9,I5XFDD$]AM1'Y])$A<XJT;09T^XPY&A:LA$B(
ML"0^0T=@R%2&#&$BF3--/6?0:X84Q1: C(T8U@VTT$L*:.;&1F:J2B0&=!BQ
M!Y !\YPI)I(A-D),-U-$-7->,,9 N$285A*]G2TYP$@F$/!7 LF5I.M15(C\
MQ)OY\IA"PA2<W F$VXIT6-+>E%"/BS12\ZN'.DGXB<T4M>0T;H6Y*'GO(?)X
M+;G-\^ ]Y?LYVEA"E18D^$L:5(-[+9E$2Q9RA+]E"#;"7""3I*;P1<6S(=-F
M)K.8QTJ+V@  'SG/TQ)\IMY!A9\U\^@T,R9L)@2W!")').Y5LSY,A!YNA[C0
MBQ)2@V\DP]IEC2"42#24CXR"2PA'Y8,ALTTW8T(MX5P-1)5-0(@+BFBEA"-3
M2S22/RP1SS/)_)JY#!N)ZC"D-%M2+#93<#0#;#V$@'SFWFN&NELR4S"DOFI&
MH'WG]&\EQ0  #''&HVX^,&/-]*PD,$F$FE8"W!)Q"I[38#7#'F+,86!+(%.S
MUF2+-E/2NI9$B\Z E"R42KQ9(M\= CR                           #'
MG.@GLV,RAC3&F<- /)LYCS%DQ%8#,$LE>R5")"8"MQ/Q\!D3,F//G-=-Q/02
M25U-[,">\D8L:>0
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M+K KP;<?44F.X!H)C"D1%Y9 M <^29SV'H/!%Y")U\(-+7G!LO&12=F3^#@
M=O38#DF2*=)R#"/R."KIT.,4:4<XSHV9@TTF(Y9'1LCDF$I&=/BBQ)AVD.0Y
M3,G\C4Z7'*,LJ?(4C.CAH9<TI.?:?V0V=NS@<6].^8 !Z#BX?4:*=V3R
M                                     ?R?T  ?.?GX-',D=J2Q@
M
M
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M21SX"MY-AUU
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M\$G$T%0BZ!SB+RGDV,RQ3XE(WXA4E0RYTD
M
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M2>R&#2"2B7RK9;TA(B8MV5L/632?60^9@P9/1$Y%AFR03)'H/D)8+.GD
M
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M-V,P;&1:?*2X;&;N
M         ?_:  @! @ !!0#_ -7T?__:  @! P !!0#_ -7T?__:  @! 0 !
M!0#^?^_^$IYV(/EH5Z:AE#\96(: JBP_*B?"6R88CEC1&UP38A[C(M<2@):)
M4GD4FL,*^EP=LX6'I77%[3'2:9ZJ-B1CW+B78601&:)?87)(X#HX<6"V[:3I
MJ"N/#[MWL).**]&S)MF3+1BP4RR-6($U<_QF'C;3G+:2[3.X6.5=QX6^)@@%
MJ7\8/E!T@L0+6OXV!:,F"-.Y[8<1!68N$WLGD-I$;'#%*J]^=^6+W0BE5FV?
MOX :V9. T")/8N;BZ<%*S:4C:>!8H&TVK-%GY8#:"*%,P5=\TT.;$CRII\VT
M=AL(9%>S"3B*<L:ZK" V8SZT#;9X-$4NWDTTVULUE8^@#=/:9%$TC*G\I!87
M+VQ\F(IJACP\Q!(.(]$BU26GMZV"#TWT]E.O(VQ&IBEI SYV^+(1 "FJQ0J#
MV53,Y3R**MI;,3GM]LS%BY57[/Y6[+64TN@L1W.^ 28V $YCR\'G$VYY*.Z=
MME]>")M8;OXX$>&PTD:PH.$<)Z!805+$RV+BF7&9. _&9O<+>+?*M(R1=,\K
MG]A95B>"[K:>*>"0[O7L%W8^"M6UQ (4TL:_^^H>CL-+6YTA!8-BHI*8@UAZ
MWPT#E@9:)+2+C8=/C1("0:V'C+1\-B17Y<!1VP([#;?<6!$>+,#&[#MUOPT+
M3:T1'+@]?,N2$?FBR2?!?8#-K9 3W=_7WZ 2A0)=2:5E.@A>)HB&FD#(LT"J
M"_4[7!2L)>?$*P+%Q/Q;1"A;M=#)D4$LLU., 1AB'X1J9%0SSE1*0B<HG($F
M!DC[:T"1?6,61 $+BH09FF07FV1_;M#?!AL.OP;X8+':M#D?D+- 0OSSY $>
M%D DJ[KG#EC'FF0(3:,4;M 13O<\JJC$S.&B6DX3-,2Y%ZC'=A<.NP58:Q\"
M4CW6R27UY+G)=\3UBA1<'[&!C>%W=<Z,S7>2)7A-S@D%:!%A#&![SJ=$.Y'A
MZECL;RWB2L28RSSE*%Z),MD2GB65YQ'0I8"UM]8.>?3DB-I\#="/26D 0+T2
MGZAQ$G:F%+P.!QK=DCH%X]]ID@"?B+]DK@J\9+M4)4_+S10(Q\)]OM4=!^_%
M1#0P/E^32<*Q:;"66*V+I#$9PAX7*VZ$*\#P1$K3I0#]'P1&N<1#_&C:9B2&
ME'*0D69@:WJ2@R1>$H2<'3_5S15,0IC^1U]A23[$B*G&"G"3&DX@/.AU:4CO
M0$R1H8+Y-H9DO4$(4Y'J&AJ#CG45[B*-<LR4 /RF QFO41P?>;U6HG)-MPJT
M-<.6Z>OT01^7:A*09@;>3@.+RH]^"!"CPT ;4Z+A#PW"&""22G2):$-!S#X!
MQ<;%&+(X'(L'?%/A9_\ >!J6!Q=)IV_[?T3_ ,LDKN6SMC4"&C ^:]I\*<G5
M,D< Q'=JFI,&YBV0384(&J)2QMH7&-L\*2!T[AD\;00#3M:$GPYD<>CE14;X
MH6#5RB48U6PU0 >$<")N(N 2S6LS^^V!)(\_"YCW\W"^C\^,^SH7R61#II8M
MQ9MD!D#90CV^S5BSXDVR=Q_11<N"37D[CINL.',NEOB2E7S :T8J["\CAV+A
MV!;B[K4:G7Z'5?T&0>6]\=%QR"[3_1^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_=A
MU^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_
M=AU^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS]V'7Y^[#K
M\_=AUWW]V/7Y^[#K\_=AU^?NPZ_/W8]?G[L.OS]V'7Y^[#K\_=AU^>NPZ_/W
M8=^OS]V'7Y^['K\_=AU^>NPZ_/W8=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=
M^OS]V'[?G[L/W_/78=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS]V'7
MY^[#K\_=AU^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS]V
M'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS]V'7Y^[#K\_=AU^?NPZ_/W8=?G[L.OS
M]V'7Y^[#K\_=AUWW]V'2ZY;2YL-_;_+TF3?%&8XX_<H67S\/N3+-U]R59NON
M2K-U]R59NON2K-U]R59NON2K-U]R59NON2K-U]R59NON2K-U]R99NON3+-U]
MR99NON2K-U]R59NON3+-U]R59NON2K-U]R59NON2K-U]R59N_7W)5FZ^Y*LW
M7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5F
MZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*L
MW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5
MFZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*
MLW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)
M5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y*LW7W)5FZ^Y
M*LW56=F<%M0 W7+Y]N+CS[B*X]3O89-(@1HG^MN'\41$=3.#8)QL'8Q:,BDT
M6K3VHHKOHS/[$T[%[)G4[BQ:1<)[24$-DKA=BR<D-DP;8<GS)F6<&87#66,D
MSP-4(71"T9"YI(CO8NERPF1E6@ *>"8&G06LF+AH:188LGOT4+$4]#+#X-BZ
M6YK5ZT_BW;&W,?M6O^80L? XQ47_ *Y_X_@O E81B;(S5N6QHD!; .!8DHA;
M!+WV#M<$:OG2;VTE *C+)V+L2%+)O,-U=EWR^@;H,62",Y$RX=/XL^P]K#:P
MB-]4XAW?_P#C1HGRC-,TQ>GEXLCVS[HO_P E$0K/8"RE%%KSREKO;5H3R)'D
MW;>Q#+R*2NKEV1@K?>MA-I3L7KBGL.HGD/?!&D=7:6L^O(B1TY5TH0J>)7>M
M^\WQY./S\[,OV^T?;Y5!O;!B2E%M)L=Q+O4WU,5\*=H2-X0.N;^O<OCY^?&J
M=68@4-K'9K;$+VD1OD6%;@[,7U8A\/A2.(5#:M<NNY6!\,Y7V_AW[?OT3@%_
MR85_&OT"Z;1C6E%=Q-7I&Z@X7$E-,%4(<-#]MFM<9<%>$H46$HHN(MJ?#PDL
M 6FI,3*@Q<91N$Q]*(G16N,-KS-]':B,2F<%5C-AQ<G%1*J2=%AY6U$!</7I
MJ9!;]FY=J[<<&6=GRJ0.L0\P[7SS'IK&B< H0,0!JM(*G<F8"L<:L%H/Z\6]
M7.]X*O"OWV^O]'Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?
MOM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\
M=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'
M[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?
M'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q
M^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^W
MQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\
M?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM
M\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?
M'[[?'7Q^^WQU\?OM\=?'[[?'7Q^^WQU\?OM\=?'][?'550@L9"R\?YB,$:=@
M*+VFIV$]T5KI5),B07V!HXU/-H54NA"ST<B87:6(S!OJH;K6N(===2SFA3+5
M"@AK&JFY?L2K@@T?PEHT&N=,T;!US-H@!>9ROM8BG'KGVLB[*K4J+MOD[ K3
MA#E4!2]-=M0QS*SUK;=)&W#VZ4YEPX7BE=C,A#+7SU[)XS))9FRSV&9'N(A4
M.P+-F',U.OK^!<2G_KNBCE<Y$J!!7EM%K% EW#.+*[-(Q)1I:O7.QYK$%W%E
M\BS]3?I6N*CE9%3]42Q,VLR67VD9A,QE48.FB):T6A5JB?+?VE>J.T(M'>DK
MUW6ZF+"K.+FED62@MIWF8M)9,@3&F@(WHFDS3UR?8N%11EJUW^44;[:-RM7M
M(S":#.HQ@#65ZW[ D?R]_+&V5%ER\65$M4,&Z#%]UO;#%:J.J_15D@V$0)_P
MIP+C:HWFRF>@MB+I(D2 ^P#HFI\XZKUE$N?Y7\"J S+6Q"<*-..&3OQ Y//&
MFOI%Q@G0&N(5%GS&5$'\^?PQ,-6;-)_P7J6DZ-XDZ<+_ .!>K,D+1QPB_P A
M/K?W\IW7L,!J;P=1U#H/=$K$><^OSNY1*&L-&/J9$$JJ&A/2>'-7Y83_ "IN
MI3TNK8H?)GO>,H6 7X@38+?5H^(3QP;1X9U,9YHJWD%M+@CGX5/VS%3:UPH3
MXBC%5;^;W_[]0&L'3PFRMRZZAPV1.']<>JQG1B_KYKSX*X%$X(XRXC-0.MY#
MKZ,RYCQEETDE-V83E3-M5,2+CRX^!CZ_ 0RN'7HN4)I6!'IY92&:)UI%*[3J
MH?+/X4R54RI$=JO:O\:K> I96=A)DT#* *4G3AXZN@V0YANZ:LV=*&Q52T<-
M3;,/5;*FM"Y@I_%9J7B&BP_XN9656MJZQ Q6S6=I:W,0)5&35<C<5J:>,HEE
M1*[!$IQ38>LS9&U]T$K>$]>\8K_K-UR#%&SNOJ.6<JU#*I8-E./#*>LH(KN/
M*YQB%M1$:K=$,;'XSZ\"[<"1%^GF3' C*978)%9,;$UTPLM-@$*W= *V#J[K
M-AU7P'LZKYCMG*MP:K$??W&ANHWB"A/[>O2"_-&235#)B2])4JB&K0K &E[8
M^#Z%N:S-:V+E.;76.6W)4!KBU7$Z,8]?9>O%8Q6B3"AG*2M,Q\D B2:L'1ID
MPQLKCBDV<P.U?1483K ]=A?>! 2Z!R.6U=>VI,>.WV'(1EL2*@NK 'JW@P^H
MD%&'/GE6;R0"P#?)IYYVIDE5$3Y+*UHJ4(2A3*$+KD#I3M37D).,_#RC"+#I
M3P'7$0@;$ E45.EP)C=5HZ!NJ\V&0'@8VO$()9*P?IHF@P"@;HZFF_$%2[)P
MK4$297_Z;8<=2,KR1<5X3/ -.Y.Z:L0PQ8SX*#EGJ$OHGY'W6CMTK8DVV<VY
MN*C#5PZP5,)\#-E8PC^BA8"9D(M>*$ LPF3+[&N9_P#>V*XDTW&\C\/!EK[F
M#-I4]N,,1C*P*M9= ;MZB=P)*/Y\_P &V;B@F'NOW;5%NXW-;\+K3*T?L4KZ
M2)GP'RU>UP&<"+FG=5SXA7+#]3%APN6 V4\O.0@:Z59A+-X2U6CTD4U2G5N,
MGO8(L%;C[@&9JH>F'+B,+.L]CS"=)76&U@7."PKG9$?=S7S5*QPS9?\ PQD<
M'!E</;_MV_RB<9H-8G8-X;/X#X3OA)@WR-UFF$2:V+?\@P+M+MQ/H)'I%$C=
M&MB/<PQB+79'68Y@SX6WW['@2,8VDGL%DF^Y)Y!^&1QLGC29Y(%<$?L.:>0X
MA7AP?%BP1R3S:$* Z+CT1L#,HS)D4!H.>+R)@W\))JC")-]HM4: ]ON>0LNO
M47B,?;N!;M@L3>:7/S8TP\#YXN43 +PJ.@XXHZ+9@TT]@LBD&60X!@2R.%$9
MS')GC@CB+R;6D@>;G=^1R"?C#6G<$=JQB3&=0@=:;)*8QPY#AS>%[#A.;B#4
M/P/R(P]\);&RH,)EFPZ<PDAZ7^IVLALHL&EQ\1[6Q'QU*I,IKQG(E$;'P@ 4
M7 ]>+>-&&#OMGNP0@8A''"(BQ#*H;B!9VY=SHXJSD8<)BRN,SC3VL]="T.9W
M(04Q>W?F.5P/!'%I0,:DO4-7'TP8 $K]-J[B5E0(G*&Q)O*NY0TO1DVV(QV$
M;:Q$<5/LI'P&9$K-1QD6"DQRUI.5U)9VR=<T^6;6&TEUM18HY0%'2%'O52PG
M+ ?I91G-U)8V5'FM=<RV.R+I%O*W(\44K;=C0+=CB\M%61CE!F*S1MSKN[NH
MQILFC-1C)L?%YHD!/VM>QMB>\PT1+FF),05P\2M?M&E3#;PMJ<EQB8A"4HU>
MYAO)_62 (1.6>/&QL?#Q_#BX^/\ E[4:#K>37^&PU^#ML"$02$#2,3>"0<EQ
MGCX_#BX_YV=@X>SPX/ H,,HQ_P!9^_\ T7[]?O\ X&_?]&_S\S5:.#/"S,P/
M2</:+VO'PS. ;,^J_N17?OJ(XS:XS#2 ^Q<(%/2<[=JCBR7!:47S&1[9OU1C
M_GQ,VNO/$&H?,&K8K1W<W@!PNV;8J_I1KE-(M&%/2C9JNPYG6F80"2+FW)2&
MT?ATE=I-X;@9[8*[JR-E,P!/"4:5T5WPH=PN$M/GO6L;J/+NFFN=J3PLZ>#8
M+!YQW*:,7[KD8Q]A"( $Z;0[=20PK;9\##RPTM)L(:<HX?=M&8GN'$BOD<A"
M]8Z.+=[-@@5I91$6>6^?:Q5'-C;8RR&VL2/,BY =]>=%B[-B )I)&,SP$C/S
MZ9MB68Y^.Y)N9C -B[IWV1\"]C:9&\=Z-DU[DN$1;+EW%Q_RCF%\&7[?<:F/
M:GD;%8>#6']X ,$EJA!\AN^7;E:-;.*-SMEQ'$]^F[C"UR SSGH(XQ57QR\Y
MCR%\IB\9<ZWS!@B+2;L[:<^6/H]YI9/I/^>0G_NZ"FH0$Z&Z5VDWDF!SN0I.
M-J/^=P?Y2#2-V&L 3^!T"_(1)M/X(,]#Q'4(Y'ESV%C/%'2M-,+VK%_@_&AV
M[/$]OHM"R"MC5:8W "'->KY#P8VT:U3#7X;  C8Z#9.PG6FAQ3-X<!V@-[H\
M\/,TG8 %PJ:MF]PS7%<<)O53V<&G#T 75Z[7-RM^P*FW;A;M-,](XP/UHHWK
M0+;%Y@6"MCC38P5FUR)\G_C_ .1$&3!%+%>"L]PI$'4*'I6U?%KD!<75Z;=U
M^.MAQW+51_H^3X(@DOA^4-5A<*,SD>@Z;LDHIK49UN(]&!$FNU<-8U=#43E[
M\TL=H=[V8USGK:QW7K*QNX).J2W@$W@W\%*6]B(A64VC@FC96ID1##"D$:'$
MU>]K5<#9+R1$_.DGD9X7!N3%3P<%V;9O)UW05T99$O[(&@RBG'D.;Z1H]90!
MBLT2HP,21):>$YKZ;H.^..E#<X1CV=8S.YVD2$(-5J6O+*DN+.&@SJWW6X!8
MB@O/$,+.@K+9[8C.;(JP^[5PR)RY9&89#%//0(,\*6UCE4P45&QE7=?M*.W5
M$+D*[6J9%4)PM5^R.#\NW2V?# @ZBO%O!SD3R3&YDT3B*3MER,7%D&?45C8U
MK>TV0AK.HVUI,7P-A!O8&1Z^DW85>BGR(@R.R(2 "8MAR!"1#VRC(^ :+-H+
M9, 499\;;:MK7&L%!,JIFV!&81&AJ?1 '%O38T.+5^R:7L++)KA)HQHT9_"2
MIU13'XTKS$ AG9[ ^SVH\J">M1!#^":_V\$@]1)5CP##<:D\9^:9H[3YJ]65
MAN*"*"JW!LC3!M6ITH15D93*/.M1E!^J<)4HO28RM&&#;Y-XD:-'Q4"\45H8
M7;/GDUC.Q-UX*23&X@S(E(N[<W"I[3AG986 TFS40=@PHC+? O9Y=7#7PL*/
M %"@;-@M*0LH-"__ ![]8+SJ5L>63O6I<.'@^L1@N>T)L8X*+KK"XZ,KV)V<
MZR.++GIN[FK3_LO>6.(_']<%BHOI+W#?M#OP9OH<^JXY6K@S<K820]G/6I^M
MY&7LB @A4?3'^'ZU=.-Z4N\N%L7:U(B0&*.,E$XP-79:ML=9;+9\*9!#CEDA
M;*(@*[; -?.MDUI)F+FGBRJ'0+OG/2J.N%N].P<C6%NK!4VT.*]ME8O59;9J
MZRM#F91FPM-YGK8$VPYVFNSK*4:U\>V#8+IJR9%; 8@2GJ\787K@F@T8(/&&
M!ZMNUGW4&W5BJFZN-QUHP#+"YL6: NJ*HG8<.''(BEDJ,S>1X5D:1;0?<+EJ
MUE2&.-T-N'6QASE?F^TFDTB8YA^<[2P:Z.38Q#,=#U9;+<4[[K262I%)1UD.
M:KG!.(U9,H&^!K8V#PH"3HOLT!0'DX+M*MLB=Q6!1&4O/-+ $U'A4DCN*I#I
M3C6=HCGX!+?]?,$93:Q578Y*]>T2HQ&=K&\^G9QIE2L%AQJD678@E6NT^J>A
M4-QGPRQ-<> <Q24QR<Q>.O>MDAT.$S("V8$WS2K]&--C/VK^WW(^9!<C_(XD
MRJSY&GQ+!DOS-41G?4X2<N^8P-QH8B^RD;25C]\[RH1;-Y+%$MXH5$&'#<^(
MLI;1<H25P4UA/8MA5)L+X#1YZ*V0YR8!3QX3M -9V_5*-#PRJ,B%(GT'*Z"]
M"[ %R(Y1KU9F8D1C  =<ELTVKT*BC%AR4)8DY$$C((YFM,)OK*8(AQ:+"II5
M_9]EP26"BPD:JP9/P#FS!C Z6N$>5]M3HS_':NGG%8F.BAFDB)[$4"/>G9/5
M5Y&7EIL-*$MJ0R<8JQF0)L4RU!<_=N(N")L@',YM4E/A(,JN*B35^9DBH@QD
M@G6;7FZD"G#,JH0)N%1C74V$3ENXJK>Z.+;C(:UN),""A;19H_.H7*BP9T91
M@WE0>@*OQHA<2TK2IS0Z7V$K^8L@E]0EUEXFF<OJRG^_6DAH6RY5(J3IRPJ_
ME V* VY/;FOY5C>L,A2Y?"RT @@R2-*#NX]J]/X&QY[7\X.GET>19@XFQ$IY
M&G/R2R>M]J]YQ-2N;+$H&!>OEMX@==?7NXHF!ZW*HWZRGF UINB'M-,:_7&P
MI_9\GK5-UI-F@S-;TEJ$BKE!DISL+3IL'5CU?C4ZS22!%&+V'.1*JFOF(F+2
M*LE)"Q)ZPF>G<,44'MMI&GYZQF&DNQU*!.C+5>RU!8K5/$*JYF?@6*C<3/H"
M'G(@K0Q EIVJ?D"0CWK5/D?57BKJ-V26JY%:8M>]3JE_A3/./)*KF=,J^RI#
M&\(AV?%?I"QPEXJV'7V.F-E>#O&>>$]&VG[SI:5(.(9;LG5V'*;2U-@.6@7O
M,2N6?2,NXE;[7\ ?*JCM&3LO]7/X<G)PK'9RSA,G:8VJ0PF++O+/5TT^+H[/
MEYD^_P!;9PK.WA^?Q97/@J!:)E21:>*Q5=-MJ)Y--"-X.NQ&>UFEQC=DBSRF
M2_+JJW>(2&S1:HU,\:R4!;2.;ZVM.-/K;'FAEZGBV"NKGQ?6QRSE3=WR$^P;
M:X!=S&"@VF >RL;&':?'!IO(>'9/+3!N1UD7%GQ@T&DP7<EGC8WI;&UYWI0C
MMN"CR* ;!YP)AS ;.]RG9H2 Y19#-F4"L;WVT;_GM65C@AQ'M"%6PCOE8LO'
M"81P^(&*Y/,3^KP#)R(#L>SVXX*=@M%QNX)9R*9H.N&Q=:MWA!EYR5+QDL5H
M EF2UF&PKOLM 3+(</#;K+ME4[6X(E<T>F6;FQ_EW ,R&!V/IT=5;WUG?(S6
M=9VX/]M9O<X_C]0[&V)*JP"H5VC,))2]PV4*]EQ7'M66O)SX79FM\RW2^MJ)
MF4VS]L"8 !E0RR9:YJ00(V \8G;&1GM&'#D&WY7PXD?PLLX0\WT-?->IR?>*
MP/.&#F3^Q,.<V\/MI\W@==Q28$?!V;2E]!1'R>$V"@IZ[+B\$VF,>U-A:U;H
M0!1N14?()$;'U@G6"?K&Q)!O-6[7PR1@K*+)@+!H)-WF%<1VNC;<;]E%Y;-E
MQP<N,LEHCRJL0?%PQHH/G9LI&'-=G86(-)']O;LFVOB[$V5\L4GFSMC436!4
M6/$'30<L@_D/$L,3Y\=,W,O[?O\ QY^W/WX$S4R1J:NVFJ/-T"@X.K,G0A*(
M^K<(4#F^-3H<]<(!'S'S*CX-JT((4T*[5F,<I^^U44E4AC*K*XP:N#H/U9R@
M:Z3QJ.G/B*\VL(D['GB=9YA$AVVE*_?"$!<AAMDN!!*K.P]U7PU;2;@PRUI'
M=Q8!NP0S$C26"5E$V$$H[K#,":Q7-31+LD7 6 ,3"!+-ZI='N1OP5N$3'G>A
MIUD&&(<>N=G_  G*@5OSA8I4T2&Y#6\A=JKV9%D4J1)VI#N3E6402[SR>MR<
M20F5^B\ZQ,HG6L[;EP@+VN4O#)EGJ-$\S$V!ULF<,3H#U?%1/YV/:K"2)"5M
MZ<]M*AK(:ZB60Y!A4_D3([ZFOQM=^NV:C>_V;[L#6CNC(00&M\L#IUD];&G*
M$OW-71:SX.QB7,:SX@<97I2U$1.:P2$I'7QI_..$%?.N2?\ *+LJK\I?_*&$
MJ;I4\EQ59DS09/:JS=[3<JNMKM+V)&,6':FTQ*K6]( 3O"O75(2@9%%3<[*[
M/C=7!-RR2 XA;!B#J34WFWC$S>K5S-2!&/0*>DN4I>ILJ5[=B6NB;#?>32KC
M6;X8K;!#C QY":F8;!B5&T%,T0,>?47/9F&F2KU<)KQ/+ZS921SY,41WQ0KJ
MW%:L\G96 *ES$&*X/*S"#V#4=JQ+G@!9VC[TD36'VL4DGG&(=;Q4DQV[U@&<
M<S]?5JD84,^P6S?YSOZ*N[?@N!1+DD_-%?X97?(\<<YMPYB.9^M)S-2MA0,W
M;63[?(.Q^X;919X^$+'YFWKNE'>56@IR)?(F)Y+'"-J<=4'B,)"E,F=."PYA
MF9L"A*R3U?W"A+!$<P'W9:-D@^]+<[AA<"SL.]]SSN#D;<H*VY!<(LO79L,1
MC-B7MHXD>=_5/YHQ9OXI:H'-IL,JP_E(@U&1#C!<&TVM2$ [PL:R@6^6Q0%G
M"F40I([5(SC[-JVPCJG0Z86G!B(RN#N^/Y]NV*=.$+/)2$]\ZE3?"VSH?]UY
M[6GK3EZ;/M8@F!UH[.8!)M]"K>%VE,4U%HL+W4UCMMHHDN='66\I"N?):*1X
MF0Y98T(XX7(;:L/IT%\NW)=O")!$GGD^.7@V9A+8<,1N,7S<1W/M(&6@DT4=
MT?RM/I';@*8EIR'8%!AP6(+:]I<S"V]JL#TG@ G*C3#DB1ON)8N5]K:MJ.21
MO6:B@.MU'+41B.AGR6)S G;^N1Y-@R0WE5A$)$9UASF1F?JOEVA$&"%+96#B
M/"/;_M$4 NWXCMMVV@%,FL_&@[U&.[T"\Y0;CR:I<B,$L?TT>60FV/P07S;R
MM9&T>$O)9X/?]\;&W8%88MC%F OE!/2!ELQP5B,CKP4&E> VQ 66^*R->9C2
M_P TINPPYNUHLB%[-RVP]^S"*=3F60#3$[["UL.:G#%4ZW1'AG\C+X\GEQ8M
M7G+]I#)NB&^DNHTB6R'BXP&O,F6W?;:MC-W3)K.ODA6M58(J_811K"081XL^
M R*C #2.1UT;60LX3Z\I":-H-D9EPF+IH >\VK.*LK7DL4?XZ5_'+C^$E9'V
M\@&E8NI@$71]-B"G46(2N\T];B8ULX4MG^?4]#Y'CQ9,&7%JGK4'R #./DIP
MY=EHB359WG<O"Z0;<3 ;05(<FESW32'*<'RD%3^-)XJ%03_N]U6UKNV;1D?R
MKPDJ[SI?*KYW  [+:A(9R8&76YCY@VAE:'#"#-R4M0'8"6-(J9,B2AZK3* >
MH6Q&8*NX+RZD^+=C."H 2!8<<VL'?Q\"S"K'13#> =;,H)%>4UHY<-W"\U3;
MDU(]M*TO"73J#HSAPM0)[4WJB!#,RL;-W9]R:AXM)!IJT,,V_CD,1G%T3E,!
M6/!FA.&GKN,^:-6%6O+/$\X*B(IQCO8(1S\FS5Y ]>LI"(E:NM(!M#R:Z<7
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M=<D,BJQ$V55RP"5'\>U@!T?Z&!59#84$@UJC CJ5%F08=K3NN:LX:<QQ\:F
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MMD>W' ]E[)MSH*^#VQ[.#/M_6=OQY_-JEDK8#PH4N.I JT3U7"IBZ>$)W*S
M7?Z+%5)?L.:!!.EK6_<:17P7'_&'HFK@^ZYT35O)S)ZH@!)H4T:5K#'XW'$7
M6"*&L8! 4AC'Q:RDKPO*5US)O.-$$%9!BZZ4<U7HB)HMID<6&.R6*52(+!]
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MIQ"T14BP/Q&88R8QOA6-*EGQV:V$"&(S U-2#U[G16?8&A5M1J8M$49!.;)
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M?L,F"&R5-V*QW=U%8)NV(NG55+3&)?-0*&G !H/H")TV:C'IX9'*"JP08KC
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MVM6#+[ -8R?-?'V0K7"D=B_>$A$B,\T$>K\9&&#/1K(:PR]Z_P!;9W5LS0=
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M:R=I6>7JT)\9^9<4W-J[&IGZV=TQ\E*M9!?DAJT",,9!V2AM<TLA\WW59)'
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MGLG@TLY\9ZL/?2CCMB#/EP;JWX>1^)>=HL"Q2_-;;A,.8EGV4#^-R8EO5&-
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MVO#WI?U*V1LD"QR3/\6X19LMK0FKN=&'QT%5<L3FI-/2'>-\E,)@+2CYNO\
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M0"G#9<+HWG@Z-TZ91?1_G<JDP.DEZ=;)N??MD]F8B8_53_W0TBGZC4-XAEN
MUV+C*H&P9WZ*TFLD30F[29HD=AA7!Q(P(=F0;+"CNS;D]KLI;\EB'U M$-KB
M6IG5K^$.*D'F?+-)_**4\)+C?PIHW12,Y'Z86SU%]_<^G4#%7AR,+^_[#^\^
MS^*_M_\ X?GS_HQ"L3F;"Y-7W3UOE)^LA*;I$&:[7/-NRVO'!MQ"W(H7*524
M1/D18N5,%+0E;#)!U+3SG8J_FNN6%JM0S8:M>\\=\?01XT;=@!N15MHQO-=/
M@Z1-OA&65SZ$<ITG0E1W0DE,11UN!UJ"^@A+AP7L$]5)HP1KSWZ+]'US :@+
MY()ITNN"]+UPAA>/:E87>N.!)L:UZ"V-<* 8\5J0$$EN/<FRWX;L=WT9DG&L
M$AD//-RQ^GF"W[!H"89=.EXC2]6-'!S/;B^\[_#!*TK@1H3GT/W-AE+RY,-7
M>M<\Y'3M4S63;O6?I+2_,V6A@[%J%"ZF?R"X>C^WN[767/,F%FJ^QE7GN25A
M08:H4N29DH'=6AA?9[6KAB.<U>Q3_*?H_)J5Z:D"56%$65YCU/'YVU2=\S-C
MLB5)@V3-J6.GS#=;G]GIZT"F_0G*2[&<5LWG0+7:ZC)LHPK-M"&Z&U,FSCE[
MNMTONCT^QP!"&7F@\.HTIR@]A*?^60]-*=DH2IIN+SZW_;_^M^O1>L4^WZ0>
MLOJ6_CM/UB/<2M8(!I=U$U8%2!I8#"#U$"^!;BU*MPH/(S+WVJFF.+6VIW^\
M_3VK'K5H8>QO^>M5\SJAULK7H@1.<;*3K!J[.HB$ZJ6E)LT@G2A3L:9U_O(W
M824I;^5QWCF<9#69QHG6<NH]7SZMS;')ASCKM=IX:'7P:"LZ! %Q9TY@5 :;
M6]R.VI[J/G7\5JZKOJ6<9Z>O@CV$806VBF7J0&,4\BSS+@&,R0(D3$!#78E=
M(YO5X V5&?>E?70Q]12NNN.K<KL2Z1K/JXZE9';<)H8[4#_;/'I>67X/!K=W
MKXA]$0>1($K75Q<47/-E'R%@?',?0[.^1Z3QZKM#;!=K5VC4&)EU'D78W%,2
MJK0H:A"OV&%(ABQ3A-V;_#HWDLB2[.+2_P!O8^M*7U*NJTVNNWG6X\+6/5E%
M]CV5V*>J2)<?7\Y/9U9JNT'==I#Z(=/C&LGK[S@YQ+_U?V[B>N_*_)X]4F2=
MBT)%PI7HQKU #U>!,I<+4DZ.R>-F409=F:HWT95+4/L$@(L8J-]-RN=X,6I4
M3G6NE?3,8$ZSKQO+1&.%#K<^6B#.I0&REK4*:D!4NI&.F89,W(0D@IOLOD5?
MT.+XS_9_4SE6TC6Y@8KMNI^@C=9,FZGT,=TC8#=FLMNE%G0M*"')(%%CM<F=
M#&<FI@QY#;'>M+2RA'ZURC[)"-Z35M>TVE[!,%V&4);51= SN#38-*L.:DPP
M027K,ZO)H(QQEU<B4]U;+G%K6W(D(=TH1-''F<[V?1H.M:[D$,LRUF.C:%$<
M"R9QZQ!'(#Q)J-:9U<@23PV%-AB;!)CJ<(Q9*Y,SLFU^F6CUP>O%PR6H8N3!
M2" A=)8IM&M%KN%>5 $M@FBK!A@]>"SKDE<]SZJ9G4*3\C;*6\3U&Z %DKIY
M]LUCM>9%6ITR'^UD;75IU3-Q2+$9UMDT'E19+$SD.3QR.DH-@S.)^O#86G:&
M9S%G%53TE,$D/0V>5\[^V4?9)HNO"Z?)DVT=R(^1@O6BE H 4]T/+&?OXN$S
M'(?<H3WG1/I.*8M4"Y \7)8,-KD&4"8H<:AD[0*N+Z6P7:\N<@PV<!Q%M2$S
M4I;:9XUQ'TE+0JU^<DZINJ\FND?T,W80'\3TN/(GR?4!2_&M7GOE(.>1"$I^
M82T\X\/:?6]$&N3$K992N/%4P(UEXA;[WI%9RN)B=.M5\+PB#])S!J4&(DZO
M4@X(37:T&_BHK7!THS.1!_<RS@Z(F3(<:BQVV@?IF2!<5K]?RXQCL"PIG2T1
MET<Q9(5K[$FB$.<'3B(DK'D<'S'&U2(+!0@TRI+<V0E?\0-6;1+5"7L>W[S+
MIUTGTXU2YVF;X\[(N)Z6'9I,!U:A3LN7^S(0^C]L1/DH1U3;W4?HIE^='+A)
MI\N]:)? PVQS@LYNE2M+MA>[GJW2XXVOAX(:EC[*>F/#!O67F8#;_P!!KO(Z
M&VD8?CL.Z:TY5_/V^\](429)/U5T_(T+ESMM^Y'L9#E*;8+5KECO!)S[3C+*
MNM/I:ZYU#3?$60C(O>O1I-F]=U/VU)[%-TWZ<';:17ZS6*RL>W,H4M*:>.$T
ML4C]K>^NAU<)*G%JZX]]2SXI?M U8L$M^@5K1SEF2>KC-P<,TV^5K1*N.'R/
MX177@U="GZ<-2U#AC6$*C1?IKZKKSZW=*H^PQ3NEUW2M=I&Z.1;+)#MRJ-IN
M<QZ4Q2[+G)0"""DZS,!?R_&J;7]5]Q?$OMK4IF5(;=->F(]HO$+036+0<)7
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MBM4'9IE]@L]HJ[G?OQ3MH(VSIZZEI,TI,)R)$UR<OZOS?*UQO_W"?_(_\_\
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MBJH.'B,-B/V>.#\)S7V5L]<[Q*>^<P%GJ#0&\Q,^V<?& O>?;G0+]0ATG:;
M;E=T*\V%;##0T^%6%1 &/Q(#\I;;<AIEUM"U1O8C>@YV'D ;+[L]IG*I3;!Y
M?N1BT6"OVJG)B";P(M4R&L5S,9L!!KBG_P!J<@EFY'8[#[SSB&I(+"L.!V:_
M@8_@G?;K^/CT';),IK5_,^LVW#:W65^2]!L=NCQ;.&D"K66Y+SVPD7H\F(*:
M<#$OF6$9D/[FK$_-6M!]3!>3G,H:I]A\Z:M7=&A$K!9LN)OYQ811^F1B^EZ-
M$M548E=F0_WM33L67.Y,XU+^XD^0DT,#<[-Y>QKT-'E>IZU7Z+:8H$A6S.%:
MF/QF6L/T1"<OV=9CL,BN$+! 'LS88U;D&7):4U D?;;-:J!8S^1Y7']:+U3Q
MK6-*P*Y:[YJ/H@^4*W2-Z ;GD8Q(VRT[#MGT@B;>JLZ&X+FPK*U++#$NME&X
MY.ZVW3< CXT'G?C_ /QIA+-E-EPJ_;4]'M5#M?HV=>\9SB_188))70JM32P&
M#V6N++)0DS1CLR-%=C_21[VK.+Y==!GKRV_E%?O'EJ\A\VM%7)UB<S(\Z??;
M.YHLBOC!4+&1\4)8_P!^FNSE";# ;GC4<G/34QG@EEG@@T>IM_CJUVJ62Y7'
M ;?L-*?,DM[R@N&IBE5_D"%)N1&L"S+T*!]>9-[&^LMN&M*N\7ZGV;R_E]DO
MF1;7J.?YCZF\@V&I%PT&=6"N480,I_JC&JO8!*!'-5QNR*FQ[M#@I?BVX-#D
M==<_>@D1;NQ8H%QZ 7\H>VB-']2:2:;JH9^C4W5L4?JU9UJBVAGK*4+=WF(#
MH,\2RM*^+?BVB3SG%\^;OIV;<Z6/@B#/Y'/2MDIP(KYRN*K>4K]@S^LBX6B5
M[0)"(@@7F7TV#O7YW(/8!%E;S#<EUQSC4CSQYSQZBZJ V,?4LEM.PYM7Z#=,
M^O#N*T_T50S/IFBIED!596%T31,;F&( \7UYHP;^Z=;BH4KJEH]+V/ \ZL??
M.!7S1YKK).HA,EMW['<?3H/U_2+/4SU+RN!7(ATH;S?$X99NT%!\%M/($B!#
M?D]6.6W"\;2!Y]FZC[=O7OO=3]E+879;5B>'"-CPR ,K-&%4X*<EQ:519-J&
MQ)$>)+.-<+627.EM(2Y(^BPSDJ:C,73D9J$KEBJ)W,+=GM5+5"VAR(OD :%L
M@N#!X /"X;ZEB&7W9 R%(:CS6HZW$-=] P"N(,2<*/\ XTL8R.'*)8P3;Q@Q
MHH;==D,7.C#SDJJ-Y].LT*A'!SDN,S(4]]BZVGO.I1U*!@,1%;@B0P^$*%P6
M?F^C"'#HS4.%$:^=2U_3CQF4H3\W>]^'/Z>_^X(TJKLB)%F2))*KL<_)FP@3
MYWD-[HADU,'19Y"()=(?33)<88>>0SU2D-K5SB>H^IDWXLN.?*GZG$>A?6G4
M?/\ +SY_DZKS#Q74?-_D^/\ 3\/U_JF_%I_Q"^L_\,7Z_P!4WXM/^(7UG_AB
M_7^J;\6G_$+ZS_PQ?K_5-^+3_B%]9_X8OU_JF_%I_P 0OK/_  Q?K_5-^+3_
M (A?6?\ AB_7^J;\6G_$+ZS_ ,,7Z_U3?BT_XA?6?^&+]?ZIOQ:?\0OK/_#%
M^O\ 5-^+3_B%]9_X8OU_JF_%I_Q"^L_\,7Z_U3?BT_XA?6?^&+]?ZIOQ:?\
M$+ZS_P ,7Z_U3?BT_P"(7UG_ (8OU_JF_%I_Q"^L_P##%^O]4WXM/^(7UG_A
MB_7^J;\6G_$+ZS_PQ?K_ %3?BT_XA?6?^&+]?ZIOQ:?\0OK/_#%^O]4WXM/^
M(7UG_AB_7^J;\6G_ !"^L_\ #%^O]4WXM/\ B%]9_P"&+]?ZIOQ:?\0OK/\
MPQ?K_5-^+3_B%]9_X8OU_JF_%I_Q"^L_\,7Z_P!4WXM/^(7UG_AB_7^J;\6G
M_$+ZS_PQ?K_5-^+3_B%]9_X8OU_JF_%I_P 0OK/_  Q?K_5-^+3_ (A?6?\
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M^DGZ_P!P+V[_ )HH'^DGZN&]4#']5Q8/3M4+Y5)K.N1@\:P$" BL5*T.FH*
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M^G2ZD3M0@',*3S/0\DQ4:A3(A2/'($WNM.OQ%2$MJ2A3B^)YW];!^2FN;-Z
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MZCJDI4GT+*H1W;L1P^A_BKMF\,^+/6=\T,\3]9[1G5-N=Z7JGE^J6"SZ&!
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MV/,1/,%=#%\:&G5S^.MR!$5F%%1#9[(Y(T;'LV]&Z-J&+7&V%KW3LQT&O5Q
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M=<['4S]-++[R5^B/"^C;%H&F4'<]^,>J*Y?YM:J5<T[$O0!I@/'DWG.#01E
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M2T1D@++B"D%U^$2%DH#Z'H[[*UM/-+2M"NI[SOZ-4!6MYRBZUP=8"YZKN7(
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M8@@A1M6H7N+Q5YX]#Y'MF?3(-^J]%],ZQ1JNW)BCHMA0*93<Z3<.D %@A2C
MUQ<5]CJ>R6)+4;R=GE"GJ@><[U;O8E:V35K=0",2C6!'F+%KS;K*1S'5'3C
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MG?+Y5PEKI&:+L\TQ"EPQ->K#LP@64*E<C,+4RI2[K:00[2[/3J29\4PW+<!
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MY6V13M"*V4H]&L==H@M$D26)+E!B$:0UV.U\_.K\KBYQG3 '-G]24K'X$G/
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M"1Z&FE:.JG*M3$ 4;GC!9N3RBVV[ 6H%H'16B4-O[[[QJ+*;1+9C24NL-_\
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MMZ$5*<FAXA7ZJTTL= X--F$$2;+"D+^NXN+>[?6/,&@$6<C\K[3Z=UT,?O\
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M>.JZ >A.NU4,/S6W7D<69.U>&@@8;,!6Y*G'HDR*[#YZIKU-BR<P=\H_D/\
MQL8E6#%!M4*;8==J&[Z'Y:-WRNVIJP@8HL,,MU/V]X:XRR^TJ/\ *GO)2O[?
M?T?IU:P(P<]&5O7/4&43L=CW5Y\#,>\IQZ83NMD#Z*(H9F9,&689J%4:#(=
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M/L680,O!T9 FQG)(M+#9!,I<E+++WP7C>'XMGUUU=>1[MZ6#B[=JEBJM:LN
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MR9Q-62SR9GB!3*(S:4\8>;^=#Z'$N.<5%T*^T7P.<LP_T7DOJX2IWTW^0?\
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M$SH=V'GCU_.:$6'3(51>&0!QFFS/G9),S.)?7NVE;$O#:WJ.%:9YY\U6P"&
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M3YZQ3+'>6A5V4!Z0Z^WQ00?#C<:2AGG/U^0"L*"B^UR7^0SW:/E ?LH_1#\
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M7BDN^:+B0PUZT]=^E/)66OU?'G@$7-B'FB^^LX"S[DZ_[@^$OUYV$%B8F")
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M^OH)R)$EUH;'5 0XEEKZ2<LI^9[1Y,R[Q>(N_P#,8MA=3$4-K^/]XJ&D!]2
MFPNA<T9NJA! V^1XA<V)CUN61GE6V7_OXWU7TOZ%KUZU_*<JTOT: SR 3B7C
M3:Q1_P",A671R0*LEH02QV.$V?*14V14)4]AKX\CIC1^<YU*E.G %^"8R6OF
MTB,\9.@K(JJ.VO30>3'BUNS+[D3->X6LX^BV.;-GBU);=1#D+=<;[SO.]_6N
M+M>:XKJ-UMHBF4K<HTZ-7[,>- J03=L.?U/2H"7Y,IX55C?79PJ"01]&)+6X
M^PA+BUK[OVVBZ!Y7DZ5H% .5OTG?X<ZCR3!G/I ] BX(T^:T3<:B##0N&F*=
MES>-+(L-<;G.O)3\.?S0\UB<2F$&\[J.3]O.2DZT<XC+*2Y.Y1,__?*W/GL\
MI=3<[*X)'_4^T@J4_P#;H1U3GQ]#:A*MN,[_ *7H/I7?MG1<*+QSK^8H]"/N
MI,TM^"U>+</B6J!7?KANV!IL:4G"%*BJ0TQ\[2J=CU2SG#;%1L +D7:)4LZ(
M"6$8V1-QRH@X.K3E'*QBE#B6*!,FPB(^.[&C$(KKT>0TZUU;?;=Z\T8CAA[
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MK::7AQT_0K#?JC>7.R#UL,(K#AE^\]/G^D79E@7)2XZ7^X6Z1^O]12E6F!=
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MP7FA$!+W>K0Q^CN<4RE@+EAY_P#&U1S7Y Z8H7'(9P9OE;VT_9/,DC41'$=
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MVZ?Z?D6TJR"=TB_UF;'X%D"' \=ROCFG6_N)Z(TEUGRE<-)$^967*VQH[/A
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MD>%WYVW^M_TI[I),+C>%9)G,JJ$".LNA,YI%2JY*E5D1.E3UW=H:%APBE>"
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MZ/G?HS#[#HF;8[ /:=Z>K,/,GO1=5S$X 3%'[38+!&I_#T4(9KR>R&+)T?\
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M26%N]^D\GYO^I7#4BAVOT>JY;MAFCU/VK7:::!*]@"JE>*99[P$J=!#LHHQ
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M_4O=AV)C3SG\H26KJPP;Z3<S716O,)#5^&UUGM2B;\Y64YJZPY:&5BT&OO\
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MSDN,*JK0?1NW6Q1K3$'RYK3ZHM6^M]%;$AMSNY_C]T?%O0=Q]*>0O164^<*
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M%"MA^EV>+9*\;XS-#*'FZU*YQ3OP0['2EY'>M+0KLFVLW]+5:1FT38AQ<@F
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M6R6_ABI>I%@T&4))%'P<\B'+U]X+:&P,X+9!I\3(@/Q""8BF937>+ZE']O\
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MW+-1;-XXW5KN1$":W:H$,>09=,UXC./0>(?A=D=ZW*0[Q/6N*6G)WS-;T&O
M]<QZY;J/M9L('C5FG9Y1 P"PV8AH9)BQ255B=##VD>_R-]-]QS[GJ4_VV9"6
M<J35<XVRMUS=LS);)BE^NE+$PZ+I690$5J5'LPP[7K5955B6;&6X?-@A;$R%
ML,B$\I[[!*&'^M;=YL G ]QV/QL7RBQZ95I<=J2W23VHU8I9<^+0OJ..,32<
M8.T\KKJ6_G'25)Y\4.]3WAD[T:2,)##)Q10H,W&>+D$0(SDI<0:U-EP(KTY]
M+74M(<>:2I?><^;GZ'>E_/,.\D<I.%[2$K1*W5MBH%++/II:=7SZ188F5[,8
M8AGQK\+CDS[1M;S2OE[UOG5\U"VX<.T%H!D&M6O#+G.O=514_H:C1?LTW*L#
MX[I.;+(KKBB$=+\E#?V:U/<XTZYWB_EV_-].>V&@-^:M8S+%M\T0YEA>9EV3
MW?:4N+R;^,K=6I9](VM7M"$_;&.,+%Q>NM\FOQ>K3^BME.$X(JO@Q4TZ8,SI
M#48:-#C8;LX@3F2W%<98@PX+"W7'%=^5+:>][WX<_0S\AT"]2GO,1JEP+H*L
MZ0LY9R:T6LC5)$UEJML\<GIN!&^26@:("OE4@HYQEQ2.<4M-WH9#+M>R6\9Z
M$I-BL-;U6M@AZ7@^@O6QBN3JW:J;:;M0K>VMVESD3/VHM,Z.=2AJ5QEY?T_U
MF^"3,F]43M1VA_:4XK7!V*O=DZX.\_22S&FG:/R?8H#TD*.9"O283LM$-1:(
MIIV$E]#S75UKRA5:IM<S;;;YA!>P0=7FYZT#;>PNR-1&Q)Z;/.'AT80=<.S4
M"7!$OK!-@GQ33C*$I4YS-?6,(/O<O$]<]!H\MY_86<KY^YGMM?G$142I?PRN
MQ-GQZ)Q@/+AM394=F"J3&6GKO.<YWNH5J!0=:S>T9$>" +;7=:I7\)S7EV(,
MDV'+UB=%)F@5LKTICCK'9H^7(8;FQGXR^I>9<0G_ ,KTASCRFV&G'G$QX[\I
M]2&D*<5QF+%:>DR7NI3WY6VT*6M7]"4][WG/U@7Y"?$U;O&7^JPP1KSU[ PZ
MT4HC4B7I[RE9-"Z'LXZT4\ND:LEH>8A'VC8"=U77Y<&&TVAUU^% C_KUW/H,
M>TT*X>5TU1[R.&.X!=">@6_9\DD#M=8TS [^Q;!T(5"U:Z.L4QZ6R%*I3# (
MEN=9COMN]J]$TW!]@Q'U%8/$%DT$6S9,\LM;AY)[<RZ]Y5<ZB#A7;L-L*$>M
M5IHQ1@?(;E<^M7B"N_,EUQ#7?P_>E]TQ^^F[-4/)_H0Q[:U&C9Y:#- HV^[E
ME+ P92N3A48LN8Q7EBH@%K['[F/';AM*<4CCBN\VB]Z7YW]NS-!T7USZF#Y_
M@Q'+3Z,3<H_I/9_/UEIGHDH>E#F*S0W*Q#SV8L_+G$'230MA*6(/U><^K_U%
M^4U/Q]OEKLWY(]1"TWRX3+4550SJQ C%#L6=']0L>@7:4!K-+JU&<)?NGQ(/
M,$)J&FN08TAU?RIO?ANL0K/N>TUC\?<7S."AT<*7L1:^:)$RR'1HZ0T-J/\
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M!SVE3]1O6*'-OS/L&DS[A1,K:MQXB =.3'(I(@$CE(@]]E:WG.-+:=7^1(G
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MZ D#!5O?M@M,;,MSB6@S9Y42375-/-H'1)TAEV,I+.1P,A\Y[64UJ_;;Y?U
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M4\IQMEB6N,9V[5_,]\DX_5/4C7F2^7ZM7JF$1F=()3@(T!LUXC2/LYHK*2I
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MP),6#M%RKMFL5<$@;"W3CQR$/.084A\F#(3&8L^-'?<0WVTVK^8Q?O*/<#U
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M7_IF[K_.Z#%JU>!8=:R1HE3-($Q.U'TG,?%X7<AW"=.B/&J9I1N,Z.'EX:)
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MM..D<CI7HWPKOF9!+!:KG3C==B><;S)LFR54T!JV>' ULL=ZXZB2$L).=-7
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M9:I()632!PTB5_<K=$F "<!<JO6(9(8D0R"TN]XA[A#/=,K3UDQWRYN6*1;
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MX:\ P6D9E<30FU.R<YK=E%S+JJ&E[@.(29<C<(?+)2QY-LNHU;1\3AZINWY
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M40;-EMEG>::KIQLXS4"L]FMW I$TM^'0PS=R.1J](E.B*Q-87S[B?U0]%_\
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M+UBL 3]7"17"U?%GX8@J39Y)D-K0MUAW1_&%Q]B>G-(Q.QTRN9-E4*U]R/\
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M@_QGXI[>JMH&;A"LQWT%DU9!9?7/1]KLRET#DRF[#19-WA6-P$WT^T?'D/\
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@7ZERP%.N..<7/Y6ZJ/B?%/RI^E$1_1\?CWO_ +M?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
